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ABSTRACT 
Identification of Membrane Associated Proteins as Potential Markers for the 
DLKP Clonal Subpopulations 
Andrew McCann 
Lung cancer is one of the major causes of cancer death worldwide, it represents a 
heterogeneous group of tumours with distinct morphological, histological and molecular 
features reflected by varied clinical outcome and response to treatment. DLKP is a cell 
line originating from a lymph node metastasis of a primary lung tumour histologically 
described as a “poorly differentiated squamous cell carcinoma”. DLKPSQ, DLKPI and 
DLKPM are three distinct subpopulations derived from DLKP, which are 
morphologically and phenotypically different from each other. The research outlined in 
this thesis aims to identify membrane associated proteins that could be used as potential 
markers for the DLKP clones, but also to identify potentially novel proteins associated 
with lung cancer. 
Cell surface protein isolation and label-free mass spectrometry analysis were performed 
on proteins isolated from DLKP and the DLKP clones. Eight proteins were successfully 
validated in the DLKP clones; AHNAK, HDGF, ROBO2, SLIT2, ALCAM, IQGAP1, 
INA and SPR, using Western blot analysis, Immunofluorescence and 
Immunocytochemistry. Their expression was also investigated in various tumour types 
and representative cell lines. SPR is associated with poor survival of patients with 
Luminal A and basal-like breast cancers and also shows high expression across triple 
negative breast cancer subtypes. siRNA mediated knockdown studies of three candidate 
proteins. ALCAM, INA and SPR knockdown led to a significant reduction in the invasion 
and migration of DLKPM cells, indicating a potential functional role for these proteins in 
lung cancer invasion/migration. 
A pilot in vivo study using severe combined immune-deficient (SCID) mice to investigate 
the growth of DLKP and its clones resulted in all four cell lines forming tumours 
following implantation. Tumours derived from DLKP and DLKPI were the fastest 
growing and largest tumours, DLKPM formed smaller solid tumours following an initial 
lag phase, while DLKPSQ formed large, highly vascularised tumours. 
Immunohistochemical analysis of the xenografts derived from all four cell lines revealed; 
strong Ki67 immunoreactivity, negligible CD31 immunoreactivity and strong N-cadherin 
immunoreactivity. Explant culture revealed a significant reduction in migratory capacity 
of DLKPSQ cells, but also a significant reduction in invasion/migration of DLKPM cells. 
Western blot analysis and immunohistochemical analysis indicated that expression of 
SLIT2, ALCAM, IQGAP1, INA and SPR were maintained in vivo. 
The research presented demonstrates that proteomic analysis of cell surface isolates from 
the DLKP variants can lead to the identification of proteins with potential functional roles 
in cancer. AHNAK, SLIT2, ALCAM, and SPR were identified as potential markers 
capable of distinguishing between each of the DLKP clones. In addition, SPR may 
represent a novel target for triple negative breast cancer. The DLKP cell line model could 
also prove to be an invaluable model to study the effects of potential novel therapeutics 
in lung cancer, in vivo. 
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1.1 Tumour Heterogeneity 
Cancer is not one but many diseases and has traditionally been described as a disease 
attributed to a stepwise accumulation of mutations in key oncogenes and tumour 
suppressors. Tumours are now known to be dynamically evolving entities both 
genetically and epigenetically [1]. Primary and metastatic tumours are generally 
described as heterogeneous, meaning they contain distinct cell populations with differing 
heritable alterations. Cell populations within these heterogeneous tumours can display 
remarkable variability with distinct characteristics such as cellular morphology, 
metabolic activity, motility, proliferation rate, antigen expression, drug response and 
metastatic potential [2, 3]. Within the description of tumour heterogeneity exists; intra-
tumour heterogeneity which specifically refers to heterogeneity within a tumour and 
inter-tumour heterogeneity which refers to heterogeneity in several different tumours [1], 
both types are illustrated in Figure 1.1-1 below. 
 
 
 
Figure 1.1-1:- Tumour heterogeneity in cancer. 
Subclones may intermingle (as shown by subclones 1 and 2) or be spatially separated (as shown 
by subclone 3). Tumour subclones may show differential gene expression due to both genetic and 
epigenetic heterogeneity. Within a subclonal population of tumour cells - shown here as a tumour 
section, hybridized to two fluorescent probes for the centromeres of two chromosomes 
(chromosome 2, red; chromosome 18, green) with DNA (blue) there is intercellular genetic and 
non-genetic variation of, for example, chromosome copy number, somatic point mutations or 
epigenetic modifications that result in phenotypic diversity. Intercellular genetic heterogeneity is 
exacerbated by genomic instability, and may foster the emergence of tumour subclones. Genomic 
instability and tumour subclonal architecture may vary further over time if influenced by, for 
example, cancer treatment [4]. 
 
 3 
 
There are two known models lending to heterogeneity in cancer; the cancer stem cell 
model and the clonal evolution model. Both models are illustrated in Figure 1.2-1.  
1.2 The Cancer stem cell model 
The cancer stem cell model is not a new idea and generally, assumes hierarchical 
organisation within the tumour. It suggests that a subset of cells with stem cell properties 
drive tumour initiation and progression, cancer stem cells (CSCs). CSCs have been 
defined by the American association for cancer research (AACR) as “a cell within a 
tumour that possesses the capacity to self-renew and to cause heterogeneous lineages of 
cancer cells that comprise the tumour” [5-7]. A number of cell surface proteins have been 
designated as a marker of CSCs, some of which include CD166, CD133, CD44 (EpCAM) 
and CD271 [8]. 
1.2.1 The clonal evolution model  
The Clonal Evolution model suggests that premalignant or malignant cell populations 
accumulate various hereditary changes over time that may confer certain advantages or 
disadvantages onto the cell. This model is subjected to natural selection. Carcinogenesis 
is initiated by the accumulation of several mutations in a single cell and is driven by the 
emergence of further genetic and epigenetic alterations that confer more aggressive, 
invasive and potentially drug resistant phenotypes [6].  
 
 
 
 
Figure 1.2-1:- Suggested models of heterogeneity in cancer. 
(A) The clonal evolution model: cells are subjected to the Darwinian evolutional trajectory. (B) 
The Cancer stem cell model: cells have the ability of an unlimited number of divisions. 
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1.2.2 Sources of heterogeneity 
Intratumour heterogeneity can be observed at many different levels and may be 
attributable to a number of different factors [9]. Varying degrees of clonal heterogeneity 
may arise as a result of selective outgrowth of any given clone. Subclones may continue 
to expand and evolve in a sequential linear fashion, or else they may continue to diverge, 
following a branched evolutionary trajectory [10, 11]. Diverse phenotypes can arise as a 
result of extrinsic factors such as pH, hypoxia and paracrine signalling interactions with 
stroma and other cells. These factors generate phenotypic diversity through modulation 
of cellular signalling, but also act as selection pressures supporting the clonal expansion 
of cells that proliferate efficiently in a particular micro-environment [12]. 
Genetic instability, a feature in a high proportion of solid tumours, generates a high level 
of intercellular genetic heterogeneity and has been linked with both drug resistance and 
poor prognosis in cancer. For normal cells in tissues, the goal is to accurately duplicate 
the genome and evenly divide up the duplicated genome into two daughter cells. If this 
does not happen, errors (such as amplifications, mutations, deletion, chromosome 
rearrangements etc.) will be passed on to the next generation of cells. This can have 
profound effects on the normal function of the cells (e.g. control of cell death). Normal 
cells control these errors, by preventing DNA replication until any genetic damage has 
been prepared. Certain genes are responsible for this, such as TP53, which encoded the 
checkpoint protein p53 and functions as a tumour suppressor. TP53 gene is mutated in 
approximately 70% lung tumours, 50% of these are NSCLC [1, 13, 14]. Regulation of 
such proteins helps protect the cell against tumorigenesis, which is effectively the 
accumulation of genetic alterations.  
Epigenetic, transcriptomic and proteomic heterogeneity may arise due to underlying 
genotypic variation but can also reflect cell cycle stage and stochastic variation between 
cells or hierarchical organisation of cells according to the cancer stem theory [4]. There 
are a number of routes through which a tumour cell may acquire drug resistance: 
upregulation of drug efflux pumps, drugs may be inactivated or metabolised in the cell, 
or the drug may not be efficiently taken up by the cells. However, it is possible that 
resistance may be pre-existing in minor subpopulations of heterogeneous tumours. In the 
context of EGFR, mutations in its ATP binding sequence (T790M) have been reported 
[15].  
However, the existence of genetic and epigenetic differences in different cancer cells 
within tumours may explain why some tumour cells remain present after cancer treatment. 
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Since genetic instability plays important roles in both cancer initiation and progression, 
it is hugely important to consider genetic instability during treatment regimens as it may 
ultimately be responsible for patient relapse. It is possible that the initial treatment may 
select out more aggressive or drug resistant cells which might be more difficult to treat, 
potentially resulting in a poorer patient prognosis [16]. 
Clonal heterogeneity of cells in tumours has the potential to produce many different types 
of tumours. Cells within the tumours may have certain characteristics which allow them 
to evolve down a number of different trajectories which may result varying genetic and 
phenotypic characteristics. Some of these characteristics may confer the ability of cells to 
evade therapeutic treatments leading to the development of tumours which are more 
resistant to therapy. Heterogeneity presents huge challenges for clinicians in classifying 
the disease and considering the most effective treatment for patients [17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
1.3 Lung Cancer 
Lung cancer is a heterogeneous group of lesions with differences in clinical presentation, 
pathological features and biological behaviour. Lung cancer accounts for about 27% of 
all cancer related deaths and is by far the leading cause of cancer death in both men and 
women [18]. The American Cancer Society has estimated that there will be approximately 
221,200 new cases of cancer in 201 of which 158,040 as a result of lung cancer 
(www.cancer.org). In Ireland, between 2011 and 2013 an average of 2,279 lung cancer 
cases was diagnosed, 1,005 were females and 1,274 were males (www.ncri.ie). 
Traditionally, lung cancer had been most common in men. However, it is nearly as 
common in women due to an increase in the number of women taking up smoking. 
Statistics for lung cancer in Europe for 2012 show that Hungary has the highest overall 
incidence in both men and women (51.6 cases per 100,000). For Ireland during the period 
between 1994 to 2013 lung cancer has been decreasing in men from 71 to 54 cases per 
100,000, but increasing in women from 26 to 41 cases per 100,000. According to the 
National Cancer Registry Ireland (NCRI), these trends are comparable to those seen in 
other northern and western European countries [19]. While, according to the world health 
organisation, the lowest incidence of lung cancer is eastern, middle and western Africa 
(1.7 - 2.0 cases per 100,000).   
Ireland is currently ranked 31st in the world for deaths related to lung cancer with 27.67 
deaths per 100,000, irrespective of sex. The net 5-year survival of patients with lung 
cancer in Ireland has been steadily increasing from 9.3% between 1994 and 1999 to 
15.3% between 2008 to 2012 (www.ncri.ie). Similarly, the rates in the UK have also been 
increasing from 4.6% between 1971 and 1972 to 9.7% in 2010 to 2011 
(www.cancerresearchuk.org). However, data from the National Cancer Institute (NCI) 
also show that there is an increase in the number of people surviving to 5-year survival, 
for patients diagnosed between 1975-1977 the rate was 12.2% compared to 18.7% in 
2006-2012 irrespective of sex and race. Overall, Ireland is performing well when it comes 
to patients with lung cancer with the increases in the 5-year survival rates potentially 
owing to improvements in lung cancer awareness, screening and treatments 
(www.hse.ie). However, survival is dependent on the relative staging and time of 
diagnosis. In England and Wales, statistics presented by cancer research UK indicate that 
the one-year survival rate for patients was 71% with stage I, 48% for stage II, 35% for 
stage III and 14% for stage IV. The survival rates drop dramatically after this period; 35% 
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for stage I, 21% for stage II and 6% for stage III. Therefore, further improvements in 
screening and treatment in order to improve patient outcome and survival. 
1.3.1 Risk factors associated with Lung Cancer 
There are a number of different risk factors associated with developing lung cancer. 
Smoking cigarettes are the main risk factor attributing to someone developing lung cancer 
over the course of their life. Smoking and exposure to second-hand smoke have long been 
accepted as the primary cause of lung cancer, accounting for 86- 95% of cases in the UK 
and Ireland each year (www.cancerresearchuk.org). With an estimated cost to the Irish 
public healthcare system of €506 million per year, lung cancer and indeed smoking is a 
major public health concern. Smoking is not the only risk factor, others include exposure 
to radiation (including radiation therapy, radon gas), exposure to asbestos, chromium, 
arsenic, soot or tar, exposure to environmental pollutants, possibly a genetic susceptibility 
and age is also considered a risk factor for many cancers, including lung cancer. 
1.3.2 Tobacco control initiatives 
It is well established that smoking is the major cause of lung cancer in Ireland and indeed 
worldwide and is, therefore, one of the most preventable cancers. Tobacco control 
measures are required to completely eliminate smoking from society and increase 
smoking cessation among smokers. Ireland has led the way with a number of initiatives 
with a view to Ireland being tobacco free by 2025. Some of those initiatives include; 
introducing standardised plain packaging of cigarettes, increasing the price of cigarettes 
through taxation, protecting people from second-hand smoke, making it illegal to smoke 
in cars where children are present, introduction of the workplace smoking ban, enforcing 
bans on advertising, promotion and sponsorship and helping people who want to quit 
(http://www.hse.ie/eng/about/Who/TobaccoControl/TCP/). Similar initiatives introduced 
in United states have markedly decreased smoking rates and the number of lung cancer 
occurrence [19] and it is hoped that through these programs that Ireland will see similar 
reductions in the uptake of smoking and lung cancer diagnosis.  
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1.4 Lung Cancer Classification 
Lung cancer can be histologically classified into two main groups: non-small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC) [20, 21].  
1.4.1 Non-Small Cell Lung Cancer 
NSCLC accounts for approximately 80% of lung cancers and is subdivided into 3 main 
subtypes; (i) adenocarcinoma (AD), (ii) squamous cell carcinoma (SCC) and (iii) large 
cell carcinoma (LCC). 
i. Adenocarcinoma is the most common form of lung cancer, accounting for 
approximately 40% of cases. It develops from mucus making cells in the lining of 
the airways and is often found in the outer, or peripheral, areas of the lungs. One of 
the subtypes of adenocarcinoma is bronchioloalveolar carcinoma (BAC) and have 
been associated with middle aged women. While smoking remains an important 
factor for most lung cancers, BAC is postulated to develop from previously scarred 
tissue such as inflammation or scar tissue as a result of tuberculosis [22, 23]. 
ii. Squamous cell carcinoma accounts for 25% to 30% of lung cancers. These cancers 
start in early versions of squamous cells, which are flat cells that line the inside of 
the airways in the lungs. They are often linked to a history of smoking and tend to be 
found in the middle of the lungs, near a bronchus. 
iii. Large cell carcinoma accounts for 10-15% of lung cancer and can appear anywhere 
in the lung. Treatment of this type of lung cancer can be challenging as it tends to 
grow and spread quickly. Large cell neuroendocrine carcinoma is a subtype; it is 
similar to small cell lung cancer. 
iv. Mesothelioma is also a subtype of NSCLC but is a much rarer type of cancer that 
affects the covering of the lung (the pleura). Diagnosis of mesothelioma can be 
difficult and caused by exposure to asbestos, which is an occupational risk in some 
professions  [24, 25]  
Genetic landscape of NSCLC 
Lung cancer genomes and signalling pathways have further defined NSCLCs as a group 
of distinct diseases with genetic and cellular heterogeneity. Modern treatment strategies 
focus on the pathological classification of NSCLC, including the assessment of protein 
expression by immunohistochemistry to assess cell differentiation markers such as TIF1 
and p63. A number of drugs have now been identified to specifically target molecular 
pathways that lead to lung cancer. Some of the most common genetic alterations targeted 
in NSCLC include BRAF, EGFR, ALK, ROS1, RET, MET, FGFR1, PTEN and PIK 
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oncogene and their prevalence, among others, in NSCLC are illustrated in Figure 1.4-1. 
Activating EGFR mutations were the first biomarkers to discriminate a molecular 
subpopulation in NSCLC patients. Patients with activating EGFR mutations then to show 
good prognostic value and benefit from treatment with EGFR tyrosine kinase inhibitors 
[26] 
Small molecule inhibitors that target the tyrosine kinase activity of EGFR, include 
erlotinib and gefitinib, were the first to be made clinically available. Table 1.4-1 indicates 
the current number of targeted therapies available for treatment of lung adenocarcinoma 
[20] some of which may prove to be important as the genetic landscape of NSCLC 
evolves. A study indicated differences in mutations identified in never smokers (EGFR 
mutations and ROS1 and ALK fusions) and smokers (KRAS, TP53, BRAF, JAK2, JAK3), 
indicating that the genomic landscape is markedly distinct in these two groups [27].  
PD-L1 is a checkpoint protein in cells called T-cells. It’s interaction with PD-1 and the 
B7.1 receptor on activated T cells plays an important role in tumour evasion of the host 
immune system [28]. PD-L1 was a significant poor prognostic factor in a 5 year follow 
up with patients with NSCLC, with PD-L1 positive patients having a poorer 5-year 
overall survival than PD-L1 negative patients. A number of MAb based immune therapies 
targeting either PD-1 or PD-L1 can boost the immune response against cancer cells and 
have shown great promise, Pembrolizumab and Nivolumab.  There are other MAbs being 
used for the treatment of NSCLC; Bevacizumab (Avastin) and Ramucirumab (Cyramza), 
they are humanised monoclonal antibodies used to treat advanced NSCLC which both 
target vascular endothelial growth factor (VEGF) [29, 30]. 
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Figure 1.4-1:- Evolving genomic classification of NSCLC 
 
Target Prevalence (%) Therapeutic agents 
EGFR 
Asians ~40%; 
Caucasians ~10 
Erlotinib, Gefitinib, Afatinib 
ALK < 5 Crizotinib 
Her2 < 3 Afatinib, Neratinib, Dacomitinib 
PIK3CA < 5 GDC-0941, XL-147, BKM120 
BRAF < 5 Vemurafenib, GSK2118436 
MEK < 1 AZD6244 
ROS1 ~1 Crizotinib 
RET ~2 Sunitinib, Sorafenib, Vandetanib, Cabozantinib 
MET 1-11 
Onartuzumab, Rilotumumab, Cabozantinib, 
Tivantinib, Crizotinib 
FGFR1 ~3 AZD4547, S49076, Ponatinib, Brivanib 
PTEN < 10 Vandetanib 
PD-1/PD-L1 ~30 Nivolumab, MPDL3280A 
NaPi2b ~70 DNIB0600A (early development) 
Table 1.4-1:- Current molecular targets and treatments for adenocarcinoma. 
Anaplastic lymphoma kinase (ALK); Epidermal Growth Factor Receptor (EGFR), Fibroblast 
Growth Factor Receptor 1 (FGFR1), Interaction of Programmed Death Ligand 1 (PD-L1), 
Phosphatidylinositol 3-kinase, catalytic subunit alpha (PIK3CA) [20]. 
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1.4.2 Small Cell Lung Cancer 
Small cell lung cancer (SCLC) is the lung neoplasia with the poorest outcome, due to its 
high metastatic potential and chemo-resistant phenotype upon relapse. It accounts for 
15% to 20% of all lung cancers and exhibits rapid growth, aggressive behaviour and a 
tendency for early metastasis to distant sites [31]. SCLC occurs exclusively in smokers, 
especially heavy smokers but is also common in former smokers [32]. If left untreated, 
the aggressive nature of SCLC usually results in the death of patients within 2-4 months 
[20]. 
A feature of the cells in SCLC is the dense neurosecretory granules, which give this 
tumour type an endocrine/paraneoplastic syndrome association. These neurosecretory 
granules are believed to contain a variety of secretory products (including neuroendocrine 
hormones), cell surface antigens and enzymes [33]. Incidence rates have increased more 
rapidly in women than men. Depending on the presence of metastasis diagnosis of SCLC 
is described as limited stage or extensive stage disease. Sixty to seventy percent of 
patients have extensive disease (which cannot be targeted within a single radiation 
therapy field) at presentation. Late stage disease cannot usually be targeted with single 
field radiation therapy.  
Although SCLC is a highly aggressive form of lung cancer it is responsive to 
chemotherapy and radiation, improving both quality of life and survival duration. Despite 
this good response to chemotherapy, patients with SCLC usually relapse within one to 
two years. Patients who experience a relapse tend to be more resistant to subsequent 
therapies, at which point different types of chemotherapies can be considered to help 
relieve symptoms and generally offer only a modest improvement of survival. A number 
of platinum based agents may be administered to patients at this point including; 
topotecan, cyclophosphamide and doxorubicin [34]. Combination therapies for the 
treatment of relapsed SCLC have been investigated involving platinum based agents and 
etoposide, vincristine, paclitaxel or irinotecan, their efficacies did not appear to be high 
enough compared to other standard topotecan therapy [35]. 
Alternative names for SCLC are oat cell cancer, oat cell carcinoma and small cell 
undifferentiated carcinoma [36]. SCLC is defined as a tumour with cells that are small in 
size, a round-to-fusiform shape, scant cytoplasm, finely granular nuclear chromatin and 
absent or inconspicuous nucleoli, nuclear moulding is frequent.  Necrosis is frequent and 
often extensive [37].  
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There are two main types of SCLC; 
i. SCLC (pure-SCLC) is primarily a neuroendocrine carcinoma. There are four main 
types of lung neuroendocrine tumours: typical carcinoid tumour (low grade 
malignancy), atypical carcinoid tumour (medium grade malignancy), large cell 
neuroendocrine carcinoma and small cell lung cancer (high grade malignancy) [38]. 
ii. Combined small cell lung carcinoma (c-SCLC) is currently the only recognised 
subtype of SCLC. It is small cell carcinoma combined with an additional component 
consisting of any non–small cell histologic type, including adeno-carcinoma, 
squamous cell carcinoma and large cell neuroendocrine carcinoma. Approximately 
30% of small cell lung carcinoma contain a non–small cell lung carcinoma 
component. Patients with cSCLC have a better overall survival, however, they are 
believed to have a poorer response to chemotherapy [39]. 
Genetic landscape of SCLC 
NSCLC has been widely researched to identify oncogenic drivers responsible for this type 
of lung cancers. However, researching oncogenic drivers in SCLC is lagging behind 
mainly due to the scarcity of patient material available for research use. Some genomic 
studies to date indicate high mutation rates in SCLC, possibly linked to mutagens in 
tobacco smoke. Loss of function of TP53 and RB1 tumour suppressors are the most 
striking alterations found in SCLC. The TP53 gene encodes a transcription factor which 
is activated in response to several forms of cellular stress, including hypoxia and other 
anti-proliferative effects. The presence of p53 and HIF-1α appears to be necessary for the 
hypoxia-induced cell death. The importance of TP53 gene in SCLC is indicated by its 
reported mutation frequency of 75 and 90% [40, 41]. Implications for MYC and 
phosphatidylinositol-3-kinase (PI3K) proto-oncogene have also been identified in SCLC. 
MYC are transcriptional activators that contribute to cell cycle progression but have an 
association with control of pluripotency, self-renewal and Epithelial to mesenchymal 
transition (EMT). PTEN (phosphatase and tension homolog) an inhibitor of the PI3K 
pathway was found to be lost in SCLC. Other genetic alterations in SCLC include 
mutations in CREBBP, EEP300 (histone acetyltransferases) and MLL, MLL2 and EZH2 
(histone methyltransferases). There are a number of targeted therapies in clinical trials for 
the treatment of SCLC some of which are outlined in Table 1.4-2 below. 
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Mechanism of 
action 
Targets Agents 
Inducers of 
apoptosis 
BCL2, BCL-W, BCL-XL, cl-1 AT-101, Oblimersen 
Kinase inhibitors 
AURKA, CDK, EGFR, FGFR, 
IGF1R, KIT, PDGFR, FLT3, 
MET, mTOR, PI3K, PLK1 
Alisertib, Roniciclib, 
Erlotinib, Gefitinib 
NE targeting GD2, GD3, NCAM, NTS1 
BIW-8962, BEC2, 
Lorvotuzumab 
Anti-
angiogenesis 
Matrix metalloproteinases, 
VEGF-A, VEGFB 
BAY12-9566, 
Bevacuzumab, Afliberept 
Immunotherapy CTLA-4, PD-1, TLR 
Ipilimumab, Nivolumab, 
Pembrolizumab, MGN1703 
Table 1.4-2:- Examples of targeted therapies for SCLC in clinical trials. 
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1.5 Heterogeneity in Breast Cancer  
Like lung cancer, breast cancer is also a complex and heterogeneous disease. Breast 
cancer is the second most common cause of cancer related death worldwide, after lung 
cancer and will account for approximately 72,330 deaths in the United States [42]. In 
Ireland, the Irish Cancer Society suggest that there are 2600 women diagnosed each year 
with breast cancer of which approx. 660 women die from the disease 
(www.irishcancersociety.ie).  
Heterogeneity in cancer cell phenotypes and dynamic plasticity of the tumour 
microenvironment make tumour categorization demanding in relation to therapeutic 
responses and disease progression. Molecular profiling and immunohistochemical 
expression of ERα, progesterone receptor (PR) and HER2 led to further classification into 
at least five molecular subtypes Luminal A, Luminal B, HER2, basal and normal. Luminal 
A and Luminal B due to their expression of ER may be treated with hormone therapy 
[43]. The histological and the molecular subtypes identified in breast cancer are illustrated 
in Figure 1.5-1 below. 
1.5.1 Luminal breast cancers 
This group represents the majority of diagnosed breast cancers accounting for 
approximately 60% of breast cancer cases. They typically comprise of tumours 
expressing estrogen receptor (ERs) and are generally broken down into two main 
subtypes: Luminal A is ER positive, HER2 negative, Ki-67 low, and PR high. Luminal B 
(HER2 negative) - ER positive, HER2 negative, and either Ki-67 high or PR low; Luminal 
B-like (HER2 positive)- ER positive, HER2 overexpressed or amplified, any Ki-67, and 
any PR; HER2 positive - HER2 over-expressed or amplified, ER and PR absent; and triple 
negative - ER and PR absent and HER2 negative [44]. Two ERs are known to exist ERα 
and ERβ. More than 70% of breast cancers are ER positive, so the determination of ER 
status has proved to be successful therapeutic target for treatment [45]. Some of the 
standard hormone therapies used to treat luminal breast cancers include tamoxifen 
displays anti-oestrogen activity upon binding which ultimately inhibits the oestrogen 
receptor. Aromatase inhibitors (e.g. anastrozole) which prevent the conversion of 
androgens to oestrogens resulting in a reduction in the amount of estrogen available to 
the oestrogen receptor. Fulvestrant (also known as Faslodex) prevents dimerization and 
nuclear localization by binding to the oestrogen receptor [46]. 
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Figure 1.5-1:- Histological and molecular subtypes in breast cancer. 
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1.5.2 Her2+ Breast Cancer 
Human epidermal growth factor receptor 2 (Her2) is a transmembrane protein that 
belongs to the ErbB/HER family of tyrosine kinases. The HER2 gene is amplified in up 
to 30% of breast cancers leading to an overexpression of HER2 receptor. This type of 
breast cancer is generally a more aggressive disease with higher recurrence rates and a 
poorer patient prognosis. Trastuzumab has become the standard treatment for patients 
with HER2 positive breast cancer. Patients receiving trastuzumab therapy have shown 
improved disease free and overall survival in a metastatic setting.  However, resistance to 
therapy is a problem with the use of multiple anti-Her2 antibodies, dual tyrosine kinase 
inhibitors, and antibody-drug conjugates, alone or in combination as some of the methods 
used to overcome resistance [46, 47]. One of the newer treatments for HER2+ breast 
cancer is an antibody drug conjugate (ADC), T-DM1 which was approved by the 
European Medicines Agency and the Food and Drug Administration (FDA). It is a 
compound developed by conjugation of trastuzumab and a potent maytansine-derived 
cytotoxic drug (DM1), using a stable thiolinker [48]. T-DM1 was shown to have 
antitumor effects by inhibiting cell division and inducing cell death. It is also very specific 
as an ADC showing minimal effect on non-cancerous cells [49, 50]. 
1.5.3 Triple Negative Breast Cancer 
Heterogeneity also exists in triple negative breast cancer (TNBC) one of the subtypes of 
breast cancer [51]. Within breast cancer, 15-20% are TNBC of which 85% are of the basal 
phenotype. TNBC are characterised as ER-ve, PR-ve & HER2-ve and are biologically 
aggressive and tend metastasize earlier [52]. Within TNBC, 6 additional molecular 
subtypes have been identified, 2 basal-like (BL1 and BL-2), an immunomodulatory (IM), 
a mesenchymal (M), a mesenchymal stem-like (MSL) and a luminal androgen receptor 
(LAR) [43]. Despite advances in treatment resistance to conventional therapy and 
metastasis remain the major causes of death in patients with TNBC. It is thought that the 
onset of metastasis may arise as a result of cells within a tumour with an ability to self-
renewal and tumour initiating abilities. These cells are often referred to as CSCs [53]. 
Currently, there is no targeted therapy available for the treatment of patients with TNBC. 
Therefore, TNBC represents a challenge to patients and clinicians due to the poor 
prognosis and fewer treatment options. In terms of managing TNBC, there are several 
agents being developed including some associated with EGFR (Cetuximab (Erbitux)), 
FGFR2 (FGFR inhibitors) in addition to VEGF inhibition, and mTOR (combination of 
cisplatin and mTOR inhibitors) [54, 55]. 
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1.6 Metastatic Process 
Patients presenting with lung cancer generally do so at a late stage, when metastasis has 
already occurred and therefore beyond the realm of treatment by surgery or radiotherapy. 
Ninety percent of deaths from solid tumours can be attributed to the metastatic spread of 
cancer cells [56]. Invasion and migration, therefore, play crucial roles in lung cancer 
metastasis, which ultimately allow the majority of lung cancers to develop un-noticed. 
While progress has been made in understanding cancer biology and the process of how 
cancer spreads, our understanding of the molecular mechanisms remains poor. Metastasis 
is the spread of malignant tumour cells from their primary site to a distant site or 
secondary site, via a multistep process known as the metastatic cascade. 
1.6.1 Epithelial to Mesenchymal Transition 
In the 1980s, Elizabeth Hay made initial observations which described epithelial to 
mesenchymal phenotypic changes in primitive streaks of chick embryos. Epithelial to 
mesenchymal transition (EMT) was initially known as “epithelial to mesenchymal 
transformation” is a cellular mechanism recognised as a central feature of normal 
development [57, 58]. 
EMT is a biological process that allows a polarized epithelial cell, which normally 
interacts with its basement membrane via its basal surface, to undergo multiple 
biochemical changes that enable it to assume a mesenchymal cell phenotype [59]. Cells 
with a mesenchymal phenotype have distinctive characteristics including enhanced 
migratory and invasive capacity, elevated resistance to apoptosis, greatly increased 
production of ECM components and in some cases stem-like properties. A number of 
distinct molecular processes are engaged in order to initiate an EMT and enable it to reach 
completion. These include activation of transcription factors, over-expression of specific 
cell-surface proteins, reorganization and expression of cytoskeletal proteins and 
production of ECM-degrading enzymes. The plasticity of EMT is revealed by the 
occurrence of the reverse process called mesenchymal-epithelial transition (MET), which 
involves the conversion of mesenchymal cells to epithelial cells; but little is known about 
this process.  
There are three classes of EMT: Type1 (associated with implantation, embryo formation, 
and organ development), Type2 (associated with wound healing, tissue regeneration, and 
organ fibrosis) and Type3 (associated with tumour growth and cancer progression) [59]. 
One hallmark of EMT is the downregulation or even loss of E-cadherin, which is an 
essential component of adherence junctions. E-cadherin binds with its extracellular 
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domain of an E-cadherin molecule of the neighbouring epithelial cell which stabilizes 
cell-to-cell contacts. Intracellularly, E-cadherin binds to β-catenin, α-catenin and p120-
catenin which mediates intracellular signalling and links adherence junctions to the actin 
cytoskeleton. The beginning of the metastatic process is believed to start with EMT. The 
basic process of an EMT is illustrated in Figure 1.6-1 below. 
 
 
Figure 1.6-1:- Process of epithelial-mesenchymal transition. 
An EMT involves a functional transition of polarized epithelial cells into mobile and ECM 
component–secreting mesenchymal cells. The epithelial and mesenchymal cell markers 
commonly used by EMT researchers are listed. Co-localization of these two sets of distinct 
markers defines an intermediate phenotype of EMT, indicating cells that have passed only partly 
through an EMT.  
 
Primary and secondary microenvironments are known to promote metastasis by gene 
products of metastatic cells and/or by direct cell-cell and paracrine interactions between 
cancer cells and stromal cells.  However, very few of the tumour cells released from a 
primary tumour lead to the development of metastasis, therefore the process of metastasis 
is said to be highly inefficient. The main steps involved in the development of metastasis 
are illustrated in Figure 1.6-2 [60]. However, these steps are briefly described below. To 
set up secondary tumours at a distant site, tumour initiating cells must; 
1. Dissociate and leave the primary tumour, through loss of expression of cell-cell 
adhesion molecules such as cadherin’s (e.g. E-cadherin/N-cadherin), selectins (e.g. 
PECAM, ALCAM, L1CAM) and integrin’s (e.g. α3, α5, α6, αv). 
2. Infiltrate the surrounding stroma, invade and migrate through the basement 
membrane of the endothelium of blood or lymphatic vessels using a plethora of 
proteases (e.g. MMPs, serine proteases, cathepsin D, cysteine cathepsin). 
3. Enter into the bloodstream by a process of intravasation, cells survive in the 
bloodstream by evading apoptosis (and anoikis - detachment mediated apoptosis) 
and elements of the immune system (macrophages, neutrophils). 
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4. By a process of extravasation, cells must then leave the vasculature, invade local 
stroma and develop their own microenvironment. Newly formed tumours require 
an oxygen supply, so the development of new blood vessels is stimulated through 
angiogenesis (e.g. VEGF, FDGF) [61, 62]. 
 
Figure 1.6-2:- The main steps involved in the formation of metastases  
Disseminated metastatic tumour cells present in these organs often undergo a period of 
dormancy, whereby cells (and tumours) can remain asymptomatic for years. Dormancy 
is becoming a recognised step in cancer progression as it may lead to the formation of 
tumours years later. Clinical dormancy is frequently observed in many types of tumours 
such as B-cell lymphoma, melanoma, breast cancer and prostate cancer [63]. Tumours 
which are clinically dormant typically show no signs of active disease and are said to be 
asymptomatic tumours. 
Dormant cells may be the source of disease recurrence. Cancer dormancy is poorly 
understood but there are mechanisms that can potentially explain this characteristic of 
tumours [64]. Tumour cells might exhibit a slowdown in the proliferation of the tumour 
cell population, this is known as tumour mass dormancy. In this mechanism, tumour cells 
are usually dividing but due to limitations in blood supply (or presence of an active 
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immune system), the tumour does not expand beyond a certain size. Other mechanisms 
of tumour dormancy result in the arrest of tumour cell growth, this is known as tumour 
cell dormancy or cellular dormancy. During this type of dormancy, tumour cells may 
enter a state of quiescence or senescence [65, 66]. Senescence is said to be an irreversible 
state of cellular growth arrest, while quiescent cells are in a state of ‘rest’ and can resume 
growth when more favourable environmental conditions arise [67].  
Cellular dormancy appears to be an active process that can be activated through a variety 
of signalling mechanisms that ultimately downregulate the RAS/MAPK and PI(3)K/AKT 
pathways. Cancer cells rely on these pathways for their growth and survival [68]. These 
pathways are the subject of intensive research in human cancers [69, 70]. Other 
mechanisms may also play a role in tumour dormancy; including genetic and epigenetic 
changes, cancer stem cells, tumour microenvironment, epithelial-mesenchymal transition 
and non-coding RNA manipulation [63].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
 
1.7 Development of animal models to study heterogeneity 
Traditionally, the mechanisms of cancer invasion and metastasis have been investigated 
in vitro, through the use of human tumour derived cell lines. Invaluable information can 
be gained from cell line based studies however, it does not represent the tumour 
environment [71]. While animal models do not represent the ideal model to study human 
cancers, they do offer the best method to study the growth and behaviour of cancer cells 
in vivo [72], but also to study the effect of potential drug treatments on xenograft tumours. 
This is one of the main advantages animal studies have in comparison to cell line based 
studies.  
Some examples of animal used for research include; mice, hamsters, rats, rabbits, 
zebrafish, Mouse models more than any other model system have revolutionised our 
ability to study gene function in vivo and to understand the molecular mechanisms driving 
cancer. There are several advantages when choosing mice as a model to study cancer, 
they are; (i) small in size (ii) inexpensive to maintain, (iii) produce rapidly and have large 
litters; and (v) are amenable to genetic manipulation [73]. Genetically engineered mouse 
models (GEMMs) have enabled numerous studies of non-small-cell-lung cancer that 
wouldn’t normally be possible using patient material. 
There are a number of criteria which should be considered when choosing genetically 
engineered mice (GEM) to study human tumours; (1) the mice must carry the same 
mutation that occurs in human tumours; (2) mutations should be engineered within the 
endogenous locus, and not expressed as a transgene (a transgene is a gene/genetic material 
that has been transferred from one organism to another either naturally or by any genetic 
engineering techniques); (3) mutated genes should be silent during embryogenesis and 
early postnatal development, (4) Mutations should be within the specific target tissues in 
selected cell types and (5) mutations must occur in a limited number of cells. Reproducing 
the tumour microenvironment is difficult to achieve in these mouse models, but should 
also be considered. This will help us to understand the interactions of tumour cells and 
cells of the tumour microenvironment, but also the impact of microenvironment has on 
tumour progression [74]. 
The discovery of the Prkdcscid (protein kinase, DNA activated, catalytic polypeptide) 
mutation was one of the turning points for animal based research. This mutation was first 
identified by Bosma et al., in BALB/c-lghb (CB-17/lcr) mice [75] and it results in the 
absence of Prkdc expression. Animal models are widely used to study cancer, and decades 
of breeding led to the identification and development of numerous strains for use by 
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researchers. Nude and SCID (Severe Combined Immune Deficient) mice are immune 
compromised, by their inability to generate enough T lymphocytes, in the case of nudes 
for the inability to produce any B or T lymphocytes, which are vital in mounting an 
immune response [76]. This is due to the absence of Prkdc expression that results in the 
failure of the VDJ (Variable, Diversity, Joining) rearrangement of lymphocyte antigen 
receptor genes. When considering Nude or SCID mice for animal studies, due to their 
immune deficient status they should be housed in sterile environments (environments free 
from pathogens). A phenomenon known as “leakiness”, was observed in some mice 
bearing the SCID mutation which resulted in the development of functional T and B 
lymphocytes [75]. However, leakiness was mainly observed in aging mice that housed in 
non-sterile environments (www.thejax.org).  
Genetically engineered mouse models (GEMMs) have enabled numerous studies of non-
small-cell-lung cancer that wouldn’t normally be possible using patient material. These 
immune alterations also allow foreign cancer cells to grow and develop in the xenograft 
models. Many studies have been carried out to investigate the factors involved in 
malignant transformation, invasion and metastasis, as well as to examine the response to 
therapy.  GEMMs for the most common driver mutations in NSCLC have been generated 
e.g. KRAS and EGFR (epidermal growth factor receptor) [77]. Some of these mouse 
models have been developed to study various cancers including colon cancer [78], renal 
adenocarcinoma [79], Prostate cancer [80] and lung cancer [81, 82].  
1.7.1 KRASG12D mouse model 
KRAS (also known as V-Ki-ras2 Kirsten rat sarcoma) is a guanine nucleotide transferase 
that can link cell surface receptors to intracellular signalling pathways including kinase 
cascades such as the MAPK pathway, lipid kinases such as phosphoinositide 3-kinase 
(PI3K), and other small molecular weight GTPases including Ral, Rac, and Rho. KRAS 
is known to regulate a number of processes such as cell proliferation, survival, 
differentiation, migration, and extracellular communication. It is an oncogene in approx. 
30% of human cancers, including the majority of lung adenocarcinomas, but are 
uncommon in lung squamous carcinomas. Mutational activation of KRAS generally 
results in aggressive cancers, which confers poor prognosis on patients harbouring the 
mutation. Patients with the KRAS mutation generally show a poor response to current 
therapies [83]. A number of attempts to target KRAS activity, but all appear to have failed 
clinically, for this reason, KRAS has been considered undruggable [84].  
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Mouse models have been developed to investigate the growth of tumours harbouring the 
KRAS mutation. One example is the conditional oncogenic KRASG12D mouse model has 
been used to elucidate the steps from early to late tumorigenesis, owing to the temporal 
controls it affords, and it is easy to combine with mice bearing conditional null alleles for 
other genes of interest. In these mice, KRASG12D tumours only reach a full 
adenocarcinoma stage with a very long latency but KRASG12D-expression and 
transformation related protein 53 (Trp53)-null (p53) tumours are more advanced and 
show a decreased response to certain treatment strategies when compared to KRASG12D 
tumours [85-87]. 
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1.8 Characteristics of DLKP and its clonal subpopulations 
It is well established that primary and metastatic tumours are heterogeneous in nature and 
are home to subpopulations of cancer cells that differ in their genetic, phenotypic and 
behaviour characteristics. Two theories have been described to explain the establishment 
and maintenance of tumour heterogeneity; the cancer stem cell (CSC) theory and the 
clonal evolution/selection model. Both had been thought to be exclusive from each other, 
however, the processes are now believed to be potentially complementary. Heterogeneity 
in tumours has its implications for the approach taken to personalised medicine as it can 
limit therapeutic efficacy, lead to resistance to therapies, impact the strategy taken for 
tumour biopsies and also interfere with the regimes associated with treatment planning 
[88-90]. 
1.8.1 History of DLKP 
DLKP is a human lung cancer cell line which was established by Dr. Geraldine Grant. 
The DLKP cell line was established from lymph node metastasis of a primary lung tumour 
which was initially described as a ‘poorly differentiated squamous cell carcinoma’. This 
tumour was taken from a 52-year old patient who was believed to have smoked 40 
cigarettes per day for most of his adult life. The karyotype of DLKP was previously 
determined  [91] to consist of a hyperdiploid subpopulation (65% of cells with 56 
chromosomes) and hypertetraploid subpopulation (35% of cells with 95-115 
chromosomes).  
DLKP was found to contain at least three morphologically distinct subpopulations, 
DLKPSQ, DLKPI and DLKPM. DLKPSQ resembled a squamous like morphology, with 
distinct cell boundaries and a cobble stone appearance. DLKPM resembled mesenchymal 
appearance with a fibroblast-like morphology, while DLKPI grew in tightly packed 
colonies with indistinct cell boundaries (Figure 1.8-1). The karyotype of the DLKP clones 
was also established; examination of the chromosome distribution found that DLKPM 
was near diploid having between 50-59 chromosomes in 60% of its population and was, 
therefore, the most homogenous. DLKPI was near tetraploid with 36% of its population 
containing 90-99 chromosomes and the remaining population containing 40-110 
chromosomes. DLKPSQ was found to contain 3 large chromosomal populations with 90-
99, 100-110, and 80-89 chromosomes. The morphological diversity seemed to be 
reflected in their respective chromosome numbers, however, the chromosomal 
distribution of the clones was not substantially found in the parental population [92, 93].  
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The ratio of clones present within the DLKP parental cell line seems to be tightly 
controlled through a model of interconversion proposed in previous studies performed by 
McBride, 1995. The model proposed that DLKPSQ may interconvert with DLKPI and 
DLKPI may interconvert with DLKPM. However, interconversion was not observed 
between DLKPSQ and DLKPM. It was therefore suggested that DLKPI resembled a 
potential stem cell-like population in DLKP with its ability to interconvert and give rise 
to both DLKPSQ and DLKPM-like cells.  
A core property of a stem cell is one with a self-renewal capacity. These initial studies 
also indicated that DLKP should be classified as either a variant small cell lung carcinoma 
or non-small cell lung carcinoma with neuroendocrine differentiation. Keratins are the 
first intermediate filament proteins detectable during foetal development and are among 
the most differentiation-specific proteins synthesised in epithelial cells. DLKP contains 
neurofilament and vimentin markers, but no keratin proteins were detected during early 
Immunohistochemical analysis. BrdU is a thymidine analogue capable of inducing 
epitheloid morphology and altering expression of neuroendocrine markers in SCC. Upon 
treatment with BrdU keratin 8 and keratin 18 appeared to be synthesised, and it was 
postulated that a posttranslational block on keratin can be reversed using agents such as 
BrdU [94]. 
 
 
Figure 1.8-1:- Growth and invasion characteristics of the DLKP clones in vitro.  
Morphology of DLKP clones on plastic (A, C and E) and visual analysis of the level of invasion 
of the DLKP clones (B, D and F) (original magnification = 100×, scale bar 50μm). 
 
DLKPSQ DLKPI DLKPM 
   
   
 
A 
B 
C 
D 
E 
F 
c c c 
 26 
 
In addition, later studies carried out on DLKP and its clones indicated that they displayed 
differences in the levels of in vitro invasion (Figure 1.8-1), migration and anoikis 
resistance. The DLKPSQ clone displays a poor invasive and migratory capacity, is 
anoikis resistant and displays low level expression of integrin-αv. The DLKPM clone 
displays a high invasive and migratory capacity but is anoikis sensitive. DLKPI clone 
displays an intermediate level of invasive and migratory capacity, with an intermediate 
ability to resist anoikis [95]. Both DLKPI and DLKPM display high adherence capacity 
to bind fibronectin and vitronectin, potentially explained by its increased expression of 
integrin-αv. There was also differences in expression of matrix-metalloproteinases 
(MMPs) which appear to correlate the invasive profile of the clones (Figure 1.8-1). 
DLKPSQ was previously found to express MMP2 and MMP10 at low levels, while 
MMP2 is expressed in DLKPI and MMP2 is expressed in DLKPM [95, 96].  
The DLKP parental cell line was previously used as a model to investigate the mechanism 
of resistance to adriamycin in vitro. Adriamycin is a drug commonly used to treat a variety 
of malignancies including lung and breast cancer. A proteomic comparison between 
DLKP parental vs. DLKPA (adriamycin resistant variant) identified 80 differentially 
regulated proteins including NDPK, RPA2, CCT2, HSP70 and Annexin. Many of the 
other proteins identified correlated with known targets of adriamycin resistance including 
DNA damage repair, apoptosis and ROS [97]. 
Previous attempts were made to identify specific markers for the DLKP clones, for which 
immunocytochemical methods were employed. These methods were qualitative and 
therefore did not allow for the quantitative analysis of expressed proteins. To date, no 
markers have emerged that can allow for the differentiation of individual DLKP clones 
in DLKP. Ideally, a good marker would be one that is expressed in 1 or 2 of the clones, 
but not in all 3 clones. Quantitative proteomic analysis could allow for the identification 
of proteins that are differentially expressed between the clonal variants and could 
potentially act as markers for the clones. Also, identification of such protein markers 
could provide the means to study the model of interconversion between the clones, as 
well as their potential involvement in cell invasion and migration. Identification of 
markers specific to the DLKP clones is also hugely important in the context of tumour 
heterogeneity because if cells within a given tumour have the ability to regenerate through 
a model of interconversion this could have implications for the effectiveness of 
treatments, (i.e. leading to renewed tumour growth after cessation of therapy). Therefore, 
any markers identified to differentiate each of the clonal subpopulations in DLKP, with 
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further investigation, could have the potential to be used in the development of more 
targeted or combination therapies allowing for more personalised treatment of patients 
with lung cancer. The phenotypic differences displayed within the DLKP cell line model 
presents an opportunity to explore both differences in expression of potentially 
biologically relevant proteins but also is a unique model to investigate tumour 
heterogeneity in lung cancer. 
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1.9 Aims of Thesis 
The aims of this thesis are as follows: 
1. To isolate and identify membrane associated proteins from DLKP, DLKPSQ, DLKPI 
and DLKPM and to carry out proteomic profiling to identify differentially expressed 
proteins that could be used as potential markers of the individual clones, but also to 
identify potentially novel proteins associated with lung cancer. 
2. To investigate the functional roles (in vitro) of selected proteins in lung cancer, using 
siRNA silencing. 
3. To examine the expression of selected proteins in human tumours and in 
representative cell lines (lung, pancreatic and breast cancers), using Western blot 
analysis and immunohistochemistry. 
4. To investigate the growth and potential tumour development of DLKP, DLKPSQ, 
DLKPI and DLKPM in vivo, using SCID mice.  
5. To investigate the expression of established markers associated with cancer 
progression (including; Ki-67, CD31, E-cadherin and N-cadherin) and the expression 
of the candidate protein markers in explanted tumour cells and xenograft tissues, 
from the in vivo study. 
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Chapter 2  MATERIALS AND METHODS 
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2.1 Cell lines and cell culture 
All cell culture work was carried out in class II laminar air-flow cabinets (NuAIR). Before 
and after use the laminar flow cabinet was cleaned with 70% industrial methylated spirits 
(IMS). Any items brought into the cabinet were also swabbed down with IMS. At any 
time only one cell line was used in the laminar flow cabinet and upon completion of work 
with any given cell line, 15 mins clearance was given to eliminate any possibilities of 
cross-contamination between the various cell lines. The cabinet was cleaned routinely 
with Virkon (Antech International, P0550) and IMS. Details pertaining to the cell lines 
used for the experiments are provided in Table 2.1-1. All cells were incubated at 37oC 
and where required, in an atmosphere of 5% CO2. Cell lines were maintained in their 
appropriate complete medium (Table 2.1-1) and subcultured, as per section 2.1.1, every 
2-3 days or as required in order to maintain active cell growth. 
2.1.1 Sub-culturing of adherent cell lines 
Waste cell culture medium was removed from the tissue culture flask and discarded into 
a sterile glass bottle. The flask was then rinsed out with 2-5mls trypsin/EDTA solution 
(0.25% trypsin (Gibco, 043-05090), 0.01% w/v EDTA (Sigma, E9884) solution in PBS 
(Oxoid, BRI4a)) to ensure the removal of any residual media. Depending on the size of 
the flask, 2-5ml of trypsin was then added to the flask, which was then incubated at 37oC, 
for approximately 5 mins until all of the cells detached from the inside surface of the flask 
monitored by microscopic observation. Adding an equal volume of complete media 
(described in Table 2.1-1) to the flask deactivated the trypsin. The cell suspension was 
removed from the flask and placed in a sterile universal container (Sterilin, 128A) and 
centrifuged (Beckman, Allergra™, 6KR centrifuge) at 1000rpm for 5 mins. The 
supernatant was then discarded from the universal and the pellet was suspended gently in 
complete medium. A cell count was performed and an aliquot of cells was used to seed a 
flask at the required density. All cell waste and media exposed to cells were autoclaved 
before disposal. 
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Cell line Details Source Complete Media 
DLKP parent 
Human poorly differentiated 
lung carcinoma 
NICB DMEM-HAMS-F12, 5% FCS 
DLKPSQ 
(McBride et al., 1998) 
Squamous-like subpopulation 
clone of DLKP 
NICB DMEM-HAMS-F12, 5% FCS 
DLKPI 
Intermediate sub-Population 
cloned from DLKP 
NICB DMEM-HAMS-F12, 5% FCS 
DLKPM 
Mesenchymal-like clone of 
DLKP 
NICB DMEM-HAMS-F12, 5% FCS 
SQ-Mitox-BCRP-6P 
Mitoxantrone selected variant of 
DLKPSQ 
NICB DMEM-HAMS-F12, 5% FCS 
DLRP 
(Law et al., 1992) 
Human poorly differentiated 
lung carcinoma 
NICB DMEM-HAMS-F12, 5% FCS 
NCI-H69 Small cell lung carcinoma NICB RPMI 1640, 10% FCS 
NCI-H82 Small cell lung carcinoma NICB RPMI 1640, 10% FCS 
DMS-53 Small cell lung carcinoma NICB RPMI 1640, 10% FCS 
NCI-H460 Lung large cell carcinoma NICB RPMI 1640, 10% FCS 
NCI-H1229 Lung large cell carcinoma NICB 
RPMI 1640, 5% FCS, 1mM Na 
Pyruvate 
A549 Lung adenocarcinoma NICB DMEM-HAMS- F12, % FCS 
SK-LU-1 Lung adenocarcinoma NICB 
MEM, 5% FCS, 1% NEAA, 1mM 
Na Pyruvate 
SK-MES-1 Squamous cell lung carcinoma NICB DMEM-HAMS-F12, 5% FCS 
HCC-1937 Triple Negative Breast Cancer ATCC RPMI 1640, 10% FCS 
HCC1143 Triple Negative Breast Cancer ATCC RPMI 1640, 5-10% FCS 
MDA-MB-468 Triple Negative Breast Cancer ATCC RPMI 1640, 10% FCS 
CAL-85-1 Triple Negative Breast Cancer ATCC 
DMEM, 10% FCS, 2mM L-Glut, 
1mM Na pyruvate 
HDQP-1 Triple Negative Breast Cancer ATCC DMEM, 10% FCS 
CAL-51 Triple Negative Breast Cancer ATCC 
DMEM, 5-10% FCS, 1% Na 
pyruvate, 2mM L-Glut 
Hs-578-T Triple Negative Breast Cancer ATCC 
DMEM, 10% FCS, 0.01mg/ml 
insulin 
MDA-MB-231 Triple Negative Breast Cancer ATCC RPMI 1640, 10% FCS 
MDA-MB-157 Triple Negative Breast Cancer ATCC RPMI 1640, 10% FCS 
BxPc-1 Pancreas adenocarcinoma ATCC 
RPMI 1640, 5% FCS, 1mM Na 
pyruvate 
HPAC Pancreas adenocarcinoma ATCC RPMI 1640, 10% FCS 
Panc-1 Pancreas adenocarcinoma ATCC DMEM, 10% FCS, 2mM L-Glut 
MiaPaca2 Pancreas adenocarcinoma ECACC DMEM, 5% FCS 
MiaPaca2 clone3 
Pancreas adenocarcinoma clone 
of MiaPaca2 
NICB DMEM, 5% FCS 
AsPc-1 
Pancreatic adenocarcinoma from 
metastatic ascites 
ATCC RPMI 1640, 10% FCS 
Capan-1 
Liver metastasis of pancreas 
adenocarcinoma 
ATCC DMEM, 20% FCS, 2mM L-Glut 
SW480 
Dukes’ type B colorectal 
adenocarcinoma 
ATCC RPMI 1640, 10% FCS 
SW620 
Dukes’ type C colorectal 
adenocarcinoma 
ATCC RPMI 1640, 10% FCS 
SNB-19 Glioma DSMZ DMEM, 5% FCS 
Lox IVMI Human melanoma NICB RPMI 1640, 10% FCS 
SK-N-SH Neuroblastoma NICB DMEM-HAMS-F12, 5% FCS 
Table 2.1-1:- Description of cell lines used in during this project. 
ATCC: - American Type Culture Collection, Rockville, MD, USA. 
DSMZ: - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German 
Collection of Microorganisms and Cell Cultures). 
ECACC: - European Collection of Animal Cell Cultures, Salisbury, Wiltshire, UK. 
NICB: - National Institute for Cellular Biotechnology, DCU, Dublin, Ireland. 
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2.1.2 Sub-culturing of suspension/aggregate cell lines 
The cell suspension was removed from the flask and placed in a sterile universal container 
and centrifuged at 1000rpm for 5 mins. The supernatant was then discarded from the 
universal container and the pellet was re-suspended in complete medium. The aggregates 
were broken up by gently pipetting the suspension up and down using a 10ml pipette. An 
aliquot of the cell suspension was used to seed a flask. 
2.1.3 Assessment of cell number 
Prior to cell counts, cells were prepared for sub-culturing as detailed in section 2.1.1 and 
section 2.1.2. An aliquot was then applied to the chamber of a glass coverslip-enclosed 
haemocytometer. For each of the four grids, cells in the 16 squares were counted. The 
average of the four grids was multiplied by a factor of 104 (volume of the grid) and the 
relevant dilution factor to determine the average cell number per ml in the original cell 
suspension. On this basis, the cell number per ml could be calculated. The cell pellet was 
then resuspended in an appropriate volume to obtain a cell suspension of 1x106cells/ml. 
2.1.4 Cryopreservation of cells 
Cells for cryopreservation were harvested in the log phase of growth as described in 
section 2.1.1 and section 2.1.2. Cell pellets were re-suspended in a suitable volume of 
serum. An equal volume of a 10 - 20 % DMSO (Sigma, D2438)/serum solution was added 
dropwise with mixing, to the cell suspension. The cell suspension was then aliquoted in 
1ml volumes to cryovials (Greiner, 122278) and immediately placed at -20oC for up to 
four hours. After four hours, the cryovials were transferred to -80oC for short term storage, 
after which the vials were gradually transferred to the liquid phase of liquid nitrogen for 
long term storage (-196oC). 
2.1.5 Thawing of cryopreserved cells 
A volume of 5ml of fresh growth medium containing serum was added to a sterile 
universal. The cryopreserved cells were removed from the liquid nitrogen and thawed at 
37oC quickly. The cells were removed from the vials and transferred to the aliquoted 
media (also at 37oC). The resulting cell suspension was centrifuged at 1000rpm for 5 
mins. The supernatant was removed and the pellet re-suspended in fresh culture medium. 
Cell viability of thawed cells was noted. Thawed cells were then added to an appropriately 
sized tissue culture flask with a suitable volume of growth medium and allowed to attach 
overnight. The following day, flasks were re-fed with fresh media to remove any 
remaining DMSO and non-viable cells. 
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2.1.6 Monitoring of sterility of cell culture solutions 
Sterility testing was performed in the case of all cell culture media and cell culture related 
solutions. Samples of prepared basal media were incubated at 37oC for a period of seven 
days. This ensured that no bacterial or fungal contamination was present in the media or 
the solutions. 
2.1.7 Serum batch testing 
To prevent batch to batch variation in foetal calf serum (FCS) which is a common problem 
in cell culture, a range of FCS batches were screened and the most suitable were chosen 
for a block of work (HyClone®, ThermoFisher Scientific, SV30143.03). Screening 
involved growing cells in 96-well plates and growth was recorded as a percentage of 
growth of a serum with known acceptable growth rate.  
More specific screening involved performing invasion assays to determine the effects of 
different batches of serum on the ability of particular cell lines to invade through an 
extracellular matrix, in vitro. Invasion assays were performed and evaluated as per section 
2.4.1. 
2.1.8 Indirect mycoplasma analysis of cell lines 
Mycoplasma testing was carried out quarterly, using the indirect method. Mycoplasma-
negative NRK (normal rat kidney fibroblast) cells were used as indicator cells for this 
analysis. NRK cells were seeded onto 35mm petri dishes (Sigma) in DMEM 
supplemented with 10% FCS. A 1ml volume of conditioned medium (from test cell lines) 
was inoculated onto the petri-dishes containing NRK cells and incubated for 4 days at 
37oC in a 5% CO2 atmosphere. Prior to inoculation, test cell lines must be in log phase of 
growth, passaged a minimum of 3 times, free from antibiotics and the conditioned 
medium collected from cell lines must be at least 3 days old. Cells were fixed in Carnoys 
Fixative (1 part of glacial acetic acid to 3 parts of methanol at -20oC) at a ratio of 50:50 
Carnoys: PBS. A fluorescent Hoechst stain was used in for analysis. The stain binds 
specifically to DNA and so stains the nucleus of the cells in addition to any mycoplasma 
present. Mycoplasma infection was indicated by fluorescent bodies in the cytoplasm of 
the NRK cells. The analysis was performed by Michael O’Donohoe or Michael Henry. 
Cell lines used throughout this thesis were mycoplasma negative. 
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2.2 Proteomic analysis 
Proteomic analysis detailed in this thesis was carried out with the help and guidance of 
Dr. Paul Dowling and Mr. Michael Henry. 
2.2.1 Cell surface membrane protein Isolation 
Isolation of cell surface proteins was carried using the Cell Surface Isolation kit 
(ThermoFisher Scientific, 89881). This kit used a biotinylation approach to efficiently 
label proteins with accessible lysine residues and sufficient extracellular exposure. The 
process uses a cell impermeable, cleavable biotinylation reagent to label exposed primary 
amines of proteins on the cell surface of intact cells. Biotinylation is a rapid and specific 
process of covalently attaching biotin to a protein. Biotin has a high affinity to streptavidin 
and avidin so proteins can be easily recovered for examination. 
DLKP, DLKPSQ, DLKPI and DLKPM cell lines were obtained from NICB culture 
collection. Cell lines were maintained in 75cm2 flasks in DMEM/Hams-F12 
supplemented with 5% FCS at 37oC in an atmosphere of 5% CO2. Cells were cultured 
until they were approximately 90-95% confluency before treated and processed as per 
manufacturer’s instructions. Triplicate biological replicates of cell surface proteins were 
isolated from all four cell lines. Briefly, for labelling and lysis, cells were treated using 
Sulfo-NHS-SS-Biotin on a rocking platform for 30 mins at 4oC, followed by lysis and 
multiple sonication steps. To isolate labelled proteins, the clarified supernatant was added 
to washed NeutrAvidin agarose slurry and incubated for 60 mins at room temperature 
with end over end mixing on a rotator, after which agarose beads were washed using wash 
buffers. Protein elution was performed during a 60 min incubation at room temperature 
with end over end mixing using 50 mM DTT in PBS. 
2.2.2 In-solution tryptic digestion 
Initial preparation of individual protein fractions for LC-MC/MS analysis was carried out 
by buffer exchange overnight by acetone precipitation. Protein pellets were resuspended 
in Label-Free buffer solubilisation buffer containing 6 M urea, 2 M thiourea, 10 mM Tris, 
pH 8.0 in LC-MS grade water. Re-suspended protein samples were then carefully 
vortexed, sonicated and centrifuged to ensure pellets were fully resuspended. For label-
free MS analysis, volumes were initially equalised with label free buffer and kept to a 
minimum. Protein was re-quantified using the Quick Start Bradford assay kit (Bio-Rad, 
5000201) and 5 µg of each sample were reduced for 30 mins at 56oC with 10 mM DTT 
in 50 mM ammonium bicarbonate. The samples were then alkylated for 20 mins in the 
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dark with 25 mM iodoacetamide in 50 mM ammonium bicarbonate. A final volume of 
0.1% ProteaseMAX (v/v) was added to each fraction and protein digestion was carried 
out using sequencing-grade trypsin at a ratio of 1:20 (protease: protein) overnight at 37oC. 
Ahead of mass spectrometry, digestion was stopped by adding Trifluoroacetic Acid 
(TFA) to a final concentration of 0.5% (v/v). Peptide suspensions were purified using 
Pierce C18 Spin Columns (ThermoFisher Scientific, 89870) and the resulting peptide 
samples were dried through vacuum centrifugation and suspended in 25µl of loading 
buffer consisting of 2% acetonitrile (ACN) and 0.05% TFA in LC-MS grade water. 
Protein suspensions were vortexed and sonicated again to ensure an even suspension. 
2.2.3 Label-Free Liquid chromatography mass spectrometry Analysis 
An Ultimate 3000 nanoLC system (Dionex Corporation, Sunnyvale, CA, USA) coupled 
to an LTQ Orbitrap XL mass spectrometer from ThermoFisher Scientific (Dublin, 
Ireland) was used for the nano LC-MS/MS analysis of differentially expressed proteins 
from cell surface protein preparations of DLKP, SQ, I and M, as previously described. 
Digested peptide mixtures (5 l volume) were loaded onto a C18 trap column (C18 
PepMap, 300 m id × 5 mm, 5 m particle size, 100 Å pore size; Dionex). Desalting was 
carried out at a flow rate of 25 l/min in 0.1% TFA and 2% ACN for 5 min. The trap 
column was switched on-line with an analytical PepMap C18 column (75 m id × 500 
mm, 3 m particle, and 100 Å pore size; Dionex). Peptides generated from skeletal 
muscle proteins were eluted with the following binary gradients: solvent A (2% ACN and 
0.1% formic acid in LC-MS grade water) and 0%–25% solvent B (80% ACN and 0.08% 
formic acid in LC-MS grade water) for 240 min and 25%–50% solvent B for a further 60 
min. The column flow rate was set to 350 nL/min. Data was acquired with Xcalibur 
software, version 2.0.7 (ThermoFisher Scientific). The MS apparatus was operated in 
data-dependent mode and externally calibrated. Survey MS scans were acquired in the 
Orbitrap in the 400–1800 m/z range with the resolution set to a value of 30,000 at m/z 
400 and lock mass set to 445.120025 u. CID fragmentation was carried out in the linear 
ion trap with up to three of the most intense ions (1+, 2+ and 3+) per scan. Within 40 s, a 
dynamic exclusion window was applied. A normalised collision energy of 35%, an 
isolation window of 3 m/z, and one microscan were used to collect suitable tandem mass 
spectra. 
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2.2.4 Quantitative Profiling of Label-Free LC-MS/MS Analysis 
Progenesis label-free LC-MS software version 3.1 from Non-Linear Dynamics 
(Newcastle upon Tyne, UK) was used to process the raw data generated from LC-MS/MS 
analysis. Data alignment was based on the LC retention time of each sample, allowing 
for any drift in retention time given and adjusted retention time for all runs in the analysis. 
A reference run was established with the sample run that yielded most features (i.e., 
peptide ions). The retention times of all of the other runs were aligned to this reference 
run and peak intensities were then normalized. Prior to exporting the MS/MS output files 
to MASCOT (www.matrixscience.com) for protein identification, a number of criteria 
were employed to filter the data. This included (i) peptide features with ANOVA ≤ 0.05 
between experimental groups, (ii) mass peaks (features with charge states of +1, +2 and 
+3, and (iii) greater than one isotope per peptide. A MASCOT generic file was used for 
peptide identification using proteome discoverer 2.0 (ThermoFisher Scientific) against 
MASCOT (version 2.2) and Sequest HT (SEQUEST HT algorithm, licence 
ThermoScientific, registered trademark University of Washington, USA) and was 
searched against the UniProtKB-SwissProt database (downloaded January 2015, 
taxonomy: Homo Sapiens). The following search parameters were used for protein 
identification. (i) peptide mass tolerance set to 20ppm, (ii) fragment mass tolerance set to 
0.02 Da, (iv) up to two missed cleavages were allowed, (v) carboxymethylation set as a 
fixed modification, (vi) methionine oxidation set as a variable modification. For re-
importation back into Progenesis LC-MS software, further analysis on only peptides with 
ion score set to minimum of 40.00 of more (from Mascot) and Sequest HT XCorr set to 
minimum of >1.9 for singly charged ions, >2.2 for doubly charged ions and >3.75 for 
triply charged ions or more (from SEQUEST HT) were selected. Target FDR for PSMs 
and peptide validation, peptide and protein filtering, protein scoring, protein FDR 
validation, protein grouping and ProteinCenter annotation was carried out. The 
ProteinCenter annotation node retrieves from the ProteinCenter information from Gene 
Ontology (GO) database, protein annotations from the Ensembl database and PTM 
modifications from the UniProt database. All protein identifications for each sample were 
exported to Microsoft Excel [98, 99]. 
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2.3 Western blot analysis 
2.3.1 Preparation of whole cell lysates 
Cells were grown to 80 - 90% confluency in culture flasks (T75cm2 flask), media was 
removed, cells were washed 3 x in ice cold PBS and then removed. 500 μl (per T75cm2 
flask) or 1 ml (per T175cm2 flask) of RIPA lysis buffer (Sigma, R0278) containing 1X 
Halt protease/phosphatase inhibitor cocktail (ThermoScientific, 78440) and incubated on 
ice for 30 mins with regular agitation. Following centrifugation at 16,000 g (Eppendorf) 
for 5 mins at 4°C, the resulting lysate was stored at -80°C.  
2.3.2 Preparation of membrane proteins 
Membrane proteins were isolated from cells using the ProteoExtract Native Membrane 
Protein Extraction Kit (Calbiochem, 444810) and used according to the manufacturer’s 
instructions. Samples were stored at -80oC. 
2.3.3 Preparation of conditioned medium 
Cells were seeded (1x106cells: DLKP and DLKPM, 1.25x106cells: DLKPI-and 
1.5x106cells: for DLKPSQ) in three biological replicates in T175cm2 flasks and cultured 
for 72 hrs or until 50-60% confluent. Cells were washed x 3 in serum-free media (SFM, 
DMEM/Hams-F12) and incubated in SFM (10 ml/T175cm2 flask) for 60 mins. After this 
time, cells were washed again x 3 in SFM, 30 mls of SFM was added to the cells and 
incubated for a further 72 hrs. After such time, conditioned media was collected, 
centrifuged for 5 min at 1000 rpm and filtered through 0.22μm filter. CM samples were 
kept on ice until required or stored at 4oC for no longer than 24hrs prior to concentration.  
To concentrate conditioned media, 20mls was added to a Vivaspin20 concentrator with a 
5kDa molecular weight cut off (Sartorius, VS.0112) and centrifuged at 4oC at 4000rpm 
(ThermoFisher Scientific, 11175774) until the final volume 10 times the original volume 
(e.g. 10 mls to 1 ml). The sample was removed and then stored in aliquots at -80oC.  
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2.3.4 Protein Quantification 
Protein levels were determined using the Pierce™ BCA Protein assay kit (ThermoFisher 
Scientific, 23225) or the QuickStart Bradford protein Assay Kit (Bio-Rad, 5000201) as 
follows: 
2.3.4.1 BCA protein assay 
Protein in whole cell preparations (prepared in RIPA buffer), Membrane enriched 
samples and CM was quantified using the Pierce BCA Protein Assay Kit (Thermo-Fisher 
Scientific, 23227) as per the manufacturer’s instructions. 
2.3.4.2 Bio-Rad protein assay 
The Quick Start Bradford assay kit (Bio-Rad, 5000201) was used for protein samples 
prepared in 2D lysis buffer (20 mM Tris, 7 M Urea, 2 M Thiourea, 4% CHAPS, pH 8.5). 
A protein standard curve (0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.5mg/ml) was prepared from the 
BSA stock with dilutions made in UHP and stored at -20oC. A 20 µl volume of protein 
standard dilution or sample (diluted 1:4 to 1:8) was added to appropriate wells of a 96-
well plate. A 250 µl of the Bradford reagent dye was then added to each well and 
incubated at room temperature for 5 mins. All samples were assayed in triplicate. 
Absorbance was assessed at 570nm. The concentration of the protein samples was 
determined from the plot of absorbance at 570nm versus the concentrations of the 
standard curve. 
Protein concentrations obtained using both protein quantifications were adjusted relative 
to the dilutions (e.g. If a 1:4 dilution was used to obtain a concentration of X µg/ml, then 
the value for X was multiplied by 4). 
2.3.5 Gel Electrophoresis 
Protein samples for Western blotting were separated by SDS-PAGE gel electrophoresis, 
using 4-12% gradient gels (ThermoFisher Scientific, NP0335, NP0321). Approximately 
15μg (for whole cell lysates), 8μg (for membrane proteins) and 30ug (for conditioned 
medium) of protein in 4x sample buffer (ThermoFisher Scientific, NP0007) was applied 
to each well of the polyacrylamide gel. Pre-stained molecular weight markers 
(ThermoFisher Scientific, LC5800) were also loaded onto the gel for the determination 
of the molecular weight of the protein samples. Gels were run at 200 volts and 250 
milliamps for 1 hour with 1× MOPS, Tris/ Glycine/ SDS running buffer (ThermoFisher 
Scientific, NP0001). 500 μl of antioxidant (NP0005) was then added to the inner chamber 
of the Xcell SureLock® minicell (EI0001) electrophoresis gel-rig. When the dye front of 
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the samples and the molecular weight markers had reached the end of the gel, 
electrophoresis was stopped.  
2.3.6 Enhanced Chemiluminescence detection 
Proteins were transferred to Polyvinylidene fluoride (PVDF) membranes (ThermoFisher 
Scientific, IB4010-01) using the iBlot transfer system (ThermoFisher Scientific, IB1001). 
The membrane was blocked with 5% milk powder (Biorad, 170-6404) in TBS/Tween (1x 
TBS (Sigma, T5912) and 0.1% Tween20 (Sigma, P1379-500ml)) at room temperature 
for 2 hours, then incubated overnight at 4°C in primary antibody (Table 2.3-1) diluted 
with 0.1 % TBS-Tween in 5 % milk powder. The membrane was washed three times with 
0.5 % TBS-Tween and then incubated at room temperature with secondary antibody 
(Table 2.3-1) in 5 % milk powder with 0.5 % TBS-Tween for 1 hour. The membrane was 
washed three times with 0.5 % TBS-Tween followed by one wash with TBS alone. 
Following the final wash, membranes were incubated for 5mins with 3 ml (for a full 
membrane) of a 50:50 mixture of ECL reagent A and ECL reagent B (Amersham, ECL, 
RPN 2105 or Clarity, BioRad, 170506). Immunoblots were developed using ECL 
reagents which facilitated the detection of bound peroxidase conjugated secondary 
antibody. While developments have made in the way which Western blots are developed 
such as the use of Chemiluminescence imaging systems (e.g. BioRad Chemidoc imaging 
system or ThermoFisher Scientific, MyECL imager), darkroom facilities were used for 
the duration of this thesis. In the darkroom, the PVDF membranes were exposed to 
Amersham HyperfilmTM, Chemiluminescence film (GE Healthcare, 28906837) for 
various times (from 10 seconds to 30 mins depending on the signal). The exposed auto-
radiographic film was developed for between 45 seconds to 1 mins in the developer 
(Kodak, LX-24). The film was then transferred to a fixative (Kodak, FX-40) for 2 mins. 
The film was rinsed with water for 2 mins and left to dry at room temperature. Once dry, 
the blots were then converted into a digital format using Epson Perfection photo scanner 
4990 and Epson Scan software version 3.04a. 
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 Antibody Concentration/Dilution Company 
Primary 
Antibodies 
ALCAM 1:1000 Abcam (ab109215) 
HDGF 1:1000 Abcam (ab128921) 
INA 1:7500 Abcam (ab40758) 
IQGAP1 1:1500 Abcam (ab86064) 
SLIT2 1:1000 Abcam (ab134166) 
SPR 1:6000 Abcam (ab157194) 
GAPDH 1:2000 R&D Systems 
α-tubulin 1:40000 
Sigma Aldrich 
(T9026) 
Secondary 
Antibodies 
Swine Anti-Rabbit HRP 1/2000 Dako (P0399) 
Goat Anti-Mouse HRP 1/2000 Dako (P0477) 
Goat Anti-Rabbit HRP 1/2000 Dako (P0448) 
Table 2.3-1:- List of antibodies and the dilutions used in Western blot analysis 
To control for protein loading, blots were probed with an antibody specific to α-Tubulin 
or GAPDH for whole cell lysates (Table 2.3-1). It was more difficult obtain an appropriate 
housekeeping antibody against specific proteins in membrane enriched samples and 
conditioned medium samples, in this case, a coomassie stain was used to control for equal 
loading (see section 2.3.7). 
2.3.7 Staining - Brilliant Blue G colloidal coomassie staining of gels 
After electrophoresis, the gels containing membrane enriched samples and conditioned 
medium samples were placed into a square petri dish (Sigma, Z617679) containing a 
solution of Brilliant Blue G colloidal Coomassie. A working solution of 50mls prepared 
(32mls of UHP, 8mls of Brilliant Blue G colloidal Coomassie and 10mls of methanol) 
and then applied to the gels for at least 2 hours at room temperature on a rotating platform. 
After this time the coomassie stain was removed and gels were destained in UHP 
overnight with regular changes of UHP. Coomassie stained gels when required were used 
to ensure equal protein loading in these sample types. 
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2.4 Functional analyses 
2.4.1 In vitro invasion assays 
Matrigel (BD Biosciences, 354234) was diluted to a working stock of 1mg/ml in serum- 
free DMEM. Aliquoted stocks were stored at -20oC for up to 1 year. Invasion assays were 
performed using the method modified from [100]. 
Matrigel was removed from the freezer and allowed to thaw overnight on ice at 4oC. A 
volume of 100 μl of matrigel was placed into each insert (BD Biosciences, 353097) 
(8.0μm pore size, 24-well format) and kept at 4oC for 24 hours. The insert and the plate 
were then incubated for one hour at 37oC to allow the proteins to polymerise. To remove 
excess matrigel/media, each well was rinsed by gently by adding 150 μl of warm SFM to 
each insert containing matrigel. This media was then gently removed, all the time trying 
not to disturb the thin layer of matrigel. Cells were harvested and re-suspended in culture 
media containing 5% FCS at 1×106 cells/ml. 100 μl of media (or test solution) was then 
added to each insert followed by 100 μl of the cell suspension (at the optimised cell 
number) to each insert. Finally, 500 μl of culture media containing 5% FCS was added to 
the well underneath the insert and cells were incubated for 24 hours.  
To investigate the effect of the inhibitors DFMO (Sigma, D193) and L-NNA (Sigma 
N5501) on cell invasion, cells were seeded in culture media containing 5% FCS and 
DFMO (2.5 mM and 5 mM) or L-NNA (150μM), see Table 2.5-1. Appropriate 
concentrations of inhibitor were added to the underneath of the insert in 500 μl of media 
containing 5% FCS.  
After a 24-hour incubation, the media was removed from the inside of the insert and the 
insert was wiped with a cotton swab dampened with PBS. The outer side of the insert was 
stained with 0.25% crystal violet for 10 mins and then rinsed in Ultrapure water (UHP) 
and allowed to dry. The inserts were viewed and photographed under the microscope. 
The invasion assays were quantified by counting cells in 10 random fields within a grid 
at 20x objective and graphed as the total number of cells invading at 200× magnification 
(section 2.4.2.1). A minimum of 2 inserts was used per sample tested. 
2.4.2 In vitro migration assay 
Migration assays were carried out as described in section 2.4.1, without the addition of 
extracellular matrix proteins. 
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% Anoikis = (1-(delta OD of unattached cells/delta OD of attached cells)) *100 
2.4.2.1 Determination of total number of invading or migrating cells 
To determine the total number of invading or migrating cells within an assay, the average 
number of invading or migrating cells (of 10 random fields) per insert was multiplied by 
a factor of 140 (growth area of the membrane divided by the area of the field viewed at 
200x magnification), giving the total number of invading cells per insert. The total 
number of invading or migrating cells were then imported into excel and displayed on a 
histogram chart. 
2.4.3 ROS assay 
Cells were set up at 4x104 cells/well in duplicate wells of a 24-well plate. After overnight 
incubation, the cells were washed with Hanks Balanced Salts solution (HBSS) and one 
well was exposed to HBSS and the other to the dye DCFDA at 10uM for 10 mins at 37oC. 
After the incubation, each well was washed twice with HBSS and exposed to fresh 
medium (ATCC + 5% FCS) or to fresh medium containing 100µM H2O2 for 2hrs at 37
oC.  
The wells were then washed with HBSS and 1 ml of fresh HBSS added to each well. The 
fluorescence was measured with an excitation of 485nm and emission at 525nm.  Cell 
counts were then made to compare the ROS generated per cell. 
2.4.4 Anoikis assay 
Cells were set up at 1x105 cells/well in duplicate wells of a 24-well plate and a 24-well 
ultra-low attachment plate (Sigma, CLS3473-24EA) to a final volume of 1ml of 
DMEM/Hams-F12 with 5% FCS. Cells were allowed to incubated for a total of 24 hours. 
At 21 hours, 100µl of Alamar blue (ThermoFisher Scientific, DAL1100) was added to 
each well and allowed to incubate for the remaining 3 hours. Plates were read in a dual 
beam plate reader at 570 nm with a reference wavelength of 600nm. Percent anoikis was 
determined using following equation: 
 
2.4.5 Statistical analysis 
A minimum of two replicates was used per sample and three separate biological replicates 
were performed. Triplicate biological replicates refer to a single experiment that was 
carried out in duplicate on three separate occasions e.g. three different passage numbers 
of a particular cell line. For each experiment, assays were performed weekly or bi-weekly 
until triplicate assays displayed agreement. Histograms were plotted using mean (average 
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between triplicate assays) values from triplicate experiments. Error bars were applied to 
each graph indicating plus and minus standard deviations.  
All assays were then subjected to statistical analysis using student’s t-test (two-tailed, 
equal variance, unpaired) in Microsoft Excel 2016. Using Microsoft Excels t-test function 
with mean figures calculated between replicates, a p value was obtained. The p value 
measures the probability that the differences between the control and test samples would 
be observed by chance.  
A p value of ≤ 0.05 was considered significant and assigned *  
A p value of ≤ 0.01 was considered more significant and assigned ** 
A p value of ≤ 0.005 was considered highly significant and assigned *** 
In siRNA experiments, scrambled siRNA or negative control siRNA transfected cells 
were used as controls and were compared to test siRNA treated cells. This was to ensure 
that no off target effects were occurring within the transfection process. Non-treated 
controls (cells only and transfection reagent) were also used within each experiment to 
ensure that the scrambled or negative control siRNA was having no effect and to 
normalise the data. 
In transfection experiments where an effect of less than 20% was observed, the siRNA 
was considered to have “little or no effect”. However, results from these experiments may 
still indicate statistical significance. It is, therefore, important to carry out statistical 
analyses of all results obtained from experiments. 
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2.5 In vitro proliferation assays 
2.5.1 Combination toxicity assays 
Cells in the exponential phase of growth were harvested by trypsinisation. Cell 
suspensions containing 1×104 cells/ml (for 96-well plates, Costar, 3599) or 1x106 cells/ml 
(for 6-well plates, Costar, 3516) were prepared in cell culture medium. To each well 
100µl (of 1x104 cells/ml, for 96-well plates) or 1 ml (of 1x106cells/ml for 6-well plates) 
of the cell suspension was added. Plates were agitated gently in order to ensure even 
dispersion of cells over the surface of the wells and cells were incubated overnight at 
37oC. Stock L-NNA and DFMO inhibitors (N5501 and D193) were diluted in UHP as 
per manufacturer’s instructions and stored at -20oC (Table 2.5-1) Subsequent dilutions 
were made in cell culture medium to the desired concentrations. Inhibitor diluent (UHP) 
was used as a control and also prepared in cell culture medium. A volume of 100 μl of 
the inhibitor dilutions was added to each well and mixed gently. Cells were incubated for 
48 hours. Assessment of cell survival in the presence of the inhibitors was determined by 
the acid phosphatase assay (section 2.5). 
Inhibitor Storage Source 
D, L-a-difluoromethylornithine (DFMO) -20oC Sigma Aldrich 
Nω-Nitro-L-arginine (L-NNA) -20oC Sigma Aldrich 
Table 2.5-1:- Inhibitors used during this project. 
 
2.5.2 Acid phosphatase assay 
Following the incubation period, media was removed from each plate/well. Each well on 
a plate was washed with 100 μl (for 96-well plates) or 500ul (for 6-well plates) of PBS. 
This was removed and 100 μl (for 96-well plates) or 1 ml (for 6-well plates) of freshly 
prepared phosphatase substrate (1.5μg/ml p-nitrophenol phosphate (ThermoScientific, 
34045) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 
5.5) was added to each well. The plates were wrapped in tinfoil and incubated in the dark 
at 37°C for 30mins to 2 hours. The enzymatic reaction was stopped by the addition of 50 
μl (96-well plate) or 500 µl (6-well plate) of 1 M NaOH to each well. Plates were read in 
a dual beam plate reader at 405 nm with a reference wavelength of 620nm.  
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2.6 Immunohistochemistry 
2.6.1 Immunofluorescence studies on fixed cells  
Aliquots of 30 μl of 1×106 cells/ml cell suspension from actively growing cultures were 
plated directly onto 10 well 7 mm microscope slides (Erie Scientific Company, 465-68X). 
Cells were allowed to attach overnight. After such time, slides were washed 3 x in PBS 
and allowed to air dry. Slides were carefully foil wrapped and stored at -80oC until 
required. When required, slides were allowed to come to room temperature, cells were 
then fixed in 4% paraformaldehyde for 5 mins. Slides were washed 3 x in PBS and in 
between the wells were then dried using a cotton bud wrapped in lint free tissue, to prevent 
the primary antibody from running into neighbouring wells. The primary antibody (Table 
2.6-1) was applied to appropriate wells and incubated overnight at 4oC. After 24 hours, 
the slides were washed 3 x in PBS and appropriate secondary antibody was applied. 
Either, Alexa Fluor488 goat anti-mouse IgG (ThermoFisher Scientific, A11029) or goat 
anti-rabbit (Thermofisher Scientific, A11034) which was diluted 1:2000 was added for 
1hr at room temperature in the dark. The secondary antibody was removed and cells 
washed as outlined. Slides were mounted with ProLong Gold mounting medium 
(ThermoFisher Scientific, P36930) and covered using a glass cover slip. Cells were 
viewed and photographed using a Nikon phase contrast microscope fitted with an FITC 
filter.  
2.6.2 Immunocytochemical analysis on fixed cells 
A 30µl volume of the appropriate cell suspension was added to slides and incubation is 
as described in section 2.6.1). After 24hrs, the excess supernatant was tapped off, and the 
microscope slides were rinsed gently with PBS. Slides were then air dried overnight, 
wrapped in tin foil, and stored at -80°C. Slides are then removed from -80°C freezers, and 
left for 15 mins prior to immunostaining. Cells were fixed in ice-cold paraformaldehyde 
for 2-4 mins. Immunostaining was carried out as per section 2.6.3, without the initial 
antigen retrieval step. 
2.6.3 Immunohistochemistry 
All Immunohistochemical (IHC) staining was performed using the Dako Autostainer 
(Dako, S3800). Deparaffinisation and antigen retrieval was performed using Epitope 
Retrieval 3-in-1 Solution (pH 6) (Dako, S1699) or the Epitope Retrieval 3-in-1 Solution 
(pH 9) (Dako, S2375) and the PT Link system (Dako, PT101). For epitope retrieval, slides 
were heated to 97°C for 20 mins and then cooled to 65°C. The slides were then immersed 
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in wash buffer (Dako, S3006). On the Autostainer slides were blocked for 10 mins with 
200 μl HRP Block (Dako, S2023). Cells were washed with 1 x wash buffer and 200 μl of 
antibody added to the slides at the optimised concentration/dilution for a minimum of 20 
mins (Table 2.6-1). Slides were washed again with 1 x wash buffer and then incubated 
with 200 μl Real EnVision (Dako, K4065) for 30 mins. A positive control slide was 
included in each staining run. Each slide was also run with Negative Control Reagent (1× 
TBS/0.05% Tween 20), to allow evaluation of non-specific staining and allow better 
interpretation of specific staining at the antigen site. All slides were counterstained with 
haematoxylin (Dako, CS700) for 5 mins, and rinsed with deionised water, followed by 
wash buffer. All slides were then dehydrated in graded alcohols (2 x 3 mins each in 70% 
IMS, 90% IMS and 100% IMS), and cleared in xylene (2 x 5 mins), and mounted with 
coverslips using DPX mounting medium (Sigma, 44581). Mounted slides were allowed 
to stand overnight before examination under the microscope. Slides were viewed and 
photographed using Olympus microscope and imaging system. 
 
Antibody 
Concentration used for: 
Company 
I/F ICC IHC 
AHNAK 1:250 --- --- 
Abcam 
(Ab168149/Ab68556) 
ALCAM 1:150 1:150 1:150 Abcam 
CD31 --- --- 1:50 Dako 
E-cadherin --- --- 2.5 µl Abcam (Ab40772) 
HDGF 1:250 1:500 1:500 Abcam 
Human Mitochondrial 
Protein 
--- --- 1:1000 Abcam (Ab92824) 
INA 1:210 1:210 1:210 Abcam 
IQGAP1 1µg/ml 1µg/ml 1:100 Abcam 
Ki67 --- --- 1:75 Dako (M7240) 
N-cadherin --- --- 3µg/ml 
Thermofisher Scientific 
(333900), Abcam 
(ab19348) 
ROBO2 1:100 1µg/ml 1µg/ml Abcam (ab75014) 
SLIT2 1:500 1:500 1:500 Abcam 
SPR 1:2000 --- 1:2500 Abcam 
Table 2.6-1:- Antibodies used in Immunofluorescence, Immunocytochemistry and 
Immunohistochemistry analysis. 
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2.7 RNA interference (RNAi) 
RNAi using small interfering RNA's (siRNAs) was carried out to silence specific genes. 
The siRNAs used were chemically synthesised and were purchased from AmbionInc or 
Qiagen. These siRNAs were 21-23 bps in length and were introduced to the cells via 
reverse transfection with the transfection agents siPORT NeoFXTM (Ambion Inc., 4511) 
or Lipofectamine 2000 (ThermoFisher Scientific, 11668019).  
2.7.1 Transfection optimisation 
RNA interference knockdown of genes is a well-established method and is used routinely 
to investigate the effect a certain gene has on a cell line of choice. In order to determine 
the optimal conditions for siRNA transfection, optimisation with kinesin siRNA (Ambion 
Inc., 16704) or AllStars Cell Death siRNA (Qiagen, S104381048) was carried out for 
each cell line. There were a number of different parameters that had to be determined to 
establish an optimised protocol for the siRNA transfection of the DLKP clones. Cell 
suspensions were prepared at 1×105, 2×105 and 3×105 cells per ml. Solutions of the 
negative control and positive control siRNA (kinesin or AllStars Cell Death siRNAs) at 
a final concentration of 10 and 30nM were prepared in optiMEM (GibcoTM, 31985047). 
Solutions containing 1.2 μl NeoFX or 2 μl lipofectamine were prepared in 50µl optiMEM 
in duplicate and incubated at room temperature for 10 mins. After incubation, either 
negative control or positive control (kinesin siRNA or AllStars Cell Death siRNA) 
solution was added to each NeoFX or lipofectamine solution. These solutions were mixed 
well and incubated for a further 10 mins at room temperature. To each well of a 6-well 
plate, 100 μl of the siRNA/NeoFX or lipofectamine solutions was added. A volume of 1 
ml of the relevant cell concentrations was added to each well and the plates were mixed 
gently and incubated at 37°C for 24 hours. After 24 hours, the transfection mixture was 
removed from the cells and the plates were fed with fresh medium. The plates were 
assayed for changes in proliferation at 72 hours using the acid phosphatase assay (section 
2.5). Optimal conditions for siRNA transfection were determined, as the combination of 
conditions gave the greatest reduction in cell number after positive control transfection 
and also the least cell kill in the presence of transfection reagent. The optimised conditions 
were 1.2 μl NeoFx or 2 μl of Lipofectamine to transfect 30nM siRNA (for ALCAM) and 
10nM (for both SPR and INA) siRNA respectively, optimised cell densities are shown in 
Table 2.7-1 below. 
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Cell line Cell density (per well in 6-well plates) 
DLKPSQ 1.5 x105 cells 
DLKPI 1.25x105 cells 
DLKPM 1x105 cells 
DLKPSQ-Mitox-BCRP-6P 1.5x105 cells 
MDA-MD-468 2x105 cells 
MiaPacC2 Clone3 2x105 cells 
AsPC-1 2x105 cells 
Table 2.7-1:- Optimization of cell number for transfections siRNA. 
2.7.2 Analysis of the growth of siRNA transfected cells 
Cells were seeded using 1.2 μl NeoFX to transfect 30nM siRNA (for ALCAM) or 10mM 
siRNA (for INA and SPR) to optimised cell numbers (shown in Table 2.7-1) per well of 
a 6-well plate. After 24 hrs, the medium was replaced with fresh medium and cells were 
allowed to grow until they reached 80 - 90% confluency over a total of 4 days. Cell 
number was assessed using the acid phosphatase assay (section 2.5). 
2.7.3 Analysis of invasion and migration of siRNA transfected cells 
To assay for changes in invasive capacity using ALCAM, INA and SPR siRNAs, siRNA 
experiments were set up as described in section 2.7.1 in 6-well plates. Transfection 
medium was removed after 24hr and replaced with fresh growth medium. The transfected 
cells were assayed at 72hrs post transfection for changes in invasive capacity using the in 
vitro invasion assay as described in section 2.4.1 and migration assay described in section 
2.4.2. 
2.7.4 Analysis of ROS generation of siRNA transfected cells 
DLKP-M cells with siRNA knock-down of SPR, lipofectamine transfected, or negative 
siRNA transfected cells or untreated cells were set up at 4x104 cells/well in a 24-well 
plate with two wells per condition. Seventy-two hours post transfection, ROS generation 
in DLKPM cells was analysed as described in section 2.4.3. 
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2.8 Development of cell line-derived tumours in vivo (xenografts) 
This in vivo study was carried out in collaboration with Prof. Robert Straubinger 
(University of Buffalo, USA), Ms Ninfa Straubinger (University of Buffalo, USA), Dr. 
Sandra Roche (NICB, DCU, Ireland) and Dr. Fiona O’Neill (NICB, DCU, Ireland) at the 
BioResource Unit (BRU) in the School of Biotechnology, Dublin City University. 
2.8.1 Mice 
For this study, 28-35 day old CB17/lcr-Prkdcscid/Crl mice were chosen based on the 
extensive experience and publishing history our collaborator has using SCID mice for in 
vivo modelling [101, 102]. Mice were used under the guidelines of the Irish Department 
of Health and procedures approved by the research ethics committee of Dublin City 
University, Dublin 9. CB17/lcr-Prkdcscid/Crl mice were purchased from Charles River 
(Charles River International Inc., Wilmington, MA). The immunodeficiency of these 
animals is as a result of the inhibition to produce B and T lymphocytes. This deficiency 
provides the mice with a wide tolerance to implanted foreign tissues and tumours, which 
makes them an ideal model for research. 
2.8.2 Preparation of cell suspensions 
DLKP, DLKPSQ, DLKPI and DLKPM were cultured in vented T75cm2 flasks until 
approximately 70% confluent. Cell counts were completed as per section 2.1.3. Cell 
suspensions were prepared in SF-DMEM as follows: 5x106 cells in 500 μl, 1.5x107 cells 
in 250 μl and 5x107 cells in 250 μl. Matrigel Matrix High concentration (BD, Franklin 
Lakes, NJ, USA, 354262) at a ratio of 1:1 was added to the cell suspensions. This matrigel 
is suited for in vivo studies where a high concentration augments the growth of tumours. 
The high protein concentration (18-22mg/ml) also allows the Corning Matrigel Matrix 
plug to maintain its integrity after subcutaneous injection into mice. This keeps the 
injected cells and/or angiogenic compounds localized for in situ analysis and/or future 
excision. Cell and matrigel suspensions were stored on ice until required. For tumour 
growth, the cells and matrigel mixture was then inoculated into the mice at a final cell 
density shown in Table 2.8-1. 
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 Right Flank Left Flank 
Mouse 1 1 x 106 cells 5 x 106 cells 
Mouse 2 1 x 106 cells 5 x 106 cells 
Mouse 3 1 x 106 cells 1 x 107 cells 
Mouse 4 1 x 106 cells 1 x 107 cells 
Table 2.8-1:- Inoculation densities used for DLKP in vivo study. 
2.8.3 Tumour development 
An appropriate needle was selected for injection of cell suspensions; this prevents the 
destruction of the cells within the matrigel plug. Using the cell suspensions in prepared 
in section 2.8.2, 200 µl of the appropriate cell lines and matrigel suspension was 
subcutaneously injected into the appropriate flank of each mouse as indicated in Table 
2.8-1 above. Mice were monitored daily and once tumours were observed they were 
measured using a digital calliper. The equation used to evaluate the tumour volume was; 
 
2.8.4 Tumour removal and explant culture 
Explant culture was performed to examine any changes in the in vitro characteristics of 
DLKP, DLKPSQ, DLKPI and DLKPM cells after a period of growth in tumours. 
Tumours were developed in mice as per section 2.8.1, 2.8.2 and 0, once tumours were 
removed from mice, they were kept cool by placing the specimen into ice-cold serum free 
DMEM-HAMS-F12 until required. Tumours were diced into small pieces and placed 
onto 0.4 µm inserts (Falcon, 353090), then placed into 6-well plates. Cells were allowed 
to migrate out of the tumour for 3 days without being disturbed. Once cells were seen to 
be attached to the insert, cells were trypsinised and moved to 12.5cm2 flasks and cultured 
as per section 2.1.1. DLKPSQ, DLKPSQ, DLKPI and DLKPM cells were examined for 
changes in morphology, proliferation (as described in section 2.5), invasion (as described 
in section 2.4.1), migration (as described in section 2.4.2) and anoikis (as per section 
2.4.4) capacities post tumour explantation. 
2.8.5 Paraffin embedding of Xenograft tissues 
Preparation of tumours for Immunohistochemical analysis was carried out by Mr Damian 
Tiernan (Royal Victoria Eye and Ear Hospital, Ireland) and Mr. Colin Barr (NICB, DCU). 
Pathological examination of tissues was performed by Prof. Susan Kennedy (Royal 
Victoria Eye and Ear Hospital, Dublin). 
H(height of tumour) x W(width of tumour) x D (depth of tumour)/2 
= volume of tumour (mm3) 
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Chapter 3  RESULTS 
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3.1 Identification of membrane associated markers in DLKP 
Lung Cancer is a leading cause of cancer related death worldwide. Cell surface proteins 
are an important subset of proteins in the cell. They play an important role in signal 
transduction, cell adhesion and in cancer invasion and migration. The accessible location 
of cell surface proteins makes them ideal candidates for use as targets for cancer therapy. 
While membrane proteins constitute 20-30% of the human they represent over 60% of all 
drug targets [103]. With the evolution of patient specific therapy in other cancers, there 
is a continuing need to identify new targets for lung cancer therapy. In this thesis, the 
Pierce cell surface protein isolation kit (ThermoFisher Scientific, 89881) was used to 
identify potential markers in the poorly differentiated squamous cell carcinoma cell line, 
DLKP and also potentially novel proteins associated with lung cancer. Sulfo-NHS-SS-
Biotin, a cleavable biotinylation reagent that is cell-impermeable was used to label 
exposed primary amines on the surface of intact cells from the parental DLKP and its 
clones, DLKPSQ, DLKPI and DLKPM.  
3.1.1 Cell surface protein isolation and protein identification 
DLKP contains at least 3 clonal subpopulations with distinct morphological and 
phenotypical differences (e.g. invasion and anoikis). To identify potential markers for 
each of the clones, cell surface protein isolation was carried out using cell surface 
isolation kit (see section 2.2.1). Reduction and alkylation steps were used to prepare 
proteins for label-free LC-MS/MS analysis. Proteins were eluted in DTT, precipitated in 
acetone (buffer exchange), reduced and alkylated in DTT, iodoacetamide (IAA) (breaks 
di-sulphide bonds and prevents refolding). The proteins were then broken up into peptides 
by a trypsin digestion step. Samples containing peptides were applied to the mass 
spectrometer. Proteome Discoverer Software 2.0 allows for peptides to be assigned to 
proteins using the Mascot and SEQUEST HT (see section 2.2.3 and 2.2.4). Each cell line 
will have a list of proteins that was identified.  Progenesis software was used to analyse 
these proteins and identify proteins that were differentially expressed between DLKP and 
its clones. To do this a number of criteria was applied to the software; (i) to ensure proteins 
are statistically significant an ANOVA score of ≤ 0.05 as used, (ii) to ensure increased 
expression between cell lines a minimum fold change of ≥ 1.5-fold was applied and (iii) 
to ensure correct proteins are identified, proteins with greater than 2 unique peptides 
matched to a particular protein were considered. Data analysis was carried out by Michael 
Henry using the standard criteria outlined above. The criteria used in the data analysis 
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gives strong confidence that the proteins identified are potentially expressed in the cell 
lines, validation needs to be carried out to confirm expression in the cell lines.  
To evaluate the differentially expressed proteins in the cell lines DLKP, DLKPSQ, 
DLKPI and DLKPM, six comparative protein lists were generated and exported to excel 
from Progenesis. The analysis was designed to identify biologically relevant differentially 
expressed proteins that correlated with increased expression, that is, from highest to 
lowest fold changes (DLKP vs. DLKPSQ, DLKP vs. DLKPI, DLKP vs. DLKPM, 
DLKPSQ vs. DLKPI, DLKPSQ vs. DLKPM, DLKPI vs. DLKPM). Unique and common 
proteins, as well as proteins with a novel aspect, were chosen. To further strengthen the 
choice of proteins selected, their expression was also examined in a combination of 
analyses previously performed in our laboratory (i) microarray analysis performed by Dr. 
Helena Joyce (ii) unpublished proteomic analysis (on conditioned medium (CM) from 
DLKP clones) performed by Dr. Joanne Keenan and (iii) unpublished proteomic analysis 
(of whole cell lysates) performed by Mr. Shane Kelly. The analysis presented in this thesis 
was performed using a protein isolation protocol. The kit may potentially allow for 
isolation and subsequent identification (through LC-MS/MS analysis) of novel proteins 
associated with cell membrane using a biotin labelling approach. Validation of selected 
proteins was performed to confirm their expression in DLKP and its clones by 
Immunofluorescence staining, Western blot analysis and immunocytochemical analysis. 
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3.1.2 Principle component analysis of DLKP and the DLKP clones 
Principle component analysis (PCA) is a statistical analysis used to visualise variation 
and strong patterns between data sets. To show differences in protein expression between 
DLKP and DLKP clones a global analysis was carried out on all four cell lines, using 
Progenesis LC-MS software. To identify proteins that are differentially expressed 
between the DLKP and its clones, it was important to ensure good separation between all 
four cell lines and that each of the replicate samples clustered together. The PCA analysis 
shown in Figure 3.1-1, indicates a clear separation between all four cell lines but also the 
individual replicates are clustering together. The analysis also indicates that DLKP 
(Green) and DLKPSQ (blue) cluster close together, this is not surprising due to the fact 
that DLKP is made up of approx. 70% DLKPSQ cells [93]. The PCA analysis indicates 
that the isolation of cell membrane associated protein and subsequent proteomic analysis 
in DLKP and its clones was robust and reproducible. 
 
 
 
Figure 3.1-1:- Principle component analysis showing separation of DLKP and its clones. 
Label free proteomic analysis was carried out on triplicate cell surface preparations of DLKP 
(Green), DLKPSQ (Blue), DLKPI (Orange) and DLKPM (purple), using the cell surface isolation 
kit. 
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3.1.3 Comparative proteomic analysis of DLKP and the DLKP clones 
Following principle component analysis of the four cell lines, six comparative protein 
lists were generated. The analysis was designed to identify biologically relevant 
differentially expressed proteins that correlated with increased expression, that is, from 
highest to lowest fold changes. The six comparisons were:  DLKP vs. DLKPSQ, DLKP 
vs. DLKPI, DLKP vs. DLKPM, DLKPSQ vs. DLKPI, DLKPSQ vs. DLKPM, DLKPI vs. 
DLKPM. Table 3.1-1 summarises the total number of proteins that were identified from 
each comparison and the number of proteins that showed increased expression. The 
subsequent tables (Table 3.1-2 - Table 3.1-7) shows the first 14 - 18 proteins in each 
comparison and are organised by maximum fold change (see appendix I for full 
differentially expressed protein lists). The proteins which were identified in these 
comparisons represent a number of different cellular processes, however, to elucidate the 
molecular function, biological processes and pathways which control these proteins 
further analysis using PANTHER classification system should be carried out.  
Experimental comparison No. of identified differentially expressed proteins 
DLKP vs. DLKPSQ 
49 proteins in total 
35 were increased in DLKP 
14 were increased in DLKPSQ 
(See Table 3.1-2) 
DLKP vs. DLKPI 
114 proteins in total 
74 were increased in DLKP 
40 were increased in DLKPI 
(See Table 3.1-3) 
DLKP vs. DLKPM 
144 proteins in total 
86 were increased in DLKP 
58 were increased in DLKPM 
(see Table 3.1-4) 
DLKPSQ vs. DLKPI 
94 proteins in total 
55 were increased in DLKPSQ 
39 were increased in DLKPI 
(see Table 3.1-5) 
DLKPSQ vs. DLKPM 
110 proteins in total 
59 were increased in DLKPSQ 
51 were increased in DLKPM 
(see Table 3.1-6) 
DLKPI vs. DLKPM 
58 proteins in total 
26 were increased in DLKPSQ 
32 were increased in DLKPM 
(see Table 3.1-7) 
Table 3.1-1:- Summary of six comparisons made using Progenesis LC-MS software and the 
number of proteins with increased expression in each cell line.
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DLKP vs. DLKPSQ 
Highest in DLKP Highest in DLKPSQ 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Q9HCK4 Roundabout homolog 2 ROBO2 56.88 P16930 Fumarylacetoacetase FAH 19.87 
P05362 Intercellular adhesion molecule 1 ICAM1 56.16 O43175 
D-3-phosphoglycerate 
dehydrogenase 
PHGDH 4.52 
P35221 Catenin alpha-1 CTNNA1 30.84 A0MZ66 Shootin-1 KIAA1598 3.87 
Q16658 Fascin FSCN1 14.08 P43358 Melanoma-associated antigen 4 MAGEA4 2.44 
P35222 Catenin beta-1 CTNNB1 12.58 P11137 Microtubule-associated protein 2 MAP2 2.24 
Q9UBR2 Cathepsin Z CTSZ 6.85 O75531 Barrier-to-autointegration factor BANF1 2.15 
Q6PIU2 
Neutral cholesterol ester hydrolase 
1 
NCEH1 6.39 Q9BUF5 Tubulin beta-6 chain TUBB6 2.01 
Q09666 
Neuroblast differentiation-
associated protein 
AHNAK 5.00 P13010 
X-ray repair cross-complementing 
protein 5 
XRCC5 1.97 
P50454 Serpin H1 SERPINH1 4.21 Q06830 Peroxiredoxin-1 PRDX1 1.75 
Q8NBJ5 
Procollagen galactosyltransferase 
1 
COLGALT1 3.31 P46940 
Ras GTPase-activating-like 
protein 
IQGAP1 1.73 
Q01581 
Hydroxymethylglutaryl-CoA 
synthase, cytoplasmic 
HMGCS1 3.10 Q15417 Calponin-3 CNN3 1.65 
O60888 Protein CutA CUTA 2.59 Q96AE4 
Far upstream element-binding 
protein 1 
FUBP1 1.58 
Q96PK6 RNA-binding protein 14 RBM14 2.40 O00264 
Membrane-associated progesterone 
receptor component 1 
PGRMC1 1.54 
P35579 Myosin-9 MYH9 2.33 P30041 Peroxiredoxin-6 PRDX6 1.54 
Table 3.1-2:- Comparison of DLKP vs. DLKPSQ. 
List of top 14 statistically significant, differentially expressed proteins in DLKP and DLKPSQ. The following criteria were applied; (i) ANOVA score ≤ 
0.05, (ii) max-fold change of ≥ 1.5 and (iii) a minimum of 2 peptides leading to the identification of proteins. 
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DLKP vs.  DLKPI 
Highest in DLKP Highest in DLKPI 
Accession  
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 82.94 P08575 
Receptor-type tyrosine-protein 
phosphatase C 
PTPRC 37.62 
P05362 Intercellular adhesion molecule 1 ICAM1 55.65 Q13740 CD166 antigen ALCAM 18.80 
P32119 Peroxiredoxin-2 PRDX2 31.26 Q05707 Collagen alpha-1(XIV) chain COL14A1 15.61 
Q9UBR2 Cathepsin Z CTSZ 9.26 P35232 Prohibitin PHB 7.71 
O75347 Tubulin-specific chaperone A TBCA 5.34 Q99623 Prohibitin-2 PHB2 7.64 
P43487 
Ran-specific GTPase-activating 
protein 
RANBP1 5.21 P46940 Ras GTPase-activating-like protein IQGAP1 7.61 
P12277 Creatine kinase B-type CKB 4.63 O75369 Filamin-B FLNB 7.44 
P55060 Exportin-2 CSE1L 4.48 P11233 Ras-related protein Ral-A RALA 6.55 
Q99798 Aconitate hydratase, mitochondrial ACO2 4.00 P02545 Prelamin-A/C LMNA 5.75 
P07602 Prosaposin PSAP 3.63 Q09666 
Neuroblast differentiation-associated 
protein 
AHNAK 5.55 
P00441 Superoxide dismutase [Cu-Zn] SOD1 3.57 Q9BSJ8 Extended synaptotagmin-1 ESYT1 4.61 
Q14240 Eukaryotic initiation factor 4A-II EIF4A2 3.53 P21333 Filamin-A FLNA 4.59 
P49419 
Alpha-aminoadipic semialdehyde 
dehydrogenase 
ALDH7A1 3.48 Q96HC4 PDZ and LIM domain protein 5 PDLIM5 4.55 
P09211 Glutathione S-transferase P GSTP1 3.43 O75947 ATP synthase subunit d, mitochondrial ATP5H 3.81 
Table 3.1-3:- Comparison of DLKP vs. DLKPI. 
List of top 14 statistically significant, differentially expressed proteins in DLKP and DLKPI. The following criteria were applied; (i) ANOVA score ≤ 
0.05, (ii) max-fold change of ≥ 1.5 and (iii) a minimum of 2 peptides leading to the identification of proteins. 
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DLKP vs.  DLKPM 
Highest in DLKP Highest in DLKPM 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
P10586 
Receptor-type tyrosine-protein 
phosphatase F 
PTPRF 89.23 Q96HC4 PDZ and LIM domain protein 5 PDLIM5 13.80 
P05362 Intercellular adhesion molecule 1 ICAM1 61.31 Q05707 Collagen alpha-1(XIV) chain COL14A1 12.64 
Q9HCK4 Roundabout homolog 2 ROBO2 60.59 P46940 Ras GTPase-activating-like protein IQGAP1 8.99 
Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 45.49 P02538 Keratin, type II cytoskeletal 6A KRT6A 8.81 
O15031 Plexin-B2 PLXNB2 27.33 P11233 Ras-related protein RALA 8.81 
Q92692 Nectin-2 PVRL2 25.06 Q99623 Prohibitin-2 PHB2 8.35 
P28906 
Hematopoietic progenitor cell antigen 
CD34 
CD34 24.97 P46087 
Probable 28S rRNA (cytosine (4447)-C (5))-
methyltransferase 
NOP2 8.25 
Q13308 Inactive tyrosine-protein kinase 7 PTK7 10.40 O75643 
U5 small nuclear ribonucleoprotein 200kDa 
helicase 
SNRNP200 8.00 
Q9UBR2 Cathepsin Z CTSZ 10.01 P35232 Prohibitin PHB 7.83 
O00410 Importin-5 IPO5 7.44 Q14008 Cytoskeleton-associated protein 5 CKAP5 7.80 
P30533 
Alpha-2-macroglobulin receptor-
associated protein 
LRPAP1 6.68 O75369 Filamin-B FLNB 7.75 
Q15084 Protein disulfide-isomerase A6 PDIA6 6.05 P62805 Histone H4 HIST1H4A 6.86 
Q13740 CD166 antigen ALCAM 5.97 Q8WXF1 Paraspeckle component 1 PSPC1 5.90 
Q9Y4L1 Hypoxia up-regulated protein 1 HYOU1 5.83 P23246 Splicing factor, proline- and glutamine-rich SFPQ 5.65 
Table 3.1-4:- Comparison of DLKP vs. DLKPM. 
List of top 14 statistically significant, differentially expressed proteins in DLKP and DLKPM. The following criteria were applied; (i) ANOVA score ≤ 
0.05, (ii) max-fold change of ≥ 1.5 and (iii) a minimum of 2 peptides leading to the identification of proteins. 
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DLKPSQ vs. DLKPI 
Highest in DLKPSQ Highest in DLKPI 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
P55957 BH3-interacting domain death agonist BID 18.07 P08575 
Receptor-type tyrosine-protein 
phosphatase C 
PTPRC 42.10 
O43175 D-3-phosphoglycerate dehydrogenase PHGDH 7.36 P19022 Cadherin-2 CDH2 29.00 
O00625 Pirin PIR 6.45 P23246 
Splicing factor, proline- and 
glutamine-rich 
SFPQ 28.92 
Q9UBB4 Ataxin-10 ATXN10 6.23 P35222 Catenin beta-1 CTNNB1 26.80 
P12277 Creatine kinase B-type CKB 6.08 Q13740 CD166 antigen ALCAM 24.30 
P43487 Ran-specific GTPase-activating protein RANBP1 5.89 Q9HCK4 Roundabout homolog 2 ROBO2 21.85 
P31937 
3-hydroxyisobutyrate dehydrogenase, 
mitochondrial 
HIBADH 5.12 Q96PK6 RNA-binding protein 14 RBM14 17.52 
P00441 Superoxide dismutase [Cu-Zn] SOD1 5.07 Q14126 Desmoglein-2 DSG2 17.34 
P04792 Heat shock protein beta-1 HSPB1 4.76 Q15233 
Non-POU domain-containing 
octamer-binding protein 
NONO 14.81 
P34897 
Serine hydroxymethyltransferase, 
mitochondrial 
SHMT2 4.68 Q16658 Fascin FSCN1 14.34 
O75347 Tubulin-specific chaperone A TBCA 4.44 P35221 Catenin alpha-1 CTNNA1 10.81 
P09211 Glutathione S-transferase P GSTP1 4.41 Q99623 Prohibitin-2 PHB2 10.26 
P00390 Glutathione reductase, mitochondrial GSR 4.31 P35232 Prohibitin PHB 10.06 
P07602 Prosaposin PSAP 4.14 Q09666 
Neuroblast differentiation-
associated protein 
AHNAK 9.29 
P00558 Phosphoglycerate kinase 1 PGK1 4.13 Q86UP2 Kinectin KTN1 8.37 
P12004 Proliferating cell nuclear antigen PCNA 3.86 P02545 Prelamin-A/C LMNA 7.38 
O43399 Tumor protein D54 TPD52L2 3.72 P21333 Filamin-A FLNA 7.07 
P35270 Sepiapterin reductase SPR 3.64 Q9BSJ8 Extended synaptotagmin-1 ESYT1 6.23 
Table 3.1-5:- Comparison of DLKPSQ vs. DLKPI. 
List of top 18 statistically significant differentially expressed proteins in DLKP and DLKPI. The following criteria were applied; (i) ANOVA score ≤ 
0.05, (ii) max-fold change of ≥ 1.5 and (iii) a minimum of 2 peptides leading to the identification of proteins. 
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DLKPSQ vs. DLKPM 
Highest in DLKPSQ Highest in DLKPM 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
A0MZ66 Shootin-1 KIAA1598 7.02 P46087 
Probable 28S rRNA (cytosine (4447)-C 
(5))-methyltransferase 
NOP2 12.26 
O43175 
D-3-phosphoglycerate 
dehydrogenase 
PHGDH 6.70 O75643 
U5 small nuclear ribonucleoprotein 200 
kDa helicase 
SNRNP200 11.69 
Q9Y2Q3 Glutathione S-transferase kappa 1 GSTK1 5.22 Q99623 Prohibitin-2 PHB2 11.52 
O00625 Pirin PIR 4.95 P23246 
Splicing factor, proline- and glutamine-
rich 
SFPQ 10.66 
P08107 Heat shock 70 kDa protein 1A/1B HSPA1A 4.84 Q15233 
Non-POU domain-containing octamer-
binding protein 
NONO 10.17 
O43399 Tumor protein D54 TPD52L2 4.31 Q96HC4 PDZ and LIM domain protein 5 PDLIM5 9.67 
P27797 Calreticulin CALR 4.12 P35232 Prohibitin PHB 9.45 
P34931 Heat shock 70 kDa protein 1-like HSPA1L 3.98 Q09666 
Neuroblast differentiation-associated 
protein 
AHNAK 8.04 
O14980 Exportin-1 XPO1 3.96 P62805 Histone H4 HIST1H4A 7.84 
P23526 Adenosylhomocysteinase AHCY 3.86 Q96PK6 RNA-binding protein 14 RBM14 7.59 
O00410 Importin-5 IPO5 3.65 P11233 Ras-related protein Ral-A RALA 7.46 
Q58FF7; 
Q58FF8 
Putative heat shock protein HSP 
90-beta-3 
HSP90AB3P 3.58 Q14444 Caprin-1 CAPRIN1 6.91 
P04792 Heat shock protein beta-1 HSPB1 3.52 P46940 Ras GTPase-activating-like protein IQGAP1 6.17 
P27824 Calnexin CANX 3.48 P35222 Catenin beta-1 CTNNB1 5.71 
Table 3.1-6:- Comparison of DLKPSQ vs. DLKPM. 
List of top 14 statistically significant differentially expressed proteins in DLKPSQ and DLKPM. The following criteria were applied; (i) ANOVA score 
≤ 0.05, (ii) max-fold change of ≥ 1.5 and (iii) a minimum of 2 peptides leading to the identification of proteins. 
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DLKPI vs.  DLKPM 
Highest in DLKPI Highest in DLKPM 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
Accession 
Number 
Protein Name 
Gene 
symbol 
Fold 
Change 
P08575 
Receptor-type tyrosine-protein 
phosphatase C 
PTPRC 41.79 P31937 
3-hydroxyisobutyrate dehydrogenase, 
mitochondrial 
HIBADH 7.32 
Q13740 CD166 antigen ALCAM 30.15 P12277 Creatine kinase B-type CKB 7.28 
Q9HCK4 Roundabout homolog 2 ROBO2 26.95 O75347 Tubulin-specific chaperone A TBCA 4.52 
P10586 
Receptor-type tyrosine-protein 
phosphatase F 
PTPRF 25.10 P49419 
Alpha-aminoadipic semialdehyde 
dehydrogenase 
ALDH7A1 4.11 
Q14126 Desmoglein-2 DSG2 24.70 P07195 L-lactate dehydrogenase B chain LDHB 3.47 
P60709 Actin, cytoplasmic 1 ACTB 22.32 P07741 Adenine phosphoribosyltransferase APRT 3.45 
P19022 Cadherin-2 CDH2 20.86 P08758 Annexin A5 ANXA5 3.45 
P30533 
Alpha-2-macroglobulin receptor-
associated protein 
LRPAP1 9.17 P43487 
Ran-specific GTPase-activating 
protein 
RANBP1 3.43 
Q92692 Nectin-2 PVRL2 7.93 P09211 Glutathione S-transferase P GSTP1 3.32 
P35222 Catenin beta-1 CTNNB1 7.92 P16152 Carbonyl reductase [NADPH] 1 CBR1 3.22 
Q15067 
Peroxisomal acyl-coenzyme A 
oxidase 1 
ACOX1 4.47 P50454 Serpin H1 SERPINH1 3.18 
Q01581 
Hydroxymethylglutaryl-CoA 
synthase, cytoplasmic 
HMGCS1 4.25 Q96HC4 PDZ and LIM domain protein 5 PDLIM5 3.03 
Q9Y2Q3 Glutathione S-transferase kappa 1 GSTK1 4.05 P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 3.02 
P21333 Filamin-A FLNA 3.89 P00441 Superoxide dismutase [Cu-Zn] SOD1 2.87 
Table 3.1-7:- Comparison of DLKPI vs. DLKPM. 
List of top 14 statistically significant differentially expressed proteins in DLKPSQ and DLKPM. The following criteria were applied; (i) ANOVA score 
≤ 0.05, (ii) max-fold change of ≥ 1.5 and (iii) a minimum of 2 peptides leading to the identification of proteins. 
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3.1.4 Summary of proteins selected for validation studies in DLKP 
Table 3.1-8 below summarises the proteins that were selected as potential protein markers 
for DLKP clones and possibly novel proteins associated with lung cancer. Two proteins 
that did not appear on the comparative proteomic lists (i) Alpha-Internexin (INA) and (ii) 
SLIT2 were also selected for validation. On further examination, less stringent criteria 
revealed HDGF as differentially expressed in DLKP vs. DLKPI (fold change 2.19), 
criteria applied was (i) an ANOVA of ≤0.05, (ii) ≥1.5 fold and (ii) proteins with ≥1 unique 
peptide matched to identify HDGF. Little is known about HDGF and its receptor and was, 
therefore, an interesting protein for follow up analysis. INA was chosen for validation in 
DLKP and its clones based on novelty, on its association with pancreatic neuroendocrine 
cancer tumour aggressiveness [104]. On further examination of INA, unpublished 
proteomic analysis on whole cell lysates of DLKP and its clones revealed its expression 
was increased in DLKPSQ vs. DLKPM. Early studies performed on DLKP indicated that 
DLKP should be characterised as either variant small cell lung carcinoma (SCLC-V) or 
non-small cell lung carcinoma with neuroendocrine differentiation [93], further 
strengthening our reasons for selecting INA. Microarray analysis carried out by Dr. 
Helena Joyce found that SLIT2 was expressed in DLKP. In this proteomic study, ROBO2 
(the receptor for SLIT2 and probably SLIT1) was found to be expressed within the DLKP 
cell line model, therefore both proteins were chosen for validation studies. Surprisingly, 
a number of the proteins selected for validation appear to have a neuronal association, 
which may further indicate the borderline nature of DLKP towards a neuroendocrine 
tumour. 
No Protein Name 
Gene 
Symbol 
Accession 
number 
Molecular function 
1.  
Neuroblast differentiation-
associated protein 
AHNAK Q09666 
Structural molecule 
conferring elasticity 
2.  
Hepatoma Derived Growth 
Factor 
HDGF P51858 
Transcription co-factor 
activity, Growth factor 
activity 
3.  SLIT2 Homolog SLIT2 O94813 Receptor activity 
4.  Roundabout 2 Homolog ROBO2 Q9HCK4 
Receptor activity, 
Phosphoprotein 
phosphatase activity 
5.  
Activated Leukocyte cell 
adhesion molecule 
ALCAM Q13740 Receptor activity 
6.  
Ras-GTPase-activating-like 
protein 1 
IQGAP-1 P46940 
Catalytic activity, small 
GTPase activity 
7.  Alpha-Internexin INA Q16352 
Structural constituent of 
Cytoskeleton 
8.  Sepiapterin Reductase SPR P35270 Oxidoreductase activity 
Table 3.1-8:- Summary of all proteins selected for validation studies. 
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3.2 Validation of protein targets from proteomic analysis 
A number of proteins were identified as differentially expressed following comparative 
proteomic analysis of DLKP and its clonal variants (DLKPSQ, DLKPI and DLKPM). 
Six comparisons were performed to identify statistically significant proteins that were 
differentially expressed: DLKP vs. DLKPSQ, DLKP vs. DLKPI, DLKP vs. DLPKPM, 
DLKPSQ, vs. DLKPI, DLKPSQ vs. DLKPM and DLKPI vs. DLKPM. Presented in 
section 3.1.3 were tables of statistically significant differentially expressed proteins of 
each comparison from which proteins were selected. Selection of proteins from these 
comparisons was based on (i) ANOVA score of ≤ 0.05, (ii) max-fold change of ≥ 1.5 and 
a minimum of 1-2 peptides matched in order to identify each protein. The aim was to 
identify differentially expressed proteins that could act as potential markers for individual 
clones and to potentially identify novel proteins associated with lung cancer. Table 3.1-8 
shows a summary of all of the proteins that were selected for validation studies.  
Western blot analysis was used to validate the expression of the selected proteins in whole 
cell lysates, membrane enriched fractions and conditioned medium samples of DLKP, 
DLKPSQ, DLKPI and DLKPM cells (section 2.3). Validation of selected proteins in 
whole cell lysate and membrane enriched fractions would indicate the expression of 
particular proteins in the cells, while validating in conditioned medium (CM) samples 
would suggest if the protein was secreted. With further investigation, this information 
could be useful for determining whether a particular protein could be used as a cancer 
biomarker. Biomarkers are proteins or factors produced by cancer cells and secreted into 
bodily fluids such as blood and urine. Immunofluorescence (section 2.6.1) and/or 
Immunocytochemical analysis (see sections 2.6.2) was performed to confirm localisation 
of expression in the cells. Commercially available antibodies described in Table 2.3-1 
and Table 2.6-1. 
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3.2.1 Validation of AHNAK expression in DLKP 
Originally identified as a nuclear phosphoprotein in human neuroblastomas and skin 
epithelial cells, AHNAK is an exceptionally large protein of ~629kDa protein.  Lee et al., 
reported that AHNAK functions as a tumour suppressor by mediating TGFβ signalling, 
leading to cell cycle arrest. AHNAK expression was found to be increased in 
differentially expressed protein comparisons: DLKP vs. DLKPSQ, DLKPI vs. DLKPSQ, 
DLKPI vs. DLKPSQ and DLKPM vs. DLKPSQ, following comparative proteomic 
analysis of membrane preparations, Tables of proteins showing expression of AHNAK 
are presented in section 3.1.3. Immunofluorescence staining was performed to validate 
the expression of AHNAK in DLKP and its clonal subpopulations, see Figure 3.2-1 
below. Immunoreactivity was observed in all of the cell lines with the DLKPI and 
DLKPM cells showing the strongest immunoreactivity, membrane reactivity was 
observed in a small population (< 10%) of DLKPSQ cells.  
 
  
  
Figure 3.2-1:- Validation of AHNAK expression in DLKP. 
Representative immunofluorescence staining of AHNAK, (A) DLKP parental cells, (B) 
DLKPSQ, (C) DLKPI and (D) DLKPM cells stained with an AHNAK specific antibody. 
Immunoreactivity was observed in all cell lines. (Original magnification of all photomicrographs, 
×400, scale-bar = 50μm (n=1). 
 
A B 
C D 
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3.2.2 Validation of HDGF expression in DLKP 
While little is known about the receptors of hepatoma derived growth factors (HDGFs), 
it is thought that HDGF contains a peptide region responsible for binding to the cell 
surface. Subsequent binding of HDGF at the cell surface is also thought to activate 
ERK1/2 in fibroblasts [105]. The ERK pathway is thought to play a key role in the 
invasion of DLKP [96]. Hepatoma derived growth factor (HDGF) was found to be 
increased in comparative proteomics analysis of DLKP vs. DLKPI (2.19 fold), however, 
less stringent criteria were applied (i) ANOVA score of ≤ 0.05, (ii) a max-fold change of 
≥ 1.5, with 1 peptide matched to identify HDGF. Refer to appendix 1, which shows 
expression of HDGF in DLKP. 
HDGF is thought to be localised mainly to the nucleus, but localisation to the cytosol has 
also been reported [106]. In DLKP, no membrane immunoreactivity was observed but 
there was strong nuclear and some cytoplasmic immunoreactivity observed. 
Immunoreactivity was strongest in DLKP with lower levels in DLKPSQ, DLKPI and 
DLKPM (see Figure 3.2-2 (A)). 
Western blot analysis of whole cell lysates, membrane enriched fractions and conditioned 
media (CM) preparations of DLKP, DLKPSQ, DLKPI and DLKPM cells was performed 
to investigate the expression of HDGF. Western blot analysis of membrane enriched 
fractions clearly shows expression of HDGF is highest in DLKP compared to the clones 
(SQ, I and M). Analysis of whole cell lysates and CM samples showed expression of 
HDGF across the four cell lines. Immunoblots show the migration of HDGF at 
approximately 37kDa, however, non-specific bands were observed in the whole cell and 
CM samples above 37kDa which may represent potential HDGF-related proteins [106] 
of HDGF (see Figure 3.2-2 (B)). Immunocytochemical analysis of HDGF in DLKP, 
DLKPSQ, DLKPI and DLKPM cells displayed strong immunoreactivity in all cell lines, 
however, DLKP showed the strongest membrane reactivity (see Figure 3.2-2 (C)). 
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Figure 3.2-2:- Validation of HDGF expression in DLKP. 
(A) Immunofluorescence staining of HDGF (n=1) (B) Representative immunoblot showing 
expression of HDGF in the DLKP clones (α-tubulin served as loading control (n=3), and (C) 
Immunocytochemical staining of HDGF in DLKP and its clones (n=1). Immunoreactivity was 
observed in all cell lines with the DLKP cells showing the strongest immunoreactivity (Original 
magnification of all photomicrographs, ×400, scale-bar = 50μm (A) and 200μm (C)). 
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3.2.3 Validation of SLIT2 ligand and ROBO2 receptor expression in DLKP 
Roundabout-2 Homolog (ROBO2) expression was found to be increased in differentially 
expressed protein comparisons: DLKP vs. DLKPSQ (~57-fold), DLKP vs. M (~60-fold), 
DLKPI vs. DLKPSQ (~21-fold) and DLKPI vs. DLKPM (27~fold), Tables of proteins 
showing expression of ROBO2 in DLKP are presented in section 3.1.3.. In addition, 
microarray analysis previously carried out on DLKP and its clones had revealed that 
ROBO2 was overexpressed in DLKPI only, while proteomic analysis on CM also 
indicated its expression in DLKP and its clones. Interestingly, ROBO2 expression in CM 
was highest in DLKPSQ, this may indicate that DLKPSQ may shed ROBO2 into the CM. 
ROBO2 acts as the receptor for SLIT2 (and probably SLIT1) guide to cellular migration 
during neuronal development [107]. Recently, it has been shown that ROBO1 expression 
in breast cancer cells coupled with SLIT2 expression from stromal fibroblasts has been 
associated with inhibition of tumour progression [108]. This indicates the influence the 
expression of proteins from cells within the tumour microenvironment may have on 
cancer progression. Both ROBO2 and SLIT2 proteins were selected for validation 
studies.  
Both Immunofluorescence and Immunocytochemical analysis of SLIT2 show 
immunoreactivity in all cell lines, DLKPM showing an overall the highest expression 
with DLKPSQ showing lower expression, this cell line appears to display membrane 
reactivity. Extracellular immunoreactivity can be observed in all cell lines (see Figure 
3.2-3 (A) & (D)), indicating potential secretion of SLIT2 into the surrounding media. 
Immunofluorescence staining for ROBO2 (Figure 3.2-3 (C)) revealed immunoreactivity 
in all of the cells with the DLKP-M cells showing the strongest immunoreactivity and 
DLKP showing weakest expression. SLIT2 expression appears to correlate with ROBO2 
expression in DLKP and its subpopulations, by immunofluorescence. 
Western blot analysis (Figure 3.2-3 (B)) was carried out to investigate the expression of 
SLIT2 in whole cell lysates, membrane enriched fractions and CM of DLKP, DLKPSQ, 
DLKPI and DLKPM cells. DLKPM and DLKP showed the highest level of expression 
while DLKPSQ and DLKPI showed the lowest level of expression in all samples. 
Western blot analysis of SLIT2 does not appear to correlate with Immunofluorescence 
analysis, however, there does appear to be similar expression trends between both 
techniques. ROBO2 expression was only validated by Immunofluorescence staining as 
the antibody did not work for Western blot analysis or Immunocytochemical analysis. 
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(a)  
 
(b)  
 
(c)  
 
(d)  
 
Figure 3.2-3:- Validation of SLIT2 and ROBO2 receptor expression in DLKP. 
(A) Immunofluorescence staining of SLIT2 in the DLKP clones (n=1). (B) Representative 
Immunoblot showing expression of SLIT2 in the DLKP clones (α-tubulin was used as an equal 
loading control (n=3)). (C) Immunofluorescence staining showing cell surface staining of 
ROBO2 (n=1). (D) Immunocytochemical staining of SLIT2 in the DLKP clones (n=1). DLKP 
parental cells, DLKPSQ, DLKPI and DLKPM cells stained with both an antibody specific to 
SLIT2 and ROBO2. Immunoreactivity was observed in all cells (Original magnification of all 
photomicrographs, ×400, scalebar = 50μm (A and C) and 200μm (D)). 
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3.2.4 Validation of ALCAM expression in DLKP 
Activated Leukocyte Cell Adhesion molecule (ALCAM), also known as CD166 antigen, 
is a highly conserved 110kDa multi-domain, transmembrane type-1 glycoprotein of the 
immunoglobulin superfamily. ALCAM was first described as a CD6 ligand but is capable 
of homophilic and heterophilic interactions [109]. ALCAM expression was found to be 
increased in a number of comparisons of differentially expressed proteins; DLKP vs. 
DLKPM (~5.97-fold), DLKPI vs. DLKPSQ (~24.3-fold) and DLKPI vs. DLKPM 
(~30.15-fold), Tables of proteins showing expression of ALCAM in DLKP are presented 
in section 3.1.3. In addition, microarray analysis previously carried out on DLKP and its 
clones revealed that ALCAM was overexpressed in DLKPI only relative to DLKPSQ, 
while proteomic analysis on CM also indicated expression in DLKP cell lines. 
Interestingly, ALCAM expression in CM was highest in DLKPSQ and DLKPM. 
Potentially indicating that DLKPSQ sheds ALCAM into the conditioned medium. A 
number of studies have identified ALCAM as a potential lung cancer stem cell marker 
[110]. Since DLKPI may show a potential ability to interconvert to DLKPSQ and 
DLKPM, it was proposed that DLKPI may resemble a possible stem cell population in 
DLKP and was therefore chosen for validation studies.  
 
Immunofluorescence (Figure 3.2-4 (A)) and Immunocytochemical analysis of ALCAM 
(Figure 3.2-4 C)) indicated strong membrane reactivity in DLKPI compared to DLKP and 
DLKPM. ALCAM appeared to be almost absent in DLKPSQ. Western blot analysis 
(Figure 3.2-4 (B)) confirms that the expression level of ALCAM was highest in DLKPI 
compared to DLKP, DLKPSQ and DLKPM. Immunofluorescence, Western blot analysis 
and immunocytochemical analysis confirmed proteomics analysis by showing strongest 
expression of ALCAM in DLKPI. ALCAM, due to its strong expression could potentially 
be a good candidate for use as a marker for DLKPI. 
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Figure 3.2-4:- Validation of ALCAM expression in DLKP. 
(A) Immunofluorescence staining of ALCAM in the DLKP clones (n=1). (B) Representative 
Immunoblot showing expression of ALCAM in the DLKP clones (α-tubulin was used as an equal 
loading control (n=3)). (C) Immunocytochemical staining of ALCAM in formalin fixed paraffin 
embedded cells from DLKP and its clones (1000x magnification (n=1). Strongest 
immunoreactivity is observed in DLKPI. (Original magnification of all photomicrographs, ×400, 
scalebar = 50μm (A) and 200μm (C)). 
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3.2.5 Validation of IQGAP1 expression in DLKP 
Ras-GTPase-activating-like protein-1 (IQGAP1) is a member of the IQGAP family of 
proteins with a molecular weight of approximately 189kDa. IQGAP1 regulates cell 
morphology and motility by its interaction with cell adhesion molecules, signalling 
molecules and components of the cytoskeleton [111]. IQGAP1 expression was found to 
be increased in a number of comparisons of differentially expressed proteins: DLKPSQ 
vs. DLKP (~2-fold), DLKPI vs. DLKP (~8-fold), DLKPM vs. DLKP (~9-fold) and 
DLKPM vs. DLKPSQ (~6-fold) obtained from comparative proteomic analysis of DLKP, 
Tables presented in section 3.1.3 show expression of IQDAP. In addition, microarray 
analysis previously carried out on DLKP and its clones revealed that IQGAP1 was 
overexpressed in DLKPI relative to DLKPSQ. IQGAP1 is thought to interact with over 
90 proteins including β-catenin, E-cadherin and N-cadherin, which are well established 
in cancer. In addition, IQGAP1 has also been reported to be a potential interacting protein 
of ALCAM [112] which we found to be almost uniquely expressed in DLKPI (see section 
3.2.4). 
 
Immunofluorescence (Figure 3.2-5 (A)) and Immunocytochemical analysis (Figure 3.2-5 
(C)) of IQGAP1 indicated that immunoreactivity was observed in all four cell lines. 
Expression appears to be strongest in DLKPM relative to DLKP, DLKPSQ and DLKPI. 
Western blot analysis Figure 3.2-5 (B)) also confirms expression levels of IQGAP1 is 
highest in DLKPM compared to DLKP, DLKPSQ and DLKPI.  
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Figure 3.2-5:- Validation of IQGAP1 expression in DLKP. 
(A) Immunofluorescence staining of IQGAP1 in the DLKP clones. (B) Representative 
Immunoblot showing expression of IQGAP1 in the DLKP clones (α-tubulin was used as an equal 
loading control). (C) Immunocytochemical staining of IQGAP1, strongest immunoreactivity was 
observed in DLKPM (Original magnification of all photomicrographs, ×400, scalebar = 50μm 
(A) and 200μm (C)). 
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3.2.6 Validation of INA expression in DLKP 
Alpha-Internexin (INA) is a 66kDa neuronal intermediate filament that is abundantly 
expressed in the peripheral nervous system. Overexpression of INA in oligodendroglial 
phenotype gliomas has been related to the 1p/19q co-deletion and been reported as a 
favourable prognostic marker [113]. Increased expression of INA was identified as a 
biomarker for neuroendocrine pancreatic cancer tumour aggressiveness and prognosis 
[104]. However, unpublished proteomic analysis performed on whole cell lysates of 
DLKP and its clones also indicated that INA expression was increased in DLKPSQ vs. 
DLKPM (~2.4-fold). Initial studies performed on DLKP indicated that DLKP should be 
characterised as either variant small cell lung carcinoma (SCLC-V) or non-small cell lung 
carcinoma with neuroendocrine differentiation. INA was therefore chosen for validation 
in DLKP based on novelty, relating to lung cancer and on its association with pancreatic 
neuroendocrine cancer. 
 
Immunofluorescence (Figure 3.2-6 (A)) and immunocytochemical (Figure 3.2-6 (C)) 
analysis of INA indicated that immunoreactivity was observed in DLKP, DLKPSQ and 
DLKPM. Expression appears to be strongest in DLKPSQ and weak immunoreactivity 
observed in DLKPI. Western blot analysis (Figure 3.2-6 (B)) confirmed expression of 
INA in whole cell lysates and membrane enriched samples of DLKP and its clones. INA 
appears to show association with the membrane of DLKPSQ and not for DLKP. 
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Figure 3.2-6:- Validation of INA expression in DLKP. 
(A) Immunofluorescence staining of INA in DLKP and the clones (n=1). (B) Representative 
Immunoblot showing expression of INA in the DLKP clones (α-tubulin was used as an equal 
loading control (n=3)). (C) Immunocytochemical staining of INA, strongest immunoreactivity 
was observed in DLKPSQ (Original magnification of all photomicrographs, ×400, scalebar = 
50μm (A) and 200μm (C)). 
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3.2.7 Validation of SPR in DLKP 
Sepiapterin Reductase (SPR) is a 27-kDa enzyme localised to the cytoplasm. It is 
involved in the final two steps in the conversion of 6-pyruvol-tetrahydrobiopterin to 
tetrahydrobiopterin (BH4), an essential co-factor of nitric oxide synthase. Nitric oxide 
synthase (NOS) is required for the conversion of L-Arginine to Citrulline or nitric oxide. 
Comparative proteomics analysis found increased expression of SPR in DLKPSQ vs. 
DLKPI (3.64 fold) (see Table 3.1-5). In addition, microarray analysis previously carried 
out on DLKP and its clones indicated that SPR was overexpressed in DLKPSQ and 
DLKPM relative to DLKPI. 
 
Immunofluorescence analysis of SPR (Figure 3.2-7 (A)) shows that immunoreactivity 
was observed DLKP, DLKPSQ and DLKPM. Expression appears to be strongest in 
DLKPSQ, with weak immunoreactivity observed in DLKPI. In DLKPSQ, 
immunoreactivity appears to be nuclear or sub-cytoplasmic. Western blot analysis (Figure 
3.2-7 (B)) confirmed expression of SPR in whole cell lysates and membrane enriched 
samples of DLKP and its clones. 
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Figure 3.2-7:- Validation of SPR expression in DLKP. 
(A) Immunofluorescence staining of SPR in DLKP and its clones, n=1. (B) Representative 
Immunoblot showing expression of SPR in the DLKP clones (α-tubulin was used as an equal 
loading control (n=3)). Strongest Immunoreactivity was observed in DLKPSQ (Original 
magnification of all photomicrographs, ×400, scalebar = 50μm). 
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3.2.8 BreastMark Analysis 
Breast cancer is a heterogeneous disease of which the majority of cases develop resistance 
to drugs despite advances in early detection and the progress made in the treatment of 
patients using systemic agents. This becomes a challenge for clinicians who are involved 
in the treatment of patients. It is, therefore, critical in the effective treatment of breast 
cancer (and other cancers) to identify and target the pathways that promote or sustain 
growth and invasion of cancer cells. There is a greater understanding of the molecular 
mechanisms underlying carcinogenesis which has led to the identification of novel 
molecular targets and development of targeted therapies [114, 115]. Targeted therapies 
for breast cancer include the use of tyrosine kinase inhibitors (TKIs) that target HER1, 
HER2, HER3, IGF receptor, C-MET and FGF receptor, but also inhibitors of intracellular 
signalling pathways such as PI3K, AKT, mTOR and ERK [116]. We used BreastMark to 
evaluate the significance of the markers identified in this thesis in relation to survival of 
patients with breast cancer. BreastMark is an algorithm developed to allow for the 
identifications of genes that are associated with disease progression in various breast 
cancer subtypes. It integrates gene expression and survival data from 26 datasets on 12 
different microarray platforms corresponding to ~17,000 genes in up to 4,738 clinical 
samples. [117]. 
The prognostic significance of each of the proteins validated in section 3.2.8 was 
determined for each breast cancer molecular subtype (i) Luminal A (ii) Luminal B (iii) 
Her2+ and (iv) Basal-like. Validated proteins were analysed using the combined survival 
option in BreastMark, where he outcome is overall survival. The Kaplan Meir survival 
curves are presented in Figure 3.2-8 to Figure 3.2-15 for each of the validated proteins, 
results are summarised in Table 3.2-1. Of the eight proteins chosen for validation studies, 
BreastMark analysis indicated that six of those were statistically significant and 
potentially worthy of further investigation in breast cancer. 
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Target 
Significance in Molecular 
subtypes 
Patient 
outcome 
Hazard 
Ratio 
p-
value 
AHNAK High expression in Luminal B Better 0.88 0.0330 
ALCAM Not significant in Luminal A, Luminal B, Her2+ or Basal subtypes 
HDGF Low expression Luminal A Better 1.27 0.0094 
INA High expression in Luminal B Better 0.27 0.0009 
IQGAP1 High expression in Luminal A Better 0.72 0.0006 
ROBO2 Expression not significant in Luminal A, Luminal B, Her2+ or Basal subtypes 
SLIT2 Expression not significant in Luminal A, Luminal B, Her2+ or Basal subtypes 
SPR 
Low expression in Luminal A Poor 1.36 0.0019 
Low expression in Basal Poor 1.33 0.0228 
Table 3.2-1:- Summary of BreastMark survival analysis performed on validated proteins. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-8:- Survival analysis of AHNAK expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of AHNAK expression in molecular subtypes 
of breast cancer; (a) Luminal A (n= 1544, HR = 0.8314 (0.6875 - 1.005), p=0.05663), (b) Luminal 
B (n= 1473, HR = 0.8344 (0.7063 - 0.9858), p=0.03305), (c) Her2+ (n= 377, HR = 0.9786 (0.719 
- 1.332), p=0.8907) and (d) Basal-like (n= 674, HR = 1.085 (0.8064 - 1.459), p=0.5907). Kaplan-
Meier graph representing survival prognosis in patients based on high or low expression of 
AHNAK in their tumour. Data generated using BreastMark at 
http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-9:- Survival analysis of HDGF expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of HDGF expression in molecular subtypes of 
breast cancer; (a) Luminal A (n= 1650, HR = 1.271 (1.06 - 1.523), p=0.0094), (b) Luminal B (n= 
1499, HR = 0.992 (0.8436 - 1.166), p=0.9224), (c) Her2+ (n= 417, HR = 1.293 (0.9678 - 1.728), 
p=0.0813) and (d) Basal-like (n= 710, HR = 0.9072 (0.6951 - 1.184), p=0.4732). Kaplan-Meier 
graph representing survival prognosis in patients based on high or low expression of HDGF in 
their tumour. Data generated using BreastMark at http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
   
Figure 3.2-10:- Survival analysis of SLIT2 expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of SLIT2 expression in molecular subtypes of 
breast cancer; (a) Luminal A (n= 1523, HR = 0.9492 (0.7858 - 1.147), p=0.5883), (b) Luminal B 
(n= 1464, HR = 0.928 (0.7851 - 1.097), p=0.3809), (c) Her2+ (n= 371, HR = 0.752 (0.5509 - 
1.026), p=0.07161) and (d) Basal-like (n= 662, HR = 1.134 (0.8808 - 1.46), p=0.3288). Kaplan-
Meier graph representing survival prognosis in patients based on high or low expression of SLIT2 
in their tumour. Data generated using BreastMark at http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-11:- Survival analysis of ROBO2 expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of ROBO2 expression in molecular subtypes 
of breast cancer; (a) Luminal A (n= 338, HR = 0.9812 (0.7023 - 1.371), p=0.9112), (b) Luminal 
B (n= 376, HR = 0.9626 (0.7186 - 1.29), p=0.7984), (c) Her2+ (n= 112, HR = 1.005 (0.6062 - 
1.666), p=0.9842) and (d) Basal-like (n= 187, HR = 1.116 (0.7032 - 1.771), p=0.6415). Kaplan-
Meier graph representing survival prognosis in patients based on high or low expression of 
ROBO2 in their tumour. Data generated using BreastMark at 
http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-12:- Survival analysis of ALCAM expression in breast cancer 
Kaplan-Meier estimates of prognostic significance of ALCAM expression in molecular subtypes 
of breast cancer; (a) Luminal A (n= 1630, HR = 0.9045 (0.7509 - 1.089), p=0.2902), (b) Luminal 
B (n= 1474, HR = 1.075 (0.9124 - 1.266), p=0.3879), (c) Her2+ (n= 399, HR = 0.8696 (0.6478 - 
1.167), p=0.3521) and (d) Basal-like (n= 704, HR = 1.064 (0.7813 - 1.449), p=0.6938).  Kaplan-
Meier graph representing survival prognosis in patients based on high or low expression of 
ALCAM in their tumour. Data generated using BreastMark at 
http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-13:- Survival analysis of IQGAP1 expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of IQGAP1 expression in molecular subtypes 
of breast cancer; (a) Luminal A (n= 1650, HR = 0.729 (0.6079 - 0.8741), p=0.0006124), (b) 
Luminal B (n= 1499, HR = 0.8769 (0.7438 - 1.034), p=0.1174), (c) Her2+ (n= 417, HR = 1.207 
(0.8871 - 1.643), p=0.2301) and (d) Basal-like (n= 710, HR = 1.004 (0.7958 - 1.267), 
p=0.9711). Kaplan-Meier graph representing survival prognosis in patients based on high or low 
expression of IQGAP1 in their tumour. Data generated using BreastMark at 
http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-14:- Survival analysis of INA expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of INA expression in molecular subtypes of 
breast cancer; (a) Luminal A (n= 1544, HR = 1.15 (0.9259 - 1.428), p=0.2061), (b) Luminal B 
(n= 1473, HR = 0.7271 (0.6018 - 0.8783), p=0.000904), (c) Her2+ (n= 377, HR = 0.9656 (0.6877 
- 1.356), p=0.84) and (d) Basal-like (n= 674, HR = 1.004 (0.7862 - 1.281), p=0.9772). Kaplan-
Meier graph representing survival prognosis in patients based on high or low expression of INA 
in their tumour. Data generated using BreastMark at http://glados.ucd.ie/BreastMark/index.html. 
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(a)  (b)  
  
(c)  (d)  
  
Figure 3.2-15:- Survival analysis of SPR expression in breast cancer. 
Kaplan-Meier estimates of prognostic significance of SPR expression in molecular subtypes of 
breast cancer; (a) Luminal A (n= 1678, HR = 1.366 (1.121 - 1.664), p=0.001923), (b) Luminal B 
(n= 1519, HR = 0.9395 (0.8002 - 1.103), p=0.4459), (c) Her2+ (n= 423, HR = 1.317 (0.9721 - 
1.783), p=0.07463) and (d) Basal-like (n= 714, HR = 1.335 (1.04 - 1.714), p=0.02289). Kaplan-
Meier graph representing survival prognosis in patients based on high or low expression of SPR 
in their tumour. Data generated using BreastMark at http://glados.ucd.ie/BreastMark/index.html. 
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3.2.9 Summary of results from validation experiments 
Proteins identified through comparative proteomic analysis performed on DLKP, 
DLKPSQ, DLKPI and DLKPM cell lines revealed a number of differentially expressed 
proteins between within DLKP cell line model. Six proteins (AHNAK, ALCAM, HDGF, 
IQGAP1, ROBO2 and SPR) were selected directly from this analysis. INA was selected 
based on its association with neuroendocrine pancreatic cancer and its novelty. SLIT2 
was selected due to its association with its receptor ROBO2, identified in the proteomic 
analysis presented in. All of the selected proteins were examined in DLKP, DLKPSQ, 
DLKPI and DLKPM cells and their expression was presented in section 3.2. Some 
differences in the expression levels of the proteins were observed between each of the 
techniques used for validation, however, overall the expression patterns of individual 
proteins showed similar trends. Table 3.2-2 presents a representative indication of the 
expression of each of the protein validated by Western blot analysis (of the whole cell, 
membrane enriched and/or conditioned medium samples), Immunofluorescence, and/or 
Immunocytochemical analysis of the cell lines.  
 DLKP DLKPSQ DLKPI DLKPM 
AHNAK + + ++++ ++++ 
ALCAM + -/+ ++++ + 
HDGF ++ + + + 
INA ++ ++ -/+ + 
IQGAP1 ++ + ++ +++ 
ROBO2 + ++ + ++ 
SLIT2 ++ + + ++ 
SPR + ++ + ++ 
Table 3.2-2:- Summary table showing representative expression of the proteins validated in 
DLKP and its clones. 
-/+  absent or weak expression 
+ weak expression 
++ moderate expression 
+++ strong expression 
++++  very strong expression 
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3.3 Expression of selected proteins in human cancer cell lines. 
Comparative proteomics analysis was used to select differentially expressed proteins as 
potential markers for DLKP clones. A number of proteins were selected and validated by 
Western blot analysis, Immunofluorescence and Immunohistochemistry. AHNAK, 
ROBO2, ALCAM, IQGAP1, and SPR were selected following membrane proteomics. 
SLIT2 was selected from microarray analysis, through its association with the ROBO2 
receptor. HDGF was selected from membrane proteomics, however, less stringent criteria 
were applied. These proteins were examined further for their expression across panels of 
representative tumour cell lines including lung cancer, pancreatic cancer, TNBC, colon, 
glioma, melanoma and neuroblastoma. 
3.3.1 Expression of validated proteins in a representative panel of lung 
cancer cell lines 
Preliminary investigations were carried out to examine the expression of HDGF, SLIT2, 
ALCAM, INA and SPR in a representative panel of lung cancer cell lines. The full panel 
of cell lines including their subtypes are shown in Table 3.3-1 below: 
Subtype Abbreviation Cell lines 
Small Cell Lung Cancer SCLC NCI-H69, NCI-H82, DMS-53 
Large Cell Lung Cancer LCLC NCI-H460, H1229 
Adenocarcinoma AC A549, SK-LU-1 
Squamous Cell Carcinoma SCC DLRP, SKMES-1 
Table 3.3-1:- Lung cancer cell lines used to examine the expression of protein targets. 
 
HDGF expression appears to be strongest in the SCLC and AC cell lines, while lower 
expression levels were observed in the remaining subtypes (Figure 3.3-1), SLIT2 (Figure 
3.3-2) and ALCAM (Figure 3.3-3) expression appears to be strongest in NCI-H69 
(SCLC) and lower expression levels were observed in the remaining subtypes. SCC cell 
lines were not available at the time of carrying out western blot analysis of HDGF, SLIT2, 
ALCAM and INA, but their expression should be examined in this lung cancer subtype. 
Expression of INA in the whole cell preparations displayed strongest expression in all 
SCLC cell lines, in one LCLC (H1229) and in one SCC (SKMES-1), while low to an 
absence of expression was observed in AC and in the remaining cell lines. Analysis of 
the panel for membrane expression appears to associate INA to SCLC cell lines since no 
 89 
 
detectable levels of INA was observed in LCLC and AC cell lines (Figure 3.3-4). 
Expression of SPR in whole cell preparations and membrane preparations appears to be 
strongest in DMS-53 (SCLC), A549 (AC) and DLRP and SKMES-1 (SCC) cell lines, 
strong expression was also observed in LCLC and AC cell lines, while low level 
expression was observed in two SCLC cell lines (Figure 3.3-5). Western blot analysis of 
the markers in cell lines representing various lung cancer subtypes appears to show strong 
expression in the SCLC subtype. The expression of these markers in DLKP could suggest 
a potential SCLC component in DLKP, which was originally proposed by McBride, 1995  
[93]. To confirm this suggestion, further analysis should be carried out using these 
markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3-1:- Western blot analysis of HDGF expression in lung cancer cell lines. 
Representative immunoblot showing expression of HDGF in; (i) SCLC: NCI-H69, NCI-H82 and 
DMS-53, (ii) LCLC: NCI-H460 and H1229 and (iii) AC: A549 and SK-LU-1. Membrane 
enriched samples were separated by SDS-PAGE and probed with an antibody specific to HDGF. 
SCLC cell lines appear to show the strongest expression of HDGF (n=1). 
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Figure 3.3-2:- Western blot analysis of SLIT2 expression in lung cancer cell lines. 
Representative immunoblot showing expression of SLIT2 in; (i) SCLC: NCI-H69, NCI-H82 and 
DMS-53, (ii) LCLC: NCI-H460 and H1229 and (iii) AC: A549 and SK-LU-1. Membrane 
enriched samples were separated by SDS-PAGE and probed with an antibody specific to SLIT2. 
NCI-H82 appears to show the strongest expression of SLIT2 (DLKPM served as a positive 
control) (n=1). 
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Figure 3.3-3:- Western blot analysis of ALCAM in lung cancer cell lines 
Representative immunoblot showing expression of ALCAM in; (i) SCLC: NCI-H69, NCI-H82 
and DMS-53, (ii) LCLC: NCI-H460 and H1229 and (iii) AC: A549 and SK-LU-1. Membrane 
enriched samples were separated by SDS-PAGE and probed with an antibody specific of 
ALCAM. NCI-H69 appears to show the strongest expression of ALCAM. (n=1). 
 
 
 
 
 
 
 
 
 
 
 
 
ALCAM 
105kDa 
SCLC LCLC AC 
 93 
 
 
 
 
 
 
 
A.   
 
 
 
 
 
    
 
B.  
 
 
 
 
 
    
 
Figure 3.3-4:- Western blot analysis of INA in lung cancer cell lines. 
Representative immunoblot showing expression of INA in; (i) SCLC: NCI-H69, NCI-H82 and 
DMS-53, (ii) LCLC: NCI-H460 and H1229, (iii) AC: A549 and SK-LU-1 and (iv) SCC: DLRP 
and SKMES-1. Expression of INA was examined in; (a) whole cell lysates (α-tubulin served as 
loading control) and (b) membrane enriched samples were separated by SDS-PAGE and probed 
with an antibody specific to INA. NCI-H69 and NCI-H82 appear to show the strongest expression 
of INA (n=1). 
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Figure 3.3-5:- Western blot analysis of SPR in lung cancer cell lines. 
Representative immunoblot showing expression of SPR in, (i) SCLC: NCI-H69, NCI-H82 and 
DMS-53, (ii) LCLC: NCI-H460 and H1229, (iii) AC: A549 and SK-LU-1 and (iv) SCC: DLRP 
and SKMES-1. Expression of SPR was examined in; (a) whole cell lysates (α-tubulin served as 
loading control), (b) membrane enriched fractions samples were separated by SDS-PAGE and 
probed with an antibody specific to SPR (n=1). 
 
 
 
 
 
 
 
 
 
SPR 
27kDa 
  
SCLC LCLC AC SCC 
α-Tubulin 
52kDa 
SPR 
27kDa 
 95 
 
3.3.2 Expression of validated proteins in a representative panel of TNBC 
cell lines 
Preliminary investigations were carried out to examine the expression of HDGF, INA and 
SPR in a representative panel of triple negative breast cancer (TNBC) cell lines. Survival 
analysis using the BreastMark algorithm did not find the expression of SLIT2 and 
ALCAM to be statistically significant in patients with breast cancer and were therefore 
excluded from this analysis. The full panel of cell lines including their subtypes are shown 
in Table 3.3-2 below: 
Molecular subtype Abbreviation Cell lines 
Basal-like-1 BL-1 HCC-1143, MDA-MB-468. 
Basal-like-2 BL-2 HCC1937, CAL-851, HDQP-1. 
Mesenchymal M CAL-51 
Mesenchymal-like MSL Hs-578-T, MDA-MB-231, MDA-MB-157. 
Table 3.3-2:- TNBC cell lines used to examine the expression of protein targets. 
Whole cell lysates were used to examine the expression of HDGF, INA and SPR in this 
cell line panel. Western blot analysis revealed strong expression of HDGF across the 
TNBC subtypes (Figure 3.3-6). INA appeared to show strongest expression in HCC-1937 
and HCC-1143 (BL-1), with strong expression was also observed in HDQP-1 (M) and 
MDA-MB-157 (MSL) cell lines. Low level to an absence of expression was observed in 
the remaining cell lines on the panel (Figure 3.3-7). Expression of SPR appeared to be 
strongest in MDA-MB-468 (BL-1), CAL-51 (M) and MDA-MB-231 and MDA-MB-157 
(MSL) cell lines, while lower expression levels were observed in BL-2 (CAL-851 and 
HDQP-1) and in the remaining cell lines on the panel (Figure 3.3-8). There are clear 
differences in the expression of these targets across the panel of TNBC cell lines, but SPR 
and INA appear to be strongly expressed in BL-1 breast cancer.  
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Figure 3.3-6:- Western blot analysis of HDGF in TNBC cell lines. 
Representative immunoblot showing expression of HDGF in; (i) BL-1: HCC1937, HCC-1143 
and MDA-MD-468, (ii) BL-2: CAL-851 and HDQP-1, (iii) M: CAL-51 and (iv) MSL: Hs-578-
T, MDA-MB-231 and MDA-MB-157. Samples were separated by SDS-PAGE and probed with 
an antibody specific to HDGF. Strong expression is observed across TNBC (α-tubulin served as 
loading control (n=1)). 
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Figure 3.3-7:- Western blot analysis of INA in TNBC cell lines. 
Representative immunoblot showing expression of INA in; (i) BL-1: HCC1937, HCC-1143 and 
MDA-MD-468, (ii) BL-2: CAL-851 and HDQP-1, (iii) M: CAL-51 and (iv) MSL: Hs-578-T, 
MDA-MB-231 and MDA-MB-157. Samples were separated by SDS-PAGE and probed with an 
antibody specific to INA. Expression of INA appears to be strongest in the BL-1 subtype. (α-
tubulin served as loading control) n=1. 
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Figure 3.3-8:- Western blot analysis of SPR in TNBC cell lines. 
Representative immunoblot showing expression of SPR in; (i) BL-1: HCC1937, HCC-1143 and 
MDA-MD-468, (ii) BL-2: CAL-851 and HDQP-1, (iii) M: CAL-51 and (iv) MSL: Hs-578-T, 
MDA-MB-231 and MDA-MB-157. Samples were separated by SDS-PAGE and probed with an 
antibody specific to SPR. SPR expression is observed across TNBC cell lines (α-tubulin served 
as loading control (n=1)). 
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3.3.3 Expression of validated proteins in a representative panel of 
pancreatic cancer cell lines 
Preliminary investigations were carried out to examine the expression of HDGF, 
ALCAM, INA and SPR in a representative panel of pancreatic cancer cell lines. SLIT2 
was not included in this analysis. INA was included in this analysis, however, extremely 
low level of expression to the absence of expression was observed (data not shown). The 
panel of cell lines was BxPc-3, HPAC, Panc-1, MiaPaca2, MiaPaca2 clone3, AsPc-1 and 
Capan-1 (all cell lines are pancreatic ductal adenocarcinoma).  
Western blot analysis was used to examine the expression of HDGF, ALCAM and SPR 
in (a) Whole cell lysates and/or (b) membrane-enriched fractions of the cell lines. HDGF 
showed strong expression across all pancreatic cancer cell lines, with Panc-1 showing 
lowest expression levels. Strong expression of HDGF was also observed in whole cell 
lysates obtained from explanted human pancreatic cancer tumour cells. An increased 
membrane expression of HDGF was observed in MiaPaca2 clone3 (invasive clone of 
MiaPaca2) compared to its parental cell line. Figure 3.3-9 shows expression of HDGF in 
(a) Whole cell lysates (b) membrane enriched fractions and (c) cells recovered via explant 
culture from two human pancreatic cancer tumours (explant culture was performed by 
Dr. Fiona O’Neill and Dr. Sandra Roche, whole cell and membrane samples were 
prepared by Edel McAuley). 
ALCAM appeared to show strong expression in BxPc-3, with low level to no expression 
observed in the remaining cell lines on the panel (Figure 3.3-10). Strong expression of 
SPR was observed in whole cell lysates across the panel of pancreatic cancer cell lines, 
with exception of BxPc-3 showing weakest SPR expression. Expression in membrane 
enriched preparations appear to be much lower, with AsPc-1 displaying strongest 
expression (Figure 3.3-11). Both whole cell lysate and membrane samples appear to show 
increased expression in the invasive MiaPaca2 clone3 cell line compared to its parental. 
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Figure 3.3-9:- Western blot analysis of HDGF in pancreatic cancer cell lines. 
Representative immunoblot showing expression of HDGF in; (a) whole cell Lysates of BxPc-3, 
HPAC, Panc-1, MiaPaca2, MiaPaca2 clone3, AsPc-1 and Capan-1 (α-tubulin served as loading 
control).  (b) membrane enriched fractions of BxPc-3, AsPc-1, Panc-1, MiaPaca2 and MiaPaca2 
clone2 and (c) membrane samples and whole cell lysates from explanted human patient tumour 
cells. Samples separated by SDS-PAGE and probed with an antibody specific to HDGF (n=1). 
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Figure 3.3-10:- Western blot analysis of ALCAM in pancreatic cancer cell lines. 
Representative immunoblot showing expression of ALCAM in membrane enriched samples of 
BxPc-3, AsPc-1, Panc-1, MiaPaCa2 and MiaPaCa2 clone3 invasive. Samples were separated by 
SDS-PAGE and probed with an antibody specific to ALCAM. Expression of ALCAM appears 
strongest in the membrane fractions of BxPc-3 (n=1). 
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Figure 3.3-11:- Western blot analysis of SPR in pancreatic cancer cell lines. 
Representative immunoblot showing expression of SPR in; BxPc-3, HPAC, Panc-1, MiaPaCa2, 
MiaPaCa2 clone3, and clone3 (B), AsPc-1 and Capan-1. SPR expression was examined in (a) 
whole cell lysates and (b) membrane enriched fractions, samples were separated by SDS-PAGE 
and probed with an antibody specific to SPR (n=1). 
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3.3.4 Expression of validated proteins in colon, glioma neuroblastoma and 
melanoma cell lines 
Preliminary investigations were carried out to examine expression HDGF, ALCAM, INA 
and SPR in representative cell lines from colon, glioma, neuroblastoma and melanoma 
tumour types. The cell lines used are presented in Table 3.3-3 below.  
Tumour type Cell line 
SW480 Primary colon 
SW620 Metastatic colon 
SNB-19 Glioma 
SK-N-SH Neuroblastoma 
LOX IVMI Melanoma 
Table 3.3-3:- Colon, glioma, neuroblastoma and melanoma cell lines used for Western blot 
analysis. 
Western blot analysis was used to examine the expression of HDGF, ALCAM, INA and 
SPR in whole cell lysates and/or membrane enriched fractions of the cell lines. Strong 
expression of HDGF was observed in the metastatic colon cancer cell line (SW620) 
versus the isogenic primary cell line (SW480) from the same patient, strong expression 
was also observed in glioma and melanoma cell lines (Figure 3.3-12). ALCAM 
expression was increased in glioma and melanoma, while expression of ALCAM 
appeared to be undetectable in both colon cancer cell lines (Figure 3.3-13).  
Increased expression of INA was also observed in membrane enriched fractions of 
neuroblastoma compared to glioma (Figure 3.3-14), while whole cell lysates indicate 
increased expression of SPR in glioma compared to neuroblastoma (Figure 3.3-15).  
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Figure 3.3-12:- Western blot analysis of HDGF in colon, glioma and melanoma cell lines. 
Representative immunoblot showing expression of HDGF in; colon (SW480 and SW620), glioma 
(SNB-19) and melanoma (Lox) cell lines. HDGF expression appears to be increased in the 
metastatic colon cell line (SW620) compared the primary colon (SW480), samples were separated 
by SDS-PAGE and probed with an antibody specific to HDGF (n=1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3-13:- Western blot analysis of ALCAM in colon, glioma and melanoma cell lines. 
Representative immunoblot showing expression of ALCAM in; colon (SW480 and SW620), 
glioma (SNB-19) and melanoma (Lox) cell lines. Low expression of ALCAM was observed in 
glioma and melanoma cell lines, samples were separated by SDS-PAGE and probed with an 
antibody specific to ALCAM (n=1). 
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Figure 3.3-14:- Western blot analysis of INA in neuroblastoma and glioma cell lines. 
Representative immunoblot showing expression of INA in neuroblastoma (SK-N-SH) and glioma 
(SNB-19). Increased expression of INA is observed in the neuroblastoma cell line vs. glioma, 
samples were separated by SDS-PAGE and probed with an antibody specific to INA. Increased 
expression of INA is observed in SK-N-SH (n=1).  
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Figure 3.3-15:- Western blot analysis of SPR in neuroblastoma and glioma cell lines. 
Representative immunoblot showing expression of SPR in neuroblastoma (SK-N-SH) and glioma 
(SNB-19). SPR expression was examined in; (a) whole cell lysates and (b) membrane enriched 
fractions, samples were separated by SDS-PAGE and probed with an antibody specific to INA. 
Increased expression of SPR was observed in SNB-19 vs. SK-N-SH cell line (n=1). 
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3.3.5 Summary of immunoreactivity in DLKP Cell lines and Human cancer 
cell lines 
 HDGF, SLIT2, ALCAM, INA and SPR were examined for their expression in a 
representative panel of lung cancer cell lines. Expression of all proteins was found 
in all subtypes, the SCLC subtype displayed the strongest expression of each 
protein target. 
 HDGF, INA and SPR were examined for their expression in a representative panel 
of TNBC cell lines. Expression of these protein targets was found in all of the cell 
lines used in this panel. However, INA appeared to show strong expression in a 
small number of the TNBC cell lines used, but absent in the remaining cell lines 
on the panel.  
 Strong expression of HDGF and SPR was observed in a representative panel of 
pancreatic cancer cell lines. HDGF expression was decreased in the invasive 
MiaPaCa2 clone 3 vs. MiaPaCa2 parent, but also in the metastatic colon cell line 
(SW480) compared to the primary (SW620). SPR expression was increased in 
MiaPaCa2 clone3 vs. MiaPaCa2 parent but was highest in the AsPc-1 (a cell line 
established from an ascites). Both proteins should be investigated further as 
having a potential association with cancer invasion. 
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3.4 Functional analysis of target proteins by siRNA knockdown 
Differentially expressed protein targets were chosen based on comparative proteomic 
analysis of DLKP, DLKPSQ, DLKPI and DLKPM cell lines. Conditions were optimised 
in 6-well plates (see section 2.7.1) using a positive control (Kinesin (Ambion) or Cell 
Death (Qiagen) and a negative control (scrambled-2 siRNA (Ambion) or negative control 
siRNA (Qiagen)). Un-transfected cells (Control) and NeoFX or lipofectamine (Lipo) 
were also included in all sets of transfections as further controls.  
 
Three protein targets were chosen to investigate their functional roles in DLKP; (i) 
Activated leukocyte cell adhesion molecule (ALCAM), (ii) α-Internexin (INA) and (ii) 
Sepiapterin Reductase (SPR) and were all shown to be expressed in DLKP and its clones 
(see section 3.2).  These three proteins were considered for follow up functional studies 
based on their expression profile in the DLKP cell line model and whether they could be 
used as potential markers for any of the clones. Other considerations included the 
availability of commercially produced siRNAs (ALCAM (AmbionInc, 4392420), INA 
(Qiagen, GC9118) and SPR (Qiagen, GS6697), a suitable antibody for evaluation by 
Western blot analysis and on their novelty. 
 
Seventy-two hours post transfection:  
 Western blot analysis (see section 2.3) was performed to confirm knockdown of 
each protein, whole cell lysates were prepared and separated by SDS-PAGE and 
analysed using specific antibodies targeted at each protein. 
 Acid-phosphatase assays (see section 2.5) were carried out on transfected cells to 
assess the impact of a specific protein knockdown on growth. 
 Invasion assays (see section 2.4.1) were carried out on transfected cells to 
investigate if the proteins play a functional role in invasion. 
 Migration assays (see section 2.4.2) were carried out on transfected cells to 
investigate if the proteins play a functional role in migration. 
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3.4.1 Investigation into the role of ALCAM in lung cancer 
The comparative proteomic analysis identified ALCAM to be differentially expressed 
between DLKPSQ, DLKPI and DLKPM, highest ALCAM expression was observed in 
DLKPI. The analysis showed that ALCAM was increased by ~30-fold when compared 
to DLKP, DLKPSQ and DLKPM. Expression of ALCAM was confirmed by 
Immunofluorescence, Western blot analysis and Immunocytochemistry in section 3.2.4. 
Three cell lines were chosen to investigate a functional role for ALCAM in lung cancer 
(i) DLKPSQ-Mitox-BCRP-6P, (ii) DLKPM and (iii) DLKPI.  
3.4.1.1 Effect of siRNA knockdown of ALCAM on DLKPSQ-Mitox-BCRP-6P 
DLKPSQ-Mitox-BCRP-6P is an invasive drug resistant variant of DLKPSQ. DLKPSQ-
Mitox-BCRP-6P was chosen for ALCAM knockdown studies because this cell line was 
previously shown to exhibit an increased invasive capacity and increased expression of 
ALCAM compared to the parental DLKPSQ cell line [96]. Figure 3.4-1 (a) shows by 
Western blot analysis, the efficient knockdown of ALCAM in one of two siRNAs used 
to transfect DLKPSQ-Mitox-BCRP-6P cells compared to negative control and un-
transfected cells.  
 
Seventy-two hours post-transfection with ALCAM siRNAs, invasion assays were 
performed. The total number of cells invading was increased in DLKPSQ-Mitox-BCRP-
6P cells transfected with ALCAM siRNAs. Figure 3.4-2 (a) shows representative images 
of invading cells and (b) the total number of invading cells post siRNA transfection.  
ALCAM siRNA transfection increased the invasion capabilities of the cells. Invasion was 
increased by 55% (p=0.0563) with ALCAM-1 and a significant increase 111% 
(p=0.0040) for ALCAM-2, when compared to negative control. This significant increase 
in the invasive ability was a surprising result as a reduction was expected following 
ALCAM knockdown. 
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(a) 
 
 
 
(b) 
 
Figure 3.4-1:- ALCAM knockdown reduced cell growth of DLKPSQ-mitox-BCRP-6P. 
(a) Representative immunoblot showing efficient knockdown of ALCAM 72hrs post-transfection 
in DLKPSQ-Mitox-BCRP-6P cells transfected with two independent siRNAs targeting ALCAM 
relative to negative control siRNA transfected cells (GAPDH served as a loading control). (b) 
Proliferation assays on siRNA transfected DLKPSQ-mitox-BCRP-6P cells targeting ALCAM. 
Results graphed as % cell survival relative to negative control siRNA in a single experiment 
(n=1).  
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(a) 
  
  
 (b) 
 
 
Figure 3.4-2:- ALCAM increases the invasive capacity of DLKPSQ-mitox-BCRP-6P. 
(a) Invasion assays of DLKPSQ-Mitox-BCRP-6P cells (i) Untreated control (ii) Negative control 
(iii) ALCAM-1 siRNA and (iv) ALCAM-2 siRNA (Magnification, x100; scale bar = 500µm) (b) 
Histogram showing an increase in the total number of invading DLKPSQ-mitox-BCRP-6P cells 
post siRNA transfection targeting ALCAM. Data plotted represents the mean ± standard deviation 
of duplicate trans-well inserts from triplicate biological assays. Statistics **p≤0.01 and compared 
with negative control siRNA. Student’s t test (two-tailed with equal variance, unpaired (n=3)). 
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3.4.1.2 Effect of siRNA knockdown of ALCAM on DLKPM 
Western blot analysis (Figure 3.4-3 (a)) shows the efficient knockdown of ALCAM in 
DLKPM cells transfected with two siRNAs, compared to negative control and un-
transfected cells. Proliferation assays (Figure 3.4-3 (b)) showed a slight reduction in 
growth in ALCAM-1 siRNA (p= 0.023) and no effect using ALCAM-2. The effect seen 
on growth using ALCAM-1 could be as a result of an off target effect. 
 
Seventy-two hours post-transfection with ALCAM siRNAs; Western blot analysis and 
invasion assays were performed. The total number of cells invading was reduced in 
DLKPM cells transfected with ALCAM siRNAs. Figure 3.4-4 (a) shows representative 
images of invading cells and (b) shows the total number of invading cells following 
siRNA knockdown. ALCAM siRNA transfection reduced the invasion capabilities of the 
cells. Invasion was significantly decreased using ALCAM-1 (p=0.05) by 19% and 51% 
(p=0.004) for ALCAM-2, when compared to negative control. 
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(a)  
 
(b)   
 
 
Figure 3.4-3:- ALCAM knockdown shows no effect on cell growth of DLKPM. 
(a) Representative immunoblot showing knockdown of ALCAM 72hrs post-transfection in 
DLKPM cells transfected with two independent siRNAs targeting ALCAM relative to negative 
control siRNA transfected cells (GAPDH served as a loading control). (b) Proliferation assays 
showing the effect of ALCAM on DLKPM cells targeting ALCAM. Results graphed as % cell 
survival relative to negative control siRNA. Data plotted represents the mean ± standard deviation 
of from triplicate biological assays. Statistics *p≤0.05 compared with negative control siRNA. 
Student’s t test (two-tailed with equal variance, unpaired (n=3)). 
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(a)  
  
  
(b)  
 
 
Figure 3.4-4:- ALCAM decreases the invasive capacity of DLKPM cells. 
(a) Invasion assays of DLKPM cells (i) Untreated control (ii) Negative control (iii) ALCAM-1 
siRNA and (iv) ALCAM-2 siRNA, (Magnification, x100; scale bar = 500µm). (b) Histogram 
showing a reduction in the total number of invading DLKPM cells following transfection 
targeting ALCAM. Data plotted represent the mean ± standard deviation of duplicate transwell 
inserts from triplicate biological assays. Statistics *p≤0.05 and **p≤0.01 compared with negative 
control siRNA. Student’s t test (two-tailed with equal variance, unpaired (n=3)). 
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3.4.1.3 Effect of siRNA knockdown of ALCAM on DLKPI 
Western blot analysis (Figure 3.4-5 (a)) shows a partial knockdown of ALCAM in DLKPI 
cells transfected with two siRNAs, compared to negative control and un-transfected cells. 
The partial knockdown achieved as a result of transfection of ALCAM in DLKPI may be 
due to the extremely high levels of ALCAM these cells. Proliferation assays (Figure 
3.4-5(b)) shows a slight decrease in growth for DLKPI cells. 
 
Seventy-two hours post-transfection with ALCAM siRNAs, invasion assays were 
performed. The total number of cells invading was increased slightly in DLKPI cells 
transfected with both ALCAM siRNAs. Figure 3.4-6 (a) shows representative images of 
invading cells and (b) shows the total number of invading cells following siRNA 
knockdown. No significant increase was observed for ALCAM transfected DLKPI cells 
using ALCAM-1 (p=0.079) and ALCAM-2 (p=0.057) siRNAs. 
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(a)  
 
 
(b)  
 
Figure 3.4-5:- ALCAM knockdown shows no effect of cell growth of DLKPI cells. 
(a) Representative immunoblot showing a partial knockdown of ALCAM at 72hrs post-
transfection in DLKPI cells transfected with two independent siRNAs targeting ALCAM 
(GAPDH served as a loading control). (b) Proliferation assays on siRNA transfected DLKPI cells 
indicate a slight reduction in monolayer cell growth. Results graphed as % cell survival relative 
to negative control siRNA in one experiment (n=1). 
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(a)  
  
  
(b)  
 
Figure 3.4-6:- ALCAM increases the invasive capacity of DLKPI cells. 
(a) Invasion assays of DLKPI cells (i) Untreated control (ii) Negative control (iii) ALCAM-1 
siRNA and (iv) ALCAM-2 siRNA, (Magnification, x100; scale bar = 500µm). (b) Histogram 
showing a slight increase in the total number of invading DLKPI cells following transfection. 
Data plotted represent the mean ± standard deviation of duplicate trans-well inserts from triplicate 
biological assays. Statistics *p≤0.05, **p≤0.01 and ***p≤0.005 compared with negative control 
siRNA. Student’s t test (two-tailed with equal variance, unpaired (n=3)). 
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3.4.2 Investigation into the role of INA in lung cancer 
As previously mentioned, DLKP was proposed to be classified as a variant small cell lung 
carcinoma (SCLC-V) or a non-small cell lung carcinoma with neuroendocrine 
differentiation (NSCLC-NE) [93]. Recently, α-Internexin (INA) was reported to have a 
novel association with pancreatic neuroendocrine tumour aggressiveness and prognosis. 
Unpublished work performed in our laboratory indicated expression of INA was 
increased in the lowly invasive DLKPSQ (~2.3-fold) compared to highly invasive 
DLKPM. INA expression was not previously reported in lung cancer but a novel 
association with pancreatic neuroendocrine cancer (PNETs) was previously reported 
[104]. INA was selected for follow up functional investigations into its role in the invasion 
process of DLKPSQ and DLKPM. 
3.4.2.1 Effect of siRNA knockdown of INA on DLKPSQ 
Figure 3.4-7 (a) shows by Western blot analysis, the efficient knockdown of INA in two 
siRNA transfected DLKPSQ cells compared to negative control and un-transfected cell. 
Negligible effect on growth was observed for DLKPSQ cells (Figure 3.4-7 (b)). 
 
Seventy-two hours post-transfection with INA siRNAs, invasion and migration assays 
were performed. There was no change in the total number of invading and migrating 
DLKPSQ cells transfected with INA siRNAs. Figure 3.4-8 (a) shows representative 
images of invading cells and Figure 3.4-9 (a) shows representative images of migrating 
cells. Knockdown of INA using two siRNAs, INA-6 and INA-8, did not affect the 
invasive or migratory capacities of DLKPSQ cells when compared to negative control 
(Figure Figure 3.4-8 (b) and Figure 3.4-9 (b)). DLKPSQ is a lowly invasive cell line,  
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(a) 
 
(b) 
 
Figure 3.4-7:- INA knockdown does not affect cell growth of DLKPSQ. 
(a) Representative immunoblot showing efficient knockdown of INA 72hrs post-transfection in 
DLKPSQ cells transfected with two independent siRNAs targeting INA relative to negative 
control siRNA transfected cells (GAPDH served as a loading control). (b) Proliferation assays on 
siRNA transfected DLKPSQ cells transfected targeting INA. Results graphed as % cell survival 
relative to negative control. Data plotted represents the mean ± standard deviation of duplicate 
biological assays (n=2). 
 
 
 
 
 
 
 
0
50
100
150
Untreated Lipo Negative Cell Death INA-6 INA-8
R
e
la
ti
ve
 C
e
ll 
Su
rv
iv
al
 (
%
)
INA 
60kDa 
GAPDH 
37kDa 
Untreated Lipo Negative INA-6 INA-8 
 119 
 
(a)   (b)  
  
 
  
 
Figure 3.4-8:- INA knockdown does not affect invasion of DLKPSQ. 
(a) Invasion assays of DLKPSQ cells (i) Untreated control, (ii) Negative control siRNA, (iii) 
INA-6 siRNA and (iv) INA-8 siRNA. (Magnification, x100; scale bar = 500µm). (b) Histogram 
showing the total number of invading DLKPSQ cells following transfection with siRNAs 
targeting INA. Data plotted represents the mean between two inserts from one single experiment 
(n=1). 
 
(a)   (b)  
  
 
  
 
Figure 3.4-9:- INA knockdown does not affect migration of DLKPSQ. 
(a) Migration assays of DLKPSQ cells (i) Untreated control, (ii) Negative control siRNA, (iii) 
INA-6 siRNA and (iv) INA-8 siRNA. (Magnification, x100; scale bar = 500µm). (b) Histogram 
showing the total number of migrating DLKPSQ cells following transfection with siRNAs 
targeting INA. Data plotted represents the mean between two inserts from one single experiment 
(n=1). 
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3.4.2.2 Effect of siRNA knockdown of INA on DLKPM 
INA expression was shown to be expressed in DLKPM cells compared to DLKP and 
DLKPI. Its expression in DLKPM was marginally lower than DLKPSQ. Seventy-two 
hours’ post-transfection with INA siRNAs, invasion and migration assays were 
performed using four siRNAs targeting INA. 
 
The efficient knockdown of INA is shown in Figure 3.4-10, by Western blot analysis, 
with negligible effect on growth was observed for DLKPM cells (Figure 3.4-10). The 
morphology of DLKPM cells was also monitored and is shown in Figure 3.4-11, under 
control conditions (i) un-transfected, (ii) lipofectamine control and post transfection with 
four independent siRNAs targeting INA; (iii) INA-6, (iv) INA-7, (v) INA-8 and (vi) INA-
9. The morphology of the cells after transfection using two siRNAs is obviously different. 
The cells are more elongated using INA-7 (iv), while using INA-9 (vi) the cells are 
notably shorter, in both cases cells were growing in a more isolated pattern, compared to 
the control (ii). 
 
Invasion and migration assays were performed on INA transfected cells. Figure 3.4-12 
(b) shows significantly reduced invasion capability of DLKPM cells following 
transfection with INA-7 (p=0.0021) and INA-9 (p=0.0015) siRNAs. A reduction in 
invasion was noted with INA-6 but did not show statistical significance (p=0.0662), while 
an increase was observed using INA-8 (p=0.07286). Figure 3.4-13 shows reduced 
migratory ability of DLKPM cells following transfection with INA-6 (n=3), INA7 (n=2), 
INA8 (n=3) and INA9 (n=2) siRNAs, however, the reduction did not prove significant. 
To investigate if reduction observed with INA7 and INA 9 was significant further 
biological replicates would need to be carried out. 
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(a)  
 
 (b) 
 
Figure 3.4-10:- INA knockdown has does not affect cell growth of DLKPM. 
(a) Representative immunoblot showing efficient knockdown of INA in DLKPM 72hrs post-
transfection with two independent siRNAs targeting INA (GAPDH served as a loading control). 
(b) Proliferation assays on siRNA transfected DLKPM cells targeting INA. Results graphed as % 
cell survival relative to negative control. Data plotted represents the mean ± standard deviation of 
duplicate biological assays (n=2). 
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Figure 3.4-11:- Morphology of DLKPM cells following siRNA knockdown of INA. 
(i) Untreated control, (ii) Negative control siRNA, (iii) INA-6 siRNA (iv) INA-7 siRNA (v) INA-
8 siRNA and (vi) INA-9 siRNA, compared to negative control. (Magnification, x100; scale bar 
= 500µm). 
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(a) 
  
  
  
 (b) 
 
Figure 3.4-12:- INA knockdown decreases the invasive capacity of DLKPM cells. 
(a) Invasion assays of DLKPM cells (i) Untreated control, (ii) Negative control siRNA, (iii) INA-
6 siRNA (iv) INA-7 siRNA (v) INA-8 siRNA and (vi) INA-9 siRNA. (Magnification, x100; scale 
bar = 500µm). (b) Histogram showing a reduction in the total number of invading DLKPM cells 
following transfection with INA-6, INA-7 siRNA and INA-9 siRNAs, while an increase for INA-
9. Data plotted represent the mean ± standard deviation of duplicate transwell inserts from 
triplicate biological assays. Statistics **p≤0.01 and ***p≤0.005 compared with negative control 
siRNA. Student’s t test (two-tailed with equal variance, unpaired, n=3). 
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 (a) 
  
  
  
 (b) 
 
 
Figure 3.4-13:- INA knockdown decreases the migratory capacity of DLKPM. 
(a) Migration assays of DLKPM cells (i) Untreated control, (ii) Negative control siRNA, (iii) 
INA-6 siRNA (iv) INA-7 siRNA (v) INA-8 siRNA and (vi) INA-9 siRNA. (Magnification, x100; 
scale bar = 500µm). (b) Histogram showing a reduction in the total number of migrating DLKPM 
cells following transfection with INA-6 siRNA, INA-7 and INA-9, an increase for INA-8 siRNA. 
Data plotted represent the mean ± standard deviation of duplicate transwell inserts from triplicate 
biological assays. Statistics *p≤0.05 compared with negative control siRNA. Student’s t test (two-
tailed with equal variance, unpaired, n=3).  
0
2000
4000
6000
8000
10000
12000
14000
Untreated Lipo Negative INA-6 INA-7 INA-8 INA-9
To
ta
l N
o
. o
f 
m
ig
ra
ti
n
g 
C
e
lls
*
i ii 
iii iv 
v vi 
** 
 125 
 
3.4.3 Investigation into the role of SPR in DLKP clones 
 
The comparative proteomic analysis identified sepiapterin reductase (SPR) to be 
differentially expressed in DLKPSQ compared to DLKPI. The analysis showed that 
expression of SPR was 4-fold highest in DLKPSQ compared to DLKPI (section 3.2.7). 
To date, there are no reports associating SPR and cancer invasion, so SPR was 
investigated further for potential functional roles in the invasion and migration processes 
of DLKPSQ and DLKPM. 
3.4.3.1 Effect of siRNA knockdown of SPR in DLKPSQ 
The efficient knockdown of SPR in two siRNA transfected DLKPSQ cells is shown in 
Figure 3.4-14, by Western blot analysis. A negligible effect was observed for cell growth 
compared to negative control and un-transfected cells. Seventy-two post-transfection with 
SPR siRNAs, invasion and migration assays were performed. There was a reduction in 
the total number of cells invading and migrating DLKPSQ cells transfected with SPR-6 
siRNAs. Figure 3.4-15 (a) shows representative images of invading cells and Figure 
3.4-16 (a) shows representative images of migrating cells. Knockdown of SPR using two 
siRNAs shows a reduction of invasion (Figure 3.4-15 (b) and migration (Figure 3.4-16 
(b) using SPR-6 siRNA but not SPR-1, compared to the negative control siRNA. 
DLKPSQ is a lowly invasive cell line and it was unclear if this result represented an off 
target effect, it was decided to continue transfections in DLKPM cells. 
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(a)  
 
 
 
(b)   
 
 
Figure 3.4-14:- SPR knockdown shows does not affect cell growth of DLKPSQ. 
(a) Representative immunoblot showing efficient knowdown of SPR 72 hrs post-transfection in 
DLKPSQ cells transfected with two independent siRNAs targeting SPR, relative to negative 
control siRNA transfected cells (GAPDH served as a loading control). (b) Proliferation assays on 
siRNA transfected DLKPSQ cells targeting SPR. Results graphed as % cell survival relative to 
negative control in two independent biological experiments (n=2). 
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(a)  
  
  
(b)  
 
 
Figure 3.4-15:- SPR-6 siRNA potentially reduces the invasive capacity of DLKPSQ. 
(a) Invasion assays of DLKPSQ cells (i) Untreated control, (ii) Negative control siRNA, (iii) 
SPR-1 siRNA, and (iv) SPR-6 siRNA (magnification, x100; scale bar = 500µm). (b)  Histogram 
showing a reduction in the total number of invading DLKPSQ cells following transfection with 
SPR-6 siRNA. Data plotted represents the mean of duplicate trans-well inserts from two 
biological experiments (n=2).  
 
 
(a)  
  
  
(b)  
 
 
Figure 3.4-16:- SPR-6 siRNA potentially reduces the migratory capacity of DLKPSQ. 
(a) Migration assays of DLKPSQ cells (i) Untreated control, (ii) Negative control siRNA, (iii) 
SPR-1 siRNA, and (iv) SPR-6 siRNA (magnification, x100; scale bar = 500µm). (b)  Histogram 
showing a reduction in the total number of migrating DLKPSQ cells following transfection with 
SPR-6 siRNA. Data plotted represents the mean of duplicate trans-well inserts from two 
biological experiments (n=2).  
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3.4.3.2 Effect of siRNA knockdown of SPR in DLKPM 
The efficient knockdown of SPR in DLKPM is shown in Figure 3.4-17 by Western blot 
analysis using four independent siRNAs (SPR-1, SPR-2, SPR-5 and SPR-6). The effect 
on proliferation (b) using SPR-1, SPR-2, SPR-5 was negligible, however, a significant 
effect on proliferation was observed using SPR-6 (p=0.0158) when compared to negative 
control. 
Seventy-two hours post-transfection with SPR siRNAs, invasion and migration assays 
were performed. SPR siRNA transfection reduced invasive and migratory abilities of 
DLKPM cells. Figure 3.4-18, shows (a) representative images of invading cells and (b) 
shows highlights the total number of invading cells. Invasion was significantly reduced 
by 71% with SPR-1 (p=0.0031) and 81% with SPR-6 (p=0.0014) siRNAs. Figure 3.4-19 
shows (a) representative images of migrating cells and (b) shows highlights the total 
number of migrating cells. Migration was reduced by 78% with SPR-1 (p=0.0054) and 
80% with SPR-6 (p=0.0048) siRNAs when compared to the negative control siRNA. 
Huge variability was observed using SPR-2 and SPR-5 siRNAs. 
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(a)  
 
 
(b)  
 
Figure 3.4-17:- SPR-6 siRNA reduces cell growth of DLKPM. 
(a) Representative Immunoblot showing efficient knockdown of SPR 72hrs post-transfection in 
DLKPM cells transfected with four independent siRNAs targeting SPR relative to negative 
control siRNA transfected cells (α-Tubulin served as a loading control). (b) Proliferation assays 
carried out on siRNA transfected DLKPM cells indicates a significant reduction in cell growth 
with SPR-6 siRNA (p-value 0.015859). Results graphed as % cell survival relative to negative 
control. Data plotted represents the mean +/- standard deviation of triplicate biological assays. 
Statistics *p≤0.05 compared with negative control siRNA. Student’s t test (two tailed with equal 
variance, unpaired, n=3).  
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(a)  
  
  
  
(b)   
 
 
Figure 3.4-18:- SPR knockdown decreases the invasive capacity of DLKPM. 
(a) Invasion assays of DLKPM cells (i) Untreated, (ii) Negative control siRNA, (iii) SPR-1 
siRNA, (iv) SPR-2 siRNA, (v) SPR-5 siRNA and (vi) SPR-6 siRNA (magnification, x100; scale 
bar = 500µm). (b) Histogram showing a reduction in the total number of invading DLKPM cells 
following transfection with SPR-1 and SPR-6 siRNAs. Data plotted represents the mean ± 
standard deviation of duplicate trans-well inserts from triplicate biological assays. Statistics 
**p≤0.01 and *** p≤0.005 compared with negative control siRNA. Student’s t test (two tailed 
with equal variance, unpaired (n=3)). 
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(a)  
  
  
  
(b)  
 
 
Figure 3.4-19:- SPR knockdown decreased the migratory capacity of DLKPM. 
(a) Migration assays of DLKPM cells (i) Untreated, (ii) Negative control siRNA, (iii) SPR-1 
siRNA, (iv) SPR-2 siRNA, (v) SPR-5 siRNA and (vi) SPR-6 siRNA (magnification, x100; scale 
bar = 500µm). (b) Histogram showing a reduction in the total number of migrating DLKPM cells 
following transfection with SPR-1 and SPR-6 siRNAs. Data plotted represents the mean ± 
standard deviation of duplicate trans-well inserts from triplicate biological assays. Statistics 
**p≤0.01 and *** p≤0.005 compared with negative control siRNA. Student’s t test (two tailed 
with equal variance, unpaired (n=3)). 
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3.4.3.3 Investigation into the effect of ornithine decarboxylase on DLKPM 
Polyamines are often elevated in cancer cells and tissues, compared to normal cells and 
tissues. D,L-α-difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine 
decarboxylase (ODC) which can be used to induce depletion of polyamines. In 2013, 
Lange et al identified SPR as a regulator of ODC enzyme activity and described a model 
in which SPR drives ODC-mediated malignant progression in Neuroblastoma (NB). In 
section 3.4.3, siRNA interference knockdown was used to investigate SPR in lung cancer 
cell lines. SPR was found to play a potential role in the invasion and migration processes 
of DLKPM. To investigate a role for ODC in the invasion process in DLKPM, the DFMO 
inhibitor was used to treat DLKPM cells prior to their addition to invasion assays. Various 
concentrations of DFMO were used to optimise conditions in 6-well plates, final 
concentrations of 2.5mM and 5mM of DFMO were used. Untreated cells were also 
included as controls. 
Prior to testing the effects of the DFMO, the appropriate concentration range for each 
inhibitor was established with the aim of finding a concentration which caused 
approximately 10% cytotoxicity. Proliferation assays were carried out over 5 days to 
assess the impact of the various concentrations (1mM, 2.5mM and 5mM) of the DFMO 
inhibitor on DLKPM cells. In preliminary investigations, a reduction in cell growth of 
47% and 40% was observed for DFMO at concentrations of 1mM and 2.5mM 
respectively, while a negligible effect was observed using 5mM DFMO, compared to 
untreated control cells. Therefore, an optimum concentration of between 2.5mM to 5mM 
of DFMO could be used for further assays (Figure 3.4-20 (a)); for the purpose of this 
investigation 2.5mM and 5mM was used. 
To assess the impact of DFMO on DLKPM, cells were treated with 2.5mM and 5mM 
DFMO 30mins (co-treat) and 24hrs (pre-treat) prior to setting up invasion assays. In a 
preliminary investigation, co-treatment with 2.5mM DFMO resulted in a significant 
reduction of 27% (p=0.0412) in the invasion of DLKPM cells, a reduction was also 
observed following 24hr pre-treatment. A modest reduction in invasion was observed for 
5mM DFMO when compared to untreated control (Figure 3.4-20 (b)). 
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(a) 
 
(b)  
 
 
Figure 3.4-20:- DFMO treatment reduces the invasive capacity of DLKPM. 
(a) Histogram showing proliferation assays carried out on DLKPM cells treated with 1mM, 
2.5mM and 5mM DFMO over 5 days’ (n=2). (b) Histogram showing a reduction in the total 
number of invading DLKPM cells following co-treatment (30mins) and pre-treatment (24hrs). 
Data plotted represents the mean ± standard deviation of duplicate trans-well inserts from 
duplicate biological assays. Statistics *p≤0.05, compared with negative control siRNA (n=3). 
Student’s t test (two tailed with equal variance, unpaired). 
 
 
 
 
* 
 134 
 
3.4.3.4 Investigation into the effect of Nω-Nitro-L-arginine on DLKPM 
SPR is an enzyme that converts 6-pyruvoyl-tetrahydropterin to tetrahydrobiopterin (BH4), 
which acts as a co-factor for Nitric-Oxide-Synthase (NOS) in the conversion of Arginine 
to Citrulline. This reaction results in the production of Nitric Oxide (NO). We have shown 
the involvement of SPR-1 and SPR-6 in the invasion and migration processes in DLKPM.  
To investigate the potential role of NO in the invasive and migratory process we aimed 
to inhibit the action of NOS using an arginase inhibitor. The Nω-Nitro-L-arginine (L-
NNA) inhibitor was used to treat DLKPM cells prior to their inclusion in invasion assays.  
Prior to testing the effects of the L-NNA, the appropriate concentration range for each 
inhibitor was established with the aim of finding a concentration which caused 
approximately 10% cytotoxicity. Proliferation assays were carried out over 5 days to 
assess the impact of the L-NNA inhibitor on DLKPM cells. In a preliminary investigation, 
an increase in growth of 33% and 85% was observed for L-NNA at concentrations of 
50µM and 150µM respectively, while a negligible effect was observed using 100µM L-
NNA, compared to untreated control cells. Therefore, an optimum concentration of 
between 100µM to 150µM of L-NNA could be used for further assays (Figure 3.4-21 
(a)); for the purpose of this investigation, 150µM L-NNA was used. 
To assess the impact of L-NNA on DLKPM, cells were treated with 150µM of L-NNA 
for 30mins (co-treatment) and 24hrs (pre-treatment) prior to setting up invasion assays. 
In a preliminary investigation, pre-treatment with L-NNA resulted in 37% reduction in 
the invasive capacity of DLKPM cells. However, the addition of L-NNA directly (co-
treatment) into invasion assay at a concentration of 150µM, did not result in any change 
in invasion (Figure 3.4-21 (b)). 
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(a)  
 
(b)  
 
 
Figure 3.4-21:- L-NNA treatment reduces the invasive capacity of DLKPM. 
(a) Histogram showing proliferation assays carried out on DLKPM cells treated with 50µM, 
100µM and 150µM L-NNA over 5 days’. Data plotted represents the mean +/- standard deviation 
of duplicate biological assays (n=2). (b) Histogram showing the invasive capacity of DLKPM 
cells following L-NNA treatment for 30mins (co-treat) and 24hrs (pre-treat), in a Boyden chamber 
assay. The total number of invading cells through the matrigel is shown. Data plotted represents 
the mean ± standard deviation of duplicate trans-well inserts from duplicate biological assays 
(n=1).  
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3.4.3.5 Investigation into the effect of SPR knockdown on the generation of ROS  
To investigate the role of reactive oxygen species (ROS) on SPR transfected in DLKPM 
cells, siRNA knockdown on DLKPM was performed and cells were tested for ROS 
generation. There was a reduction in ROS generation in SPR transfected cells using four 
independent siRNAs when compared to negative control cells. A significant reduction of 
ROS generation was observed in three out of four siRNAs targeting SPR; SPR-1 (22%, 
p= 0.04), SPR-5 (32%, p= 0.006) and SPR-6 (31%, p= 0.009), see Figure 3.4-22 below. 
The reduction in ROS generation as a result of SPR transfection may indicate that (with 
further investigation) that reactive oxygen species may be associated with SPR in 
DLKPM cells. 
 
 
 
 
Figure 3.4-22:- ROS generation is reduced in SPR transfected DLKPM cells. 
ROS assays on transfected DLKPM cells 72 hrs post-transfection using four independent siRNAs 
targeting SPR, relative to negative control siRNA transfected cells. Results graphed as % ROS 
generated per cell relative to negative control. Data plotted represents the mean ± standard 
deviation of duplicate wells from triplicate biological assays. Statistics *p≤0.05, compared with 
negative control siRNA. Student’s t test (two tailed with unequal variance, unpaired, n=3). 
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3.4.4 The investigation into the functional role of SPR in breast cancer and 
pancreatic cancer. 
BreastMark survival analysis indicated that low expression of SPR was associated with 
poor survival ability of patients with Luminal A and basal molecular subtypes of breast 
cancer. To investigate the functional role for SPR in breast cancer and pancreatic cancer, 
three cell lines were chosen for preliminary siRNA knockdown studies; (i) MDA-MB-
468 (TNBC), (ii) MiaPaCa2 clone3 (PDAC) and (iii) AsPc1 (PDAC). 
3.4.4.1 Effect of siRNA knockdown of SPR on MDA-MB-468 
In the panel of TNBC breast cancer cell lines, MDA-MD-468 showed highest expression 
of SPR (Figure 3.3-8). To represent TNBC, the MDA-MB-468 cell line was chosen to 
perform siRNA knockdown of SPR. Figure 3.4-23 (a), shows the efficient knockdown of 
SPR by Western blot analysis using four independent siRNAs, compared to negative 
control and un-transfected cells. There was approximately a 15 and 52% reduction in 
growth with SPR-1 and SPR-2 respectively (see Figure 3.4-23 (b)). This significant 
reduction in growth which was observed with SPR-2 (p=0.00945576) may be as a result 
of toxicity to the siRNA. 
 
Seventy-two hours post-transfection with SPR siRNAs, invasion assays were performed. 
There was a significant reduction in the total number of invading MDA-MB-468 cells 
transfected with SPR-6 siRNA (p=0.000908). Figure 3.4-24 (a) shows representative 
images of invading cells post transfection with SPR-1, SPR-5 and SPR-6 siRNAs, images 
for the SPR-2 siRNA could not be acquired due to the toxic effect of this siRNA. The 
total number of invading cells is presented in Figure 3.4-24 (b). These experiments 
indicate that SPR may potentially be involved in growth and invasion of the MDA-MB-
468 cell line. In order to establish a potential role of SPR in breast cancer further 
investigations would need to be completed on another breast cancer cell line. 
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(a)  
 
 
(b)  
 
 
Figure 3.4-23:- SPR knockdown reduces cell growth of MDA-MB-468. 
(a) Representative immunoblot showing knockdown of SPR 72 hrs post-transfection, in MDA-
MB-468 cells transfected with four independent siRNAs targeting SPR, relative to negative 
control siRNA transfected cells (α-Tubulin served as the loading control). (b) Proliferation assays 
on siRNA transfected MDA-MB-468 cells uing SPR-1, SPR-2 and SPR-6 siRNAs. Results 
graphed as % cell survival relative to negative control. Data plotted represents the mean ± standard 
deviation of triplicate biological experiments. Statistics *p≤0.05 compared with negative control 
siRNA. Student’s t test (two tailed with equal variance, unpaired (n=3)). 
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(a)  
  
  
  
(b)  
 
 
Figure 3.4-24:- SPR knockdown reduces the invasive capacity of MDA-MB-468. 
(a) Invasion assays of MDA-MB-468 cells (i) Untreated Control, (ii) Lipofectamine Control, (iii) 
Negative control, (iv) SPR-1 siRNA, (v) SPR-5 siRNA and (iv) SPR-6 siRNA (Magnification, 
x100; scale bar = 500µm). (b) Histogram showing a reduction in the total number of invading 
MDA-MB-468 cells following transfection with SPR-6 siRNA. Data plotted represents the mean 
± standard deviation between duplicate inserts from triplicate biological experiments. Statistics 
*p≤0.05 and *** p≤0.005 compared with negative control siRNA. Student’s t test (two tailed with 
equal variance, unpaired (n=3)). 
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3.4.4.2 Effect of SPR knockdown in pancreatic cell lines MiaPaCa2 Clone3 and 
AsPc-1 
Expression of SPR in MiaPaCa2 Clone3 and AsPc-1 was established in a previous 
investigation (see section 3.3.3), where a panel of pancreatic cancer cell lines was 
examined for SPR expression. Expression of SPR was shown to be increased in MiaPaca2 
clone3 compared to the parental MiaPaca2, while AsPc1 also showed increased 
expression of SPR. Preliminary siRNA transfections were performed on both cell lines, 
to investigate a potential functional role for SPR in pancreatic cancer. 
Figure 3.4-25 shows by Western blot analysis, the efficient knockdown of SPR using four 
independent siRNAs transfected into (a)(i) MiaPaca2 clone 2 and (b) (i) AsPc-1 cell, 
compared to negative control and un-transfected cells. A reduction in growth is shown 
for MiaPaca2 clone3 (a)(ii), with negligible effect on growth for (b)(ii) AsPc-1 cells. 
 
Invasion and migration assays were performed on SPR transfected cells. Figure 3.4-26 
shows reduced invasion capability of (a)(i) MiaPaca2 clone3 and (b)(i) AsPc-1 cells 
following transfection with SPR-6 (n=1), a negligible effect was observed for SPR-1, 
SPR-2 and SPR-5 siRNAs for both cell lines. Figure 3.4-26 (a)(ii) and (b)(ii) shows the 
total number of cells invading for MiaPaca2 Clone3 and AsPc-1 respectively. Figure 
3.4-27 shows reduced migratory capability of (a)(i) MiaPaca2 clone3 and (b)(i) AsPc-1 
cells following transfection with SPR-6 (n=1), A negligible effect was observed for SPR-
1, SPR-2 and SPR-5 siRNAs for both cell lines. The total number of migrating cells is 
shown in Figure 3.4-27 (b)(ii) MiaPaca2 Clone3 and (b)(ii) AsPc-1 cell lines. These 
transfections were preliminary investigations, further invasion and migration assays 
would need to be performed on MiaPaca2 clone 3 and AsPc-1 to establish a functional 
role for SPR in these cell lines. 
 
 
 
 
 
 
 
 141 
 
(a) MiaPaCa2 Clone3 
(i)  
 
 
 
(ii)  
 
(b) AsPc-1 
(i)  
 
(ii)  
 
 
Figure 3.4-25:- SPR knockdown reduces the growth of MiaPaca2 clone 3. 
Representative immunoblot showing efficient knockdown of SPR 72hrs post-transfection in (a) 
(i) MiaPaca2 Clone3 and (b) (i) AsPc-1 cells (α-Tubulin served as loading control). Proliferation 
assays on siRNA transfected (a) (ii) MiaPaCa2 clone3 and (b) (ii) AsPc-1 cells. Results graphed 
as percent cell survival relative to negative control. Data plotted represents a mean ±standard 
deviation of duplicate wells from one biological experiment (n=1). 
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(a) MiaPaCa2 Clone3  
i.  
  
  
  
ii.  
 
 
(b) AsPc-1  
i.  
  
  
  
ii.  
 
 
Figure 3.4-26:- SPR knockdown reduces the invasive capacity of MiaPaCa2 Clone3 and 
AsPc-1. 
Invasion assays of (a) (i) MiaPaCa2 clone3 and (b) (i) AsPc-1 cells following siRNA transfection 
with SPR-1, SPR-2, SPR-5 and SPR-6 siRNAs (magnification, x100; scale-bar = 500µm). 
Histogram showing a reduction in the total number of invading cells of (a) (ii) MiaPaCa2 Clone3 
and (b) (ii) AsPc-1, following transfection with SPR-6 siRNA. Data plotted represents the mean 
± standard deviation of two inserts from one individual experiment (n=1). 
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(a) MiaPaca2 Clone3  
i.  
  
  
  
ii.  
 
(a) AsPc-1  
i.  
  
  
  
ii.  
 
 
Figure 3.4-27:- SPR knockdown reduces the migratory capacity of MiaPaCa2 clone 2. 
Migration assays of (a) (i) MiaPaCa2 clone3 and (b) (i) AsPc-1 cells following siRNA 
transfection with SPR-1, SPR-2, SPR-5 and SPR-6 siRNAs (magnification, x100; scalebar = 
500µm). Histogram showing a reduction in the total number of migrating cells of (a) (ii) 
MiaPaCa2 Clone3, following transfection with SPR-6 siRNA. Data plotted represents the mean 
± standard deviation of two inserts from one individual experiment (n=1). 
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3.4.5 Summary of functional analyses 
 ALCAM is highly expressed in DLKPI compared to DLKPSQ and DLKPM, 
indicating its potential use as a marker for DLKPI. Knockdown of ALCAM resulted 
in a significant decrease in the invasive capacity of DLKPM and a significant 
increase in the invasive capacity of DLKPSQ-mitox-BCRP-6P. ALCAM may, 
therefore, have dual invasion roles in these cell lines. 
 DLKPSQ displayed the highest expression levels of INA and SPR compared to 
DLKPI and DLKPM, indicating their potential use as markers for DLKPSQ. Both 
INA and SPR were also expressed in DLKPM cells. 
 Knockdown of INA and SPR resulted in a significant reduction in the invasion and 
migration capacities of DLKPM. Reduced invasive capacity of MDA-MB-468 was 
also observed following knockdown of SPR. 
 Potential roles for INA and SPR in the invasion and migration capacity of these cell 
lines was shown through silencing of their respective genes. In addition, generation 
of ROS in DLKPM cells was reduced following knockdown of SPR which may 
indicate a potential link between SPR and ROS.  
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3.4.6 Immunohistochemical analysis of INA and SPR expression in lung 
cancer 
Western blot analysis of INA showed that expression was highest in DLKPSQ and DLKP 
and a lower level in DLKPM, while increased SPR expression was established in 
DLKPSQ and DLKPM compared to DLKP and DLKPI. Expression of INA had been 
associated with pancreatic neuroendocrine cancer while little Immunohistochemical 
analysis of the distribution of SPR in human cancers has been reported. To look at the 
distribution of INA and SPR expression in lung cancer, tissue microarrays (TMA) 
(Biomax, LC1502) were immunohistochemically stained using primary antibodies 
specific for INA and SPR. The arrays contained:  2 cases of normal lung, 23 cases of 
squamous cell carcinoma, 21 cases of adenocarcinoma, 5 cases of adenosquamous 
carcinoma, 5 cases of bronchioloalveolar carcinoma, 7 cases of small cell undifferentiated 
carcinoma and 3 cases of neuroendocrine carcinoma. Other cases on the TMA that 
showed negative to weak immunoreactivity included large cell carcinoma 
undifferentiated carcinoma, malignant mesothelioma, carcinosarcoma, chronic 
bronchitis, lobar pneumonia, pulmonary tuberculosis where negligible staining for INA 
was observed. There were duplicate cores per case providing 75 cases (total 150 TMA 
cores). TMA cores were scored semi-quantitatively, according to the intensity of the INA 
immunoreactivity observed (weak, moderate, strong).   
Expression of INA (Table 3.4-1) and SPR (Table 3.4-2) in human lung cancer was 
investigated further. Immunoreactivity for INA and SPR was observed in a number of 
tumour types. The overall immunoreactivity on the TMA displayed very specific 
membrane reactivity of isolated cells. Figure 3.4-28 illustrates negligible staining for INA 
in normal lung, while isolated cells displayed immunoreactivity in adenocarcinoma. 
Squamous cell carcinoma also shows immunoreactivity but the most intense staining was 
observed in the sections of neuroendocrine cancer. Overall staining for SPR on the lung 
cancer TMA displayed was variable across the lung cancer tumour, however, moderate 
to strong cytoplasmic immunoreactivity was observed in lung squamous tumour cases. 
Figure 3.4-29 illustrates negligible staining for SPR in normal lung, while moderate to 
strong immunoreactivity was observed in squamous carcinoma, while the other tumour 
types displayed a lower level of immunoreactivity. 
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Tumour Type INA staining intensity 
Squamous cell carcinoma 
17/23 - negative 
4/23 - weak 
2/23- moderate 
Adenocarcinoma 
16/21 - negative 
5/21 – weak 
Adenosquamous 
1/5 - negative 
2/5- weak 
2/5 - moderate 
Bronchioalveolar 
4/5 - negative 
1/5 – weak 
Small cell undifferentiated 
6/7- negative 
1/7 - weak 
Neuroendocrine 
1/3 - negative 
2/3 – moderate 
Table 3.4-1:- Immunoreactivity of INA on lung cancer TMA. 
The table above shows the results from staining of squamous, adenocarcinoma, adenosquamous, 
bronchioalveolar, small cell lung and neuroendocrine primary tumours using an antibody specific 
to INA. 
 
 
Tumour Type SPR staining intensity 
Squamous cell carcinoma 
8/23 - negative 
11/23 - weak 
2/23- moderate 
1/23 - strong 
Adenocarcinoma 
4/21 - negative 
14/21 - weak 
2/21- moderate 
1/21 - strong 
Adenosquamous 
4/5 - weak 
1/5- moderate 
Bronchioalveolar 5/5 - weak 
Small cell undifferentiated 
5/7- negative 
2/7 - weak 
Neuroendocrine 
2/3 - negative 
1/3 - weak 
Table 3.4-2:- Immunoreactivity of SPR on lung cancer TMA. 
The table above shows the results from staining of squamous, adenocarcinoma, adenosquamous, 
bronchioalveolar, small cell lung and neuroendocrine primary tumours using an antibody specific 
to SPR. 
 
 
 147 
 
 
 
 
 
  
  
  
 
Figure 3.4-28:- Immunohistochemical analysis of INA expression in human lung cancer. 
A TMA containing normal lung, squamous, adeno, small cell, large cell and neuroendocrine 
carcinoma was immunohistochemically stained using a primary antibody specific to INA. 
Representative photomicrographs are shown (A) Negligible staining is observed in normal lung 
tissue, (B) Isolated cells staining in Squamous, (C) Isolated cells staining in adenocarcinoma, (D) 
& (E), negligible staining in small cell and Large cell, in contrast to (F) strong isolated staining 
in neuroendocrine. Neuroendocrine carcinoma shows distinct immunoreactivity for INA 
(Original magnification of all photomicrographs, 400×, scale bar = 200 μm). 
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Figure 3.4-29:- Immunohistochemical analysis of SPR expression in human lung cancer. 
A TMA containing normal lung, squamous, adeno, small cell, large cell and neuroendocrine 
carcinoma was immunohistochemically stained using a primary antibody specific to SPR. 
Representative photomicrographs are shown; (A) Negligible staining is observed in normal lung 
tissue, (B) Intense staining in squamous, (C) weak staining in adenocarcinoma, (D) intense 
staining in mucinous and (E) strong staining for bronchioalveolar, (F) isolated cells staining in 
small cell, (G) neuroendocrine and (H) Large cell carcinomas. Squamous carcinoma shows 
moderate to strong immuno-reactivity for SPR (Original magnification of all photomicrographs, 
400×, scale bar = 200 μm). 
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3.4.7 Immunohistochemical analysis of SPR in Breast cancer 
BreastMark analysis of SPR indicated that low expression of SPR may be associated with 
poor prognosis of Luminal A and Basal-like molecular subtypes of breast cancer. SPR 
expression was then investigated in a breast cancer TMA (A712 (18)) containing 12 
invasive ductal breast carcinomas with their corresponding adjacent normal tissues. 
Immunoreactivity of SPR was observed in a number of breast cancer cases (Table 3.4-3), 
while weak immunoreactivity was observed in a number of adjacent normal tissues. 
Figure 3.4-30 shows representative staining of TMA cores that were scored semi-
quantitatively, according to the intensity of the SPR immunoreactivity observed (weak, 
moderate, strong). In addition, SPR expression was also investigated in a small panel of 
patient tumours tissues of unknown subtypes, Figure 3.4-31 shows negligible 
immunoreactivity in normal breast tissue and representative immunoreactivity for SPR in 
grade 1, grade 2 and a 3 grade breast cancer of unknown subtypes, evidence of membrane 
localisation was also observed. 
 
Breast tissue type SPR staining Intensity 
Normal 
Negative – 8/12 
Weak – 4/12 
Invasive ductal 
Negative – 4/12 
Weak – 4/12 
Moderate - 4/12 
Table 3.4-3:- Immunoreactivity of SPR in invasive ductal breast cancer tissues with 
corresponding adjacent normal tissue. 
  
Figure 3.4-30:- Immunohistochemical analysis of SPR expression in human breast cancer. 
A TMA containing invasive ductal breast and adjacent Normal breast, immunohistochemically 
stained using a primary antibody specific for SPR. Representative photomicrographs are shown 
(A) Negligible staining is observed in normal breast tissue, (B) Intense staining in invasive ductal 
breast (ER (-), PR (+), C erb B2 (2+/3), shows moderate immunoreactivity for SPR (Original 
magnification of all photomicrographs, 200×, scale bar = 200 μm). 
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Figure 3.4-31:- Immunohistochemical analysis of SPR in a panel of breast cancer tissues. 
Staining for SPR observed in seven out of eight breast cancer tissues. Representative images 
showing immunoreactivity in: (A) normal breast tissue, (B) Histological Grade 1, (C) Histological 
Grade 2 and (D) Histological grade 3 breast cancer (subtypes unknown) (magnification x400, 
scale-bar = 200µm. 
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3.5 The investigation into the growth and tumour development of DLKP and its 
clonal subpopulations in vivo. 
3.5.1 Background to DLKP clones 
Lung Squamous cell line DLKP was originally established from a tumour histologically 
diagnosed as “poorly differentiated Squamous carcinoma” and later found to contain at 
least three morphologically and phenotypically distinct clonal subpopulations [93]. 
DLKPSQ, DLKPI and DLKPM are the three established clones of DLKP and all have 
the ability to grow on monolayers. DLKPSQ are squamous-like and form colonies with 
distinct cell boundaries and account for approximately 70% of the DLKP parent. DLKPM 
make up approximately 5% of DLKP parent, are more irregular in shape with a 
fibroblastoid-like morphology and do not form colonies. DLKPI grow in colonies but 
their boundaries are less distinct in appearance and account for approximately 25% of the 
DLKP. DLKPSQ, DLKPI and DLKPM display different growth and invasion 
characteristics but also distinctly different morphologies. However, a model of 
interconversion (shown in Figure 3.5-1 below) between these clonal subpopulations was 
previously described, the model suggested that interconversion can occur between 
DLKPSQ and DLKPI, DLKPI and DLKPM and vice versa but not between DLKPSQ 
and DLKPM. 
 
Figure 3.5-1:- Proposed model of interconversion between DLKPSQ, DLKPI and DLKPM. 
Further characterisation of the clones found that the in vitro invasion (ability to 
breakdown extracellular matrix components and invade) and anoikis (ability to survive in 
anchorage-independent conditions) abilities of the clones were also different. DLKPSQ 
was found to be poorly invasive and anoikis resistant, DLKPM was highly invasive and 
is anoikis sensitive, while the intermediate, DLKPI, appears most sensitive to anoikis and 
dies more readily. Interestingly, DLKPM appears to use autophagy as cell survival 
mechanism before dying [93, 95, 96]. Autophagy is a general term for the degradation of 
cytoplasmic components within lysosomes and mediated by an organelle known as an 
autophagosome [118].  
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3.5.2 The in vivo investigation of DLKP 
The heterogeneous nature of DLKP and the distinct characteristics displayed between the 
clones make DLKP an ideal cell line model to investigate their growth and behaviour in 
vivo.  A pilot study to investigate growth and development of cell line based tumours was 
carried out by sub-cutaneous injection of DLKP, DLKPSQ, DLKPI and DLKPM cell 
lines at two sites in 4 groups of 4 CB17/lcr-PrkdcSCID/Crl mice (4 mice per cell line), in 
collaboration with Prof. Robert Straubinger, Ms Ninfa Straubinger, Dr. Fiona O’Neill and 
Dr. Sandra Roche. Three different cell numbers were used in this study (1x106 cells in 
250 μl, 5x106 cells in 250 μl and 1x107 cells in 500 µl), cells were prepared in matrigel 
and injected into mice as described in section 2.8. There are a number of potential animal 
models that could be used for this study, however as mentioned in section 2.8 our 
collaborator has extensive experience and publishing history using SCID mice for in vivo 
modelling [101, 102], which is one of the main reasons why this animal model was 
chosen. A schematic showing a summary of the experimental approach is outlined in 
Figure 3.5-2.  
After injection, animals were monitored until tumours had developed, once palpable 
tumours formed, one mouse from each group was sacrificed for exploratory surgery 
(indicated on schematic by blue boxes). The organs from this group of animals were 
paraffin embedded, sectioned and examined using haematoxylin and eosin (H&E) 
staining by a pathologist, Prof. Susan Kennedy at Royal Victoria Eye and Ear Hospital 
for evidence of metastasis. This examination did not find any evidence of metastasis 
within the organs, however, the xenograft tumours were described as “poorly 
differentiated squamous carcinoma”. The description of these tumours is in line with the 
diagnosis of the original DLKP tumour. The remaining 12 animal cohort were allowed to 
progress to experimental finality or until a guideline tumour volume of 2000mm3 had 
been reached. Animals were monitored daily and measurements were taken twice weekly 
to determine tumour volume. At the end of the experiment, representative tumours were 
embedded in paraffin and OCT medium for examination by immunohistochemistry 
(indicated on the schematic by red boxes). This study also provided a unique opportunity 
to characterise the cells within the xenograft tumours, this was performed using explant 
culture (indicated on the schematic by green boxes). Tumour growth curves from tumours 
produced by DLKP, DLKPSQ, DLKPI and DLKPM cell lines in mice were determined 
using average measurements obtained from three different inoculation densities (1x106 
cells (n=2), 5x106 cells (n=4) and 1x107 cells (n=2)). 
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Figure 3.5-2:- Schematic showing development of xenografts derived from DLKP and its clones. 
Outline of the steps involved in the generation of the cell line derived tumours and tumour xenografts from DLKP, DLKPSQ, DLKPI and DLKPM cells. 
Organs from one group of mice were examined for evidence of metastasis (Blue), explant culture was performed on tumours and recovered cells were 
examined (green) and tumours were immunohistochemically examined for expression of markers of proliferation, angiogenesis and EMT (Red).   
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3.5.2.1 Examination of the growth of DLKP in vivo 
Four 28-35 day old SCID mice received subcutaneous injections of DLKP cells at cell 
densities of 1x106 cells, 5x106 cells and 1x107 cells. All four mice displayed tumour 
formation across the three different inoculation densities of DLKP at both injection sites. 
Exploratory surgery performed on one mouse (mouse 3) to look for evidence of metastasis 
after 21 days of growth revealed no evidence of metastasis. Figure 3.5-3 gives a 
representation of the tumours produced by DLKP and their locations (indicated by red 
arrows).  
Measurements for the tumours produced by DLKP and for each of the cell densities used 
in this study are presented in Table 3.5-1 (a) 1x106 cells (n=2), (b) 5x106 cells (n=4) and 
(c) 5x107 cells (n=2). Tumours produced by DLKP appeared to be fast growing and large 
tumours. The growth curves (Figure 3.5-4) highlights the size of tumours produced by 
DLKP in SCID mice over 32 days.  
A 
 
B 
 
 
Figure 3.5-3:- Growth of xenograft tumours from DLKP cells. 
Representative images showing xenograft tumours following subcutaneous injection of DLKP 
cells at inoculation densities of 5x106 cells (Image A) and 1x107 cells (image B) in SCID mice. 
Red arrows indicate tumour location on both sides of the mouse. 
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(a)  
Mouse 
no 
DLKP: Tumour growth measurements (mm3) from mice 
inoculated with 1x106 cells (Days) 
 21 25 29 32 
1 107.64 241.28 782.93 696.7 
2 129.4 209.58 296.7 484.84 
(b)  
Mouse 
No 
DLKP: Tumour growth measurements (mm3) from mice 
inoculated with 5x106 cells (Days) 
 21 25 29 32 
1 166.12 295.12 457.52 505.68 
2 185.2 787.52 535.13 818.7 
3 209.3 Mouse sacrificed at day 21 
4 124.03 410 829.6 910.2 
(c)  
Mouse 
No 
DLKP: Tumour growth measurements (mm3) from mice 
inoculated with 1x107 cells (Days) 
 21 25 29 32 
3 378.324 Mouse sacrificed at day 21 
4 192.19 494.5 778.04 985.71 
Table 3.5-1:- DLKP xenograft tumour measurements. 
The growth of xenograft tumours following subcutaneous injection of DLKP cells. Measurements 
of the tumours in SCID mice inoculated with DLKP at cell densities of (a) 1x106 cells (n=2), (b) 
5x106 cells (n=4) and (c) 1x107 cells (n=2). 
 
 
Figure 3.5-4:- Xenograft tumour growth curves for DLKP. 
Xenografts tumours were developed following subcutaneous injection of DLKP cells in SCID 
mice over 32days post injection. Tumour growth curves for DLKP. Cell numbers injected: 1x106 
cells (n=2), 5x106 cells (n=4), 1x107 cells (n=2). Black arrow indicates when a mouse was 
sacrificed, reducing the numbers continuing on in the experiment. 
21 25 29 32
Days Post Implant
1xE6 cells (n=2) 118.5 225.4 539.8 590.8
5xE6 cells (n=4) 171.2 497.5 607.4 744.9
1xE7 cells (n=2) 285.3 494.5 778.0 985.7
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3.5.2.2 Examination of the growth of DLKPSQ in vivo 
Four 28-35 day old SCID mice received subcutaneous injections of DLKPSQ cells at cell 
densities of 1x106 cells, 5x106 cells and 1x107 cells. All four mice displayed tumour 
formation across the three different inoculation densities of DLKPSQ at both injection 
sites.  
Exploratory surgery was performed on one mouse (mouse 1) to look for evidence of 
metastasis after 21 days of growth. Figure 3.5-5 gives a visual representation of tumours 
produced by DLKPSQ and their locations (indicated by red arrows).  Measurements for 
the tumours produced by DLKPSQ at each of the cell densities used in this study are 
presented in Table 3.5-2 (a) 1x106 cells (n=2), (b) 5x106 cells (n=4) and (c) 1x107 cells 
(n=2). Tumours produced by DLKPSQ appeared to vary in size (indicated by the red 
arrows in images A, B, D, E and G), but displayed increased vascularisation and 
angiogenesis compared to tumours produced by DLKP, DLKPI and DLKPM (indicated 
by blue arrows in images B, D, E, G and H). 
Upon dissection, two out of four mice were found to have small white masses distributed 
within the peritoneal cavity, suggesting evidence of suspected metastasis (image E, F and 
H - green arrows) and an enlarged lymph node was also noted (Image C- yellow arrow). 
The growth curves (Figure 3.5-6) highlights the size of tumours produced by DLKPSQ 
in SCID mice over 32 days.  
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Figure 3.5-5:- Growth of xenograft tumours from DLKPSQ cells. 
Representative images showing xenograft tumours following subcutaneous injection of DLKPSQ 
cells at inoculation densities 1x106 cells (images B and D), 5x106 cells (images A, C, E and G) 
and 1x107 cells (images F and H) in 28-35 day old SCID mice. Red arrows indicate tumour 
locations. 
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(a)  
Mouse 
no 
DLKPSQ: Tumour growth measurements (mm3) from mice 
inoculated with 1x106 cells (Days) 
 21 25 29 32 
1 63.96 Mouse sacrificed at day 21 
2 0 449.31 426.88 663.17 
(b)  
Mouse 
No 
DLKPSQ: Tumour growth measurements (mm3) from mice 
inoculated with 5x106 cells (Days) 
 21 25 29 32 
1 54 Mouse sacrificed at day 21 
2 60.39 310.38 574.19 663.26 
3 0 0 0 0 
4 0 0 0 0 
(c)  
Mouse 
No 
DLKPSQ: Tumour growth measurements (mm3) from mice 
inoculated with 1x107 cells (Days) 
 21 25 29 32 
3 61.64 406.12 1045.90 1951.82 
4 69.79 280.30 508.38 762.96 
Table 3.5-2:- DLKPSQ xenograft tumour measurements. 
The growth of xenograft tumours following subcutaneous injection of DLKPSQ cells.  
Measurements of the tumours in SCID mice inoculated with DLKPSQ at cell densities of (a) 
1x106cells (n=2), (b) 5x106cells (n=4) and (c) 1x107cells (n=2). 
 
 
Figure 3.5-6:- Xenograft tumour growth curves for DLKPSQ. 
Xenograft tumours were developed following subcutaneous injection of DLKPSQ cells in SCID 
mice over 32 days post injection. Tumour growth curves for DLKPSQ. Cell numbers injected: 
1x106 cells (n=2), 5x106 cells (n=4), 1x107 cells (n=2). Black arrow indicates when a mouse was 
sacrificed, reducing the numbers continuing on in the experiment. 
21 25 29 32
Days Post Implant
1xE6 cells (n=2) 32.0 449.3 426.9 663.2
5xE6 cells (n=4) 28.6 103.5 191.4 221.1
1xE7 cells (n=2) 65.7 343.2 777.1 1357.4
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3.5.2.3 Examination of the growth of DLKPI in vivo 
Four 28-35 day old SCID mice received subcutaneous injections of DLKPI cells at cell 
densities of 1x106 cells, 5x106 cells and 1x107 cells.  
All four mice displayed tumour formation across the three different inoculation densities 
of DLKPI at both injection sites. Exploratory surgery performed on one mouse (mouse 
3) to look for evidence of metastasis after 21 days of growth revealed no evidence of 
metastasis. The rapidly growing tumours produced by DLKPI cells in mouse 4 had 
exceeded guideline measurement of 2000mm2, so it was necessary to sacrifice this mouse. 
Figure 3.5-7 gives a visual representation of tumours produced by DLKPSQ and their 
locations (indicated by red arrows). DLKPI appeared to produce the largest tumours and 
more quickly than those produced by DLKP, DLKPSQ and DLKPM. The DLKPI 
tumours appeared to resemble those produced by the DLKP parent. 
There was variation observed in the growth of tumours from DLKPI cells. The 
measurements for the tumours and each of the cell densities used in this study are 
presented in Table 3.5-3 (a) 1x106 cells (n=2), (b) 5x106 cells (n=4) and (c) 1x107 cells 
(n=2). The growth curves (Figure 3.5-8) highlights the large size of tumours produced by 
DLKPI in SCID mice over 32 days, it appears that tumour growth an inoculation cell 
density of 1x106cells would be optimal for DLKPI cells for further in vivo studies. 
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Figure 3.5-7:- Growth of xenograft tumours from DLKPI cells. 
Representative images showing xenograft tumours following subcutaneous injection of DLKPI 
cells at inoculation densities of 5x106 cells (Image A) and 1x107 cells (image B) in 28-35 day old 
SCID mice. Red arrows indicate tumour location on both sides of the mouse. 
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(a)  
Mouse 
no 
DLKPI: Tumour growth measurements (mm3) from mice 
inoculated with 1x106 cells (Days) 
 21 25 29 32 
1 117.20 398.36 584.06 807.79 
2 65.80 251.16 564.37 563.70 
(b)  
Mouse 
No 
DLKPI: Tumour growth measurements (mm3) from mice 
inoculated with 5x106 cells (Days) 
 21 25 29 32 
1 286.65 692.20 711.62 1080.54 
2 554.40 766.26 1498.65 1602.84 
3 460.04 Mouse sacrificed at day 21 
4 491.39 970.22 1670.92 
Mouse 
sacrificed 
(c)  
Mouse 
No 
DLKPI: Tumour growth measurements (mm3) from mice 
inoculated with 1x107 cells (Days) 
 21 25 29 32 
3 266.13 Mouse sacrificed at day 21 
4 
149.50 435.24 907.26 
Mouse 
sacrificed 
Table 3.5-3:- DLKPI xenograft tumour measurements. 
The growth of xenograft tumours following subcutaneous injection of DLKPI cells. 
Measurements of the tumours in SCID mice inoculated with DLKPI cells at cell densities of (a) 
1x106 cells (n=2), (b) 5x106 cells (n=4) and (c) 1x107 cells (n=2). 
 
 
Figure 3.5-8:- Xenograft tumour growth curves for DLKPI. 
Xenografts tumours were developed following subcutaneous injection of DLKPI cells in 
SCID mice over 32 days post injection. Tumour growth curves for DLKPI. Cell numbers 
injected: 1x106 cells (n=2), 5x106 cells (n=4), 1x107 cells (n=2). Black arrow indicates 
when a mouse was sacrificed, reducing the numbers continuing on in the experiment. 
21 25 29 32
Days Post Implant
1xE6 cells (n=2) 91.5 324.8 574.2 685.7
5xE6 cells (n=4) 448.1 809.6 1293.7 1341.7
1xE7 cells (n=2) 207.8 435.2 907.3
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3.5.2.4 Examination of the growth of DLKPM in vivo 
Four 28-35 day old SCID mice received subcutaneous injections of DLKPM cells at cell 
densities of 1x106 cells, 5x106 cells and 1x107 cells.  
Three out of four mice displayed tumour formation across the three different inoculation 
densities of DLKPM at both injection sites. Exploratory surgery performed to look for 
evidence of metastasis in one mouse (mouse 4) inoculated with DLKPM cells after 21 
days of growth revealed no evidence of metastasis. Figure 3.5-9 (A) and (B) gives a visual 
representation of tumours produced by DLKPM and their location (indicated by red 
arrows).  
Tumours produced by DLKPM were the slowest growing, smallest and were more solid 
compared to those produced by DLKP, DLKPSQ and DLKPI. However, the most 
successful tumours to be produced by DLKPM were those injected with 1x107 cells, 
indicating an optimal cell number could be required for tumour growth of DLKPM.  
Measurements for the tumours produced by DLKPM for each of the cell densities used 
in this study are presented in Table 3.5-4 (a) 1x106 cells (n=2), (b) 5x106 cells (n=4) and 
(c) 1x107 cells (n=2). The growth curves (Figure 3.5-10) highlights the size of tumours 
produced by DLKPM in SCID mice over 35 days. 
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Figure 3.5-9:- Growth of xenograft tumours from DLKPM cells. 
Representative images showing xenograft tumours following subcutaneous injection of DLKPM 
cells at inoculation densities of 5x106 cells (Image A) and 1x107 cells (image B) in 28-35 day old 
SCID mice. Red arrows indicate tumour location on both sides of the mouse. 
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(a)  
Animal 
No 
DLKPM: Tumour growth measurements (mm3) from mice 
inoculated with 1x106 cells (Days) 
 21 25 29 32 35 
1 0 0 0 470.20 698.15 
2 0 0 0 0 0 
(a)  
Animal 
No 
DLKPM: Tumour growth measurements (mm3) from mice 
inoculated with 5x106 cells (Days) 
 21 25 29 32 35 
1 0 0 0 391.04 603.65 
2 0 0 0 0 0 
3 79.67 0 0 327.63 1324.56 
4 224.40 Mouse sacrificed at day 21 
(b)  
Animal 
No 
DLKPM: Tumour growth measurements (mm3) from mice 
inoculated with 1x107 cells (Days) 
 21 25 29 32 35 
3 102.25 196.56 304.29 367.08 807.40 
4 253.34 Mouse sacrificed at day 21 
Table 3.5-4:- DLKPM xenograft tumour measurements. 
The growth of xenograft tumours following subcutaneous injection of DLKPM cells. 
Measurements of the tumours in SCID mice inoculated with DLKPM cells at cell densities of (a) 
1x106 cells (n=2), (b) 5x106 cells (n=4) and (c) 1x107 cells (n=2).  
 
 
 
Figure 3.5-10:- Xenograft tumour growth curves for DLKPM. 
Tumour xenografts were developed following subcutaneous injection of DLKPM cells in SCID 
mice over 35 days post injection. Tumour growth curves for DLKPM. Cell numbers injected: 
1x106 cells (n=2), 5x106 cells (n=4), 1x107 cells (n=2). Black arrow indicates when a mouse was 
sacrificed, reducing the animal numbers continuing on in the experiment. 
 
 
21 25 29 32 35
Days Post Implant
1xE6 cells (n=2) 0.0 0.0 0.0 235.1 349.1
5xE6 cells (n=4) 76.0 0.0 0.0 239.6 642.7
1xE7 cells (n=2) 177.8 196.6 304.3 367.1 807.4
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3.5.2.5 Summary of xenograft tumour growth from the DLKP in vivo study 
Growth curves of tumours developed by DLKP, DLKPSQ, DLKPI and DLKPM (Figure 
3.5-11) in mice were determined using average measurements obtained from the chosen 
three different inoculation densities (1x106 cells (n=2), 5x106 cells (n=4) and 1x107 cells 
(n=2)). Tumour formation was clearly visible at all inoculation densities for DLKP, 
DLKPSQ, DLKPI and DLKPM cell lines indicating that this cell line model was deemed 
compatible with the mouse model used in this study.  
 DLKP, DLKPSQ, DLKPI and DLKPM cell lines were all capable of producing 
tumours. 
 DLKP and DLKPI appeared to grow fastest giving rise to the largest tumours (DLKPI 
appeared to be marginally faster). 
 DLKP & DLKPI appeared to respond similarly with tumours produced on both 
injection sites at all cell densities by day 21. 
 DLKPM showed a range in response: at 21 days 0 out of 2 mice inoculated with 
1x106 cells had tumours, 2 out of 4 mice inoculated with 5x106 cells had tumours, 
while 2 out of 2 mice inoculated with 1x107cells had tumours). 
 DLKPI and DLKP tumours appeared to look similar, while DLKPM tumours were 
smaller and more solid.  
 Tumours produced by DLKPSQ appeared to be much more vascularised and 
angiogenic. In 2 out of 4 mice inoculated with DLKPSQ, small growths were 
produced in the peritoneal cavity (suggesting evidence of potential metastasis). Mr 
Vincent Lynch suggested that these growths were carcinomatosis of the peritoneal 
cavity. In a follow up experiment, the masses were produced in 1 out of 6 mice (data 
not shown).  
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Figure 3.5-11:- Summary growth curves of xenografts tumours developed by DLKP and its 
clones. 
 (A) Tumour growth curve for DLKP, DLKPSQ, DLKPI and DLKPM in SCID mice at an 
inoculation density of 1x106 cells, (n=2). (B) Tumour growth curve for DLKP, DLKPSQ, DLKPI 
and DLKPM in SCID mice at an inoculation density of 5x106 cells, (n=4). (C) Tumour growth 
curve for DLKP, DLKPSQ, DLKPI and DLKPM in SCID mice at an inoculation density of 1x107 
cells, (n=2). Black arrow indicates where a mouse was sacrificed, reducing the animal numbers 
continuing on in the experiment. 
21 25 29 32 35
Days Post Implant
DLKP 118.5 225.4 539.8 590.8
DLKPSQ 32.0 449.3 426.9 663.2
DLKPI 91.5 324.8 574.2 685.7
DLKPM 0.0 0.0 0.0 235.1 349.1
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21 25 29 32 35
Days Post Implant
DLKP 171.2 497.5 607.4 744.9
DLKPSQ 28.6 103.5 191.4 221.1
DLKPI 448.1 809.6 1293.7 1341.7
DLKPM 76.0 0.0 0.0 239.6 642.7
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21 25 29 32 35
Days Post Implant
DLKP 285.3 494.5 778.0 985.7
DLKPSQ 65.7 343.2 777.1 1357.4
DLKPI 207.8 435.2 907.3
DLKPM 177.8 196.6 304.3 367.1 807.4
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3.6 Characteristics of DLKP, DLKPSQ, DLKPI and DLKPM cell lines post 
tumour explant culture 
DLKP has at least three morphologically and phenotypically distinct clonal 
subpopulations (DLKPSQ, DLKPI and DLKPM). In culture, the ratios of these 
subpopulations in DLKP appear to remain balanced. Shirley McBride previously 
described a model for interconversion between the clonal subpopulations (i.e. DLKPSQ 
convert to DLKPI and DLKPI convert to DLKPM, but DLKPSQ cannot convert to 
DLKPM). One of the aims of this investigation was to establish if the DLKP clones 
developed different characteristics as a result of their growth in tumours compared to their 
growth under control conditions. The in vivo study presented an opportunity to recover 
DLKP and its clones from the tumours produced in SCID mice and to assess their 
characteristics post tumour growth. 
3.6.1 Isolation of DLKP clones from Xenograft tumours by explant culture 
Explant culture is a technique where by cells are isolated from a piece or pieces of tissue. 
Explant culture was carried out on xenograft tumours to investigate any changes in the in 
vitro characteristics of DLKP, DLKPSQ, DLKPI and DLKPM, post tumour growth. 
Table 3.6-1 indicates the names assigned to cell lines recovered from xenograft tumours 
and masses of the peritoneal cavity. This nomenclature was established to differentiate 
between the original DLKP cell lines and the DLKP cell lines established from the 
xenograft tumours, eliminating the risk of cross-contamination. The newly established 
tumour derived cell lines were initially cultured in serum free DMEM-Hams-F12 + 1% 
pen-strep to reduce the outgrowth of fibroblasts and contamination. Tumour derived cell 
lines were subsequently maintained in DMEM-Hams-F12 with 5% FCS. Established 
tumour cell lines were examined for changes in morphology, monolayer growth, anoikis, 
invasion and migration.  
Control culture Re-cultured cells Source 
DLKP DLKPt DLKP xenograft tumours 
DLKPSQ (1) DLKPSQta DLKPSQ xenograft tumours 
DLKPSQ (2) DLKPSQtn Growths from DLKSQ mice 
DLKPI DLKPIt DLKPI xenograft tumours 
DLKPM DLKPMt DLKPM xenograft tumours 
Table 3.6-1:- Nomenclature of DLKP and its clones in control culture vs. DLKP and its 
clones recovered from mouse xenografts.  
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3.6.2 Examination of the morphology of explanted tumour cells 
Once explant culture was complete, all cell lines were trypsinised from 6 well-plates into 
12.5cm2 where images were taken (early culture). Established recovered cell lines were 
then monitored for the subsequent 5 passages (late culture). Figure 3.6-1 shows the 
morphology of DLKPSQ, DLKPI and DLKPM cell lines pre-tumour growth (control) 
compared to recovered DLKPSQta, DLKPSQtn, DLKPIt and DLKPMt cell lines from 
xenograft tumours (early culture and late culture). 
Early culture (passage 1): Compared to control culture, all clones appeared to have an 
obvious morphological difference in appearance compared to control cells. Most notable 
for DLKPSQtn and DLKPMt was that individual cells appeared to be more elongated, 
late culture (between passage 3 and passage 5), DLKPSQtn and DLKPIt appeared to 
revert back to the morphology seen in control culture. However, DLKPMt appeared to 
retain a more elongated appearance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 169 
 
 
 
 
 
Control 
Explant Culture Explant culture of carcinomatosis peritoneum 
Early Culture Late Culture Early culture Late culture 
(A) 
DLKPSQ 
     
(B) DLKPI 
   
 
(C) 
DLKPM 
   
Figure 3.6-1:- Morphology of DLKP clones preimplantation vs. DLKP clones post explant culture. 
Explant culture was performed on xenograft tumours implanted with DLKPSQ, DLKPI and DLKPM. (A) DLKPSQ (i) Control, (ii)  Early culture post explant, 
(iii) Late culture post explant (DLKPSQta), cells from suspected Carcinomatosis: (iv) early culture, (v) Late culture (DLKPSQtn). (B) DLKPI (i) Control, (ii)  
Early culture post explant, (iii) Late culture post explant (DLKPIt). (C) DLKPM (i) Control, (ii)  Early culture post explant, (iii) Late culture post explant 
(DLKPMt). (Original magnification, x400; scale bar = 100 & 500µm). 
(i) (iv) (iii) 
(ii) 
(ii) 
(ii) 
(i) 
(i) (iii) 
(iii) 
(v) 
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3.6.3 Examination of growth of explanted tumour cells 
Recovered cell lines from xenograft tumours were examined for changes in growth. 
Figure 3.6-2 (A) shows a preliminary examination of the growth of explanted cells 
DLKPt, DLKPSQta, DLKPIt and DLKPMt compared to cells pre-tumour growth. 
Generally, all explanted cell lines grew in a similar fashion to control cells. However, a 
90% decrease in growth of DLKPSQtn (cells from carcinomatosis peritoneum) relative 
to DLKPSQ control cells was observed.  
3.6.3.1 Anoikis ability of explanted tumour cells 
Recovered cell lines from xenograft tumours were examined for changes in anoikis 
resistance. Figure 3.6-2 (B) shows a preliminary examination of growth under anoikis 
conditions of explanted DLKPt, DLKPSQta, DLKPIt and DLKPMt vs. control cells. 
Under anoikis conditions, explanted DLKP clones grew similar to DLKP control clones. 
However, an increase in anoikis sensitivity was observed for DLKP, from 17% in control 
cells to 43% in explanted DLKPt cells. 
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Figure 3.6-2:- Growth and anoikis capabilities of the DLKP clones post tumour growth. 
DLKP and its clones under control conditions (grey) vs. recovered DLKP and clones from 
xenografts (white). DLKPt and clones from tumour explant culture were compared to DLKP and 
its clones under control conditions for changes in (A) growth (acid phosphase) and (B) anoikis 
ability (using alamar blue). Data plotted represents the single technical replicate from one 
biological assay (n=1). 
 
 
 
 
 
0
50
100
150
DLKP DLKPt DLKPSQ SQta SQtn DLKPI It DLKPM Mt
R
e
la
ti
ve
 C
e
ll 
Su
rv
iv
al
 (
%
)
0
20
40
60
80
100
DLKP DLKPt DLKPSQ SQta SQtn DLKPI It DLKPM Mt
A
n
o
ik
is
 a
b
ili
ty
 (
%
)
 172 
 
3.6.4 Examination of invasive and migratory capacity of explanted tumour 
cells 
Recovered cell lines from xenografts tumours were examined for changes in invasion and 
migration capacity. To assess whether the growth of DLKP and subpopulations in 
xenografts effected their invasive capacity, in vitro invasion assay were performed (as 
described in section 2.4.1), on explanted cells. Representative photomicrographs in 
Figure 3.6-3 show the invasive capacity of DLKP and its clones post tumour explant 
compared to cells in control culture, while Figure 3.6-4 shows the total number of 
invading DLKPt, DLKPSQta, DLKPIt and DLKPMt cells through matrigel compared to 
control cells. This preliminary examination of explanted cells indicates an increase in the 
invasion of DLKPt vs. DLKP control cells, while a reduction in invasion was observed 
for explanted DLKPSQta and DLKPMt cells compared to control cells.  
Further examination of the invasive and migratory capacity of explanted DLKPSQta and 
DLKPMt were carried out.  Figure 3.6-5 (B) (iii) shows a significant reduction in 
migratory capacity was observed for DLKPSQta (p=0.00605) vs. control DLKPSQ cells, 
while a significant reduction in (C) (iii) invasive capacity (p=0.000976) and (D) (iii) 
migratory capacity (p=0.008014) of DLKPMt vs. control DLKPM cells (Figure 3.6-5). 
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Figure 3.6-3:- The invasive capacity of DLKP and its clones post tumour growth.  
DLKP and clones pre-implantation (Top row) vs. recovered DLKP and clones (bottom row) post 
explant culture. Explanted cell lines from xenograft tumours were examined for changes in levelss 
of invasion (A) (i) DLKP (ii) recovered DLKPt, (B) (i) DLKPSQ (ii) recovered DLKPSQta (iii) 
recovered DLKPSQtn, (C) (i) DLKPI (ii) recovered DLKPIt and (D) (i) DLKPM (ii) recovered 
DLKPMt (Original magnification x100, scale-bar = 200µm). 
 
 
 
 
 
Figure 3.6-4:- The invasive capacity of DLKP and its clones post tumour explant culture. 
Preliminary invasion assays showing: DLKP and its clones (grey) compared to DLKP post tumour 
growth (white). Explanted cell lines from xenograft tumours were examined for changes in levels 
of invasion. An increase was observed for DLKPt cells, while a reduction was observed for 
DLKPMt cells compared to control cells. The total number of invading cells is shown. Data 
plotted represents mean ± standard deviation of duplicate inserts, (n=1). 
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(A) 
 
(B) 
 
(iii) 
 
(iii) 
 
(C) 
 
(D) 
 
 
 
(iii) 
 
 
(iii) 
 
Figure 3.6-5:- Invasive and migratory capacity of DLKPSQ and DLKPM post tumour 
growth. 
Invasion and migration assays were carried out on DLKPSQ and DLKPM pre-implantation and 
post explant culture. (A) Invasive capacity of DLKPSQ (i) pre-implantation (ii) post explant 
culture (iii) Total invading cells: preimplantation vs. explant culture invasive capacity. (B) 
Migratory capacity of DLKPSQ (i) pre-implantation (ii) post explant culture (iii) Total migrating 
cells: preimplantation vs. explant culture (p=0.00605). (C) Invasive capacity of DLKPM (i) pre-
implantation (ii) post explant culture (iii) Total invading cells: preimplantation vs. explant culture 
invasive capacity (p=0.000976). (D) Migration of DLKPM (i) pre-implantation (ii) post explant 
culture (iii) Total migrating cells: preimplantation vs. explant culture (p=0.008014). Data plotted 
represents the mean +/- standard deviation duplicate inserts from triplicate biological assays. 
Statistics ** p≤0.01 and *** p≤0.005. Student’s t test (two tailed with equal variance, unpaired, 
n=3). 
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3.7 Immunohistochemical analysis of xenograft tumours 
An in vivo investigation was carried out where DLKP, DLKPSQ, DLKPI and DLKPM 
cell lines were implanted into mice. Section 3.5.2 outlines the capacity of each cell line 
to form tumours in vivo over a 32 - 35-day period post implantation of cells. After this 
period (or once the guideline tumour volume of 2000mm2 was reached) the mice were 
sacrificed and the tumours were harvested. One mouse from each cell line was sacrificed 
for exploratory surgery at day 21, the tumours from this mouse were formalin-fixed-
paraffin embedded and sectioned for immunohistochemical analysis. This investigation 
would allow us to characterise tumours for the expression of angiogenesis and 
proliferation markers, but also to evaluate any differences in expression of validated 
proteins from section 3.2 as a result of growth in tumours. 
An immunohistochemical survey was carried out using antibodies specific to a small 
number of protein markers known to be involved in cancer progression. For all xenograft 
tumours, the same tumour block was used throughout this study, however, fresh sections 
were cut when required. Antibodies targeted against the protein targets were used to stain 
xenograft tumours derived from DLKP, DLKPSQ, DLKPI and DLKPM cell lines. 
Tumours used for IHC were established from an inoculation density of 1x106 cells and 
5x106 cells.  
3.7.1 Human mitochondrial protein 
Human cells were used to form human tumours, however, the tumours were allowed to 
form in mice, these tumours may recruit murine tissue in order for the tumours to form. 
Before starting any immunohistochemical analysis, it was necessary to determine the 
amount of infiltrating murine tissue present in each of the tumours. The xenograft tissues 
were therefore stained using a commercial antibody specific to human mitochondrial 
proteins. 
Paraffin embedded sections of DLKP, DLKPSQ, DLKPI and DLKPM xenograft tissue 
sections were examined for reactivity to Human mitochondrial protein. Intense staining 
was observed in all tumours from all cell line derived tumours, some areas of the tumours 
displayed weaker expression (Figure 3.7-1). 
3.7.2 Ki-67 
Ki-67 antigen is a protein present in the nuclei of proliferating cells. It is widely used as 
a marker of proliferating tumour cells [119]. An antibody specific to Ki-67 was used to 
examine Ki67 expression in paraffin-embedded sections of xenograft tumours from the 
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in vivo study. Strong staining was observed in all tumours, however possibly more intense 
staining was found to be in tumours derived from DLKP and DLKPI cells (Figure 3.7-2). 
There appear to be more cells staining positive for Ki67 in the tumours compared to 
staining observed for human mitochondria proteins. Strong Ki-67 staining indicates that 
the xenograft tumours derived by DLKP, DLKPSQ, DLKPI and DLKPM cells were 
highly proliferative.  
3.7.3 CD31  
CD31 (PECAM-1) is found on the surface of endothelial cells and has been used routinely 
as a marker for angiogenesis [120]. An antibody specific to CD31 was used to examine 
the expression of CD31 in paraffin-embedded sections of xenograft tumours from our 
DLKP in vivo study. In xenograft tumours derived from DLKP, DLKPSQ, DLKPI and 
DLKPM, weak/low level staining of CD31 was observed (Figure 3.7-3). 
3.7.4 E-cadherin and N-cadherin 
E-cadherin and N-cadherin are proteins known to be involved in processes such as cell-
cell adhesion, differentiation, migration and invasion. Their involvement in epithelium to 
mesenchymal transition (EMT) has also been suggested. During an EMT, E-cadherin is 
downregulated while N-cadherin is upregulated during a process known as cadherin 
switching [121]. Expression of both E-cadherin and N-cadherin were examined in 
paraffin embedded sections of xenograft tumours from our DLKP in vivo study. 
In the xenograft tumours associated with DLKPSQ, low-level staining in small areas of 
the tumours was observed for E-cadherin, however, tumours derived from DLKP, DLKPI 
and DLKPM showed very low to negative immunoreactivity for E-cadherin (Figure 
3.7-4). Staining was not observed in explanted cells from the tumour xenografts (Figure 
3.7-5). N-cadherin expression was previously established in DLKP and the clones. As 
expected strong staining was observed in tumours associated with DLKP, DLKPI and 
DLKPM with low level staining in tumours associated with DLKPSQ (Figure 3.7-6). 
Interestingly, in explanted cells, the intensity of expression of N-cadherin was increased 
in explanted DLKPt cells and DLKPSQta cells and is reduced in explanted DLKPMt cells 
compared to control cells (Figure 3.7-7). Tissue section associated with DLKPI 
(inoculation density of 1x106 cells) is not shown because the section did not stain 
correctly. A summary of the immunohistochemical analysis of markers outlined above is 
presented in Table 3.7-1. 
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Figure 3.7-1:- Expression of human mitochondrial protein in xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. Strong staining 
was observed in all xenograft tumours using an antibody specific to a human mitochondrial 
protein. (Magnification, x400; scale bar = 200µm). 
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Figure 3.7-2:- Expression of Ki-67 in xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells, intense staining 
was observed in all tumours, using an antibody specific to Ki67. (Magnification, x400; scale bar 
= 200µm). 
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Figure 3.7-3:- Representative images of xenograft tumours stained for the expression of 
CD31. 
Xenograft tumours derived from; (A) DLKP (i) 1x106 (ii) 5x106, (B) DLKPSQ (i) 1x106 cells (ii) 
5x106 cells, (C) DLKPI ((i) 1x106 cells (ii) 5x106 cells and (D) DLKPM (i) 1x106 cells (ii) 5x106 
cells, weak/low level staining was observed in all xenograft tumours, using an antibody specific 
to CD31 (Magnification, x400; scale bar = 200µm). 
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Figure 3.7-4:- Representative images of xenograft tumours stained for the expression of E-
cadherin. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. Low level staining 
for E-cadherin observed in DLKPSQ tumours, using an antibody specific to E-cadherin. 
(Magnification, x400; scale bar = 200µm). 
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Figure 3.7-5:- Representative images of control cells vs. explanted cells stained for 
expression of E-cadherin. 
Control cells compared to explanted cell lines from xenograft tumours.  (A) DLKP (i) control 
cells (ii) explanted cells, (B) DLKPSQ (i) control cells (ii) explanted cells, (C) DLKPI (i) control 
cells (ii) explanted cells and (D) DLKPM (i) control cells (ii) explanted cells. Using an antibody 
specific to E-cadherin, staining was not observed in explanted tumour cells. (Magnification, x400; 
scale bar = 200µm). 
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Figure 3.7-6:- Expression of N-cadherin in xenograft tumours 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with 5x106 cells 
and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. Staining was observed in all 
xenograft tumours using an antibody specific to N-cadherin. (Magnification, x400; scale bar = 
200µm). 
 
 183 
 
A (i) 
 
(ii) 
 
B (i) 
 
(ii) 
 
C (i) 
 
(ii) 
 
D (i) 
 
(ii) 
 
 
Figure 3.7-7:- Expression of N-cadherin in cells derived from xenograft tumours. 
Xenograft tumours derived from; (A) DLKP (i) control cells (ii) explanted cells, (B) DLKPSQ (i) 
control cells (ii) explanted cells, (C) DLKPI (i) control cells (ii) explanted cells and (D) DLKPM 
(i) control cells (ii) explanted cells (ii) 5x106 cells, using an antibody specific to E-cadherin. 
(Magnification, x400; scale bar = 200µm). 
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3.7.5 Summary of staining observed in cell line derived-xenografts 
 
Target protein 
Cell line derived Xenografts 
DLKP DLKPSQ DLKPI DLKPM 
Human Mitochondrial protein +++ +++ +++ +++ 
Ki-67 +++ ++ ++ ++ 
CD31 (PECAM-1) - -/+ - - 
E-cadherin + -/+ + - 
N-cadherin + -/+ ++ + 
Table 3.7-1:- Summary of Immunohistochemical analysis carried out on xenograft tumours. 
Representative analysis of tumours formed after implantation of cells at 1x106 and 5 x106 cells. 
+++ very intense positivity, ++ intense positivity, +weak positivity: +/- some very weak 
positivity, - Negative. 
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3.8 Immunohistochemical analysis of differentially expressed proteins in 
xenograft tumours derived from DLKP clones 
DLKP, DLKPSQ, DLKPI and DLKPM cell lines were all shown to be able to produce 
tumours in SCID mice. In this section, Western blot analysis and Immunohistochemistry 
were used to investigate the expression of the differentially expressed proteins which 
were identified by comparative proteomics analysis (section 3.1.3 and section 3.1.4), in 
explanted cells and xenograft tissues. Representative tumour blocks were prepared from 
tumours derived from inoculation densities of 1x106 cells and 5x106 cells, fresh sections 
were prepared as required. 
3.8.1 Expression of SLIT2 and ROBO2 in vivo. 
SLIT2 ligand and its receptor ROBO2 were previously studied in DLKP and its clones 
(see section 3.2.3). The expression of SLIT2 and ROBO2 was examined in explanted 
tumour cells and xenograft tumours derived from DLKP and its clones. 
Western blot analysis was carried out to establish the expression of SLIT2 in membrane 
enriched fractions which were prepared from cells recovered from xenograft tumours via 
explant culture. Expression of SLIT2 was examined in recovered cells (DLKPt, 
DLKPSQta, DLKPIt and DLKPMt) and control cells (DLKP, DLKPSQ, DLKPI and 
DLKPM). A potential loss of SLIT2 was observed with DLKPSQta compared to control 
DLKPSQ cells, while a potential increase in expression of SLIT2 was observed in DLKPt 
compare to control DLKP (Figure 3.8-1), DLKPIt and DLKPMt cells appear to maintain 
expression compared to control cells. This was a preliminary investigation and would 
need to be repeated with the inclusion of appropriate loading controls. 
Immunohistochemistry was carried out to determine the expression of SLIT2 and its 
receptor ROBO2 in paraffin embedded sections of the xenograft tissues. Figure 3.8-2 
shows strong staining for SLIT2 in xenograft tissues in (A) DLKP, (B) DLKPI, (C) 
DLKPSQ and (D) DLKPM. The expression pattern of SLIT2 in xenografts is broadly in 
line with expression seen in Western blot validations in section 3.2.3. The in vivo 
expression of ROBO2 appears to show the same pattern of expression seen for SLIT2, 
increased expression in DLKP and DLKPM xenograft and lower expression levels for 
DLKPSQ and DLKPI (Figure 3.8-3). 
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Figure 3.8-1:- Expression of SLIT2 in the explanted DLKP tumour cells 
Represents expression of SLIT2 in membrane enriched fractions from explanted tumour cells 
(DLKPt, DLKPSQta, DLKPIt and DLKPMt) compared to control cells (DLKP, DLKPSQ, 
DLKPI and DLKPM), using an antibody specific to SLIT2 (n=1). 
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Figure 3.8-2:- Expression of SLIT2 in the xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells, Strong 
immunoreactivity was observed in all tumours using an antibody specific to a SLIT2 
(Magnification, x400; scale bar = 200µm). 
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Figure 3.8-3:- Expression of ROBO2 in the xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. Immunoreactivity 
was observed in all tumours using an antibody specific to a ROBO2 (Magnification, x400; scale 
bar = 200µm). 
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3.8.2 Expression of ALCAM in vivo. 
ALCAM expression was previously studied in DLKP and its clones (see section 3.2.4). 
The expression of ALCAM was investigated in explanted tumour cells and xenograft 
tumours derived from DLKP and its clones. 
Western blot analysis was carried out to establish the expression of ALCAM in 
membrane-enriched fractions which were prepared from cells recovered from xenograft 
tumours via explant culture. Figure 3.8-4 confirms expression of ALCAM to be 
maintained strongly in recovered cells from DLKPIt xenografts tumours compared to 
cells under control conditions. In the control cells, ALCAM is expressed at a notably 
lower level in DLKP, DLKPSQ and DLKPM compared to DLKPI, this expression pattern 
is also maintained in vivo. This was a preliminary investigation carried out on membrane 
enriched fractions of the and would need to be repeated but also examined in whole cell 
lysates of the cell lines with the inclusion of appropriate loading controls. 
Immunohistochemical analysis was carried out to determine the expression of ALCAM 
in paraffin embedded sections of the xenograft tissues. Representative images showing 
staining of ALCAM in xenografts tumours derived from DLKP and its clones (Figure 
3.8-5), intense expression was maintained throughout DLKPI xenograft tumour, while 
smaller areas of staining were observed for DLKP, DLKPSQ and DLKPM xenograft 
tissues.  
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Figure 3.8-4:- Expression of ALCAM in the explanted DLKP tumour cells. 
Represents expression of ALCAM in membrane enriched fractions from explanted tumour cells 
(DLKPt, DLKPSQta, DLKPIt and DLKPMt) compared to control cells (DLKP, DLKPSQ, 
DLKPI and DLKPM), using an antibody specific to ALCAM (n=1). 
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Figure 3.8-5:- Expression of ALCAM in the xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells, staining was 
observed in all tumours with DLKPI showing most intense immunoreactivity, using an antibody 
specific to a ALCAM (Magnification, x400; scale bar = 200µm). 
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3.8.3 Expression of IQGAP1 in vivo 
Expression of IQGAP1 was previously studied in DLKP and its clones (see section 3.2.5). 
The expression of IQGAP1 was examined in explanted tumour cells and xenograft 
tumours derived from DLKP and its clones. Western blot analysis was carried out to 
establish expression of IQGAP1 in membrane enriched fractions which were prepared 
from cells recovered from xenograft tumours via explant culture. Figure 3.8-6 confirmed 
expression of IQGAP1 in recovered cells (DLKPt, DLKPSQta, DLKPIt and DLKPMt) 
compared to cells cultured under control conditions (DLKP, DLKPSQ, DLKPI and 
DLKPM). Post tumour explantation, expression of IQGAP1 appears to be decreased in 
DLKPSQta, DLKPIt and DLKPMt compared to control cells, while expression in DLKPt 
appears to be increased compared to control DLKP. This was a preliminary investigation 
and would need to be repeated with the inclusion of appropriate loading controls. 
Immunohistochemistry was carried out to determine the expression of IQGAP1 in 
paraffin embedded sections of the xenograft tissues. Figure 3.8-7 shows strong 
immunoreactivity for IQGAP1 in all xenograft tissues with DLKPI and DLKPM showing 
marginally higher levels of expression compared to DLKP and DLKPSQ. Expression 
IQGAP1 appears to be maintained under in vivo conditions. 
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Figure 3.8-6:- Expression of IQGAP1 in the explanted DLKP tumour cells. 
Represents expression of IQGAP1 in membrane enriched fractions from explanted tumour cells 
(DLKPt, DLKPSQta, DLKPIt and DLKPMt) compared to control cells (DLKP, DLKPSQ, 
DLKPI and DLKPM), using an antibody specific to IQGAP1 (n=1). 
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Figure 3.8-7:- Expression of IQGAP1 in the xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. Immunoreactivity 
was observed in all tumours, using an antibody specific to a IQGAP1 (Magnification, x400; scale 
bar = 200µm). 
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3.8.4 Expression of INA in vivo 
Expression of INA was previously studied in DLKP and its clones (see section 3.2.6). 
The expression of INA was examined in xenograft tumours derived from DLKP and its 
clones. 
Immunohistochemistry was carried out to determine the expression of INA in paraffin 
embedded sections of the xenograft tissues. Figure 3.8-8, shows staining for INA in 
xenograft tissues in (A) DLKP, (B) DLKPSQ, (C) DLKPI and (D) DLKPM. The 
expression pattern of INA in the xenografts is in line with expression observed by 
Western blot validations of cultured cells, with expression observed in tumours derived 
from DLKP, DLKPSQ and DLKPM. Highest expression appears to be in DLKP and is 
absent in DLKPI, this indicates that DLKP and its clones retained their expression of INA 
under in vivo. 
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Figure 3.8-8:- Expression of INA in the xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. Immunoreactivity 
was observed in tumours derived DLKP, DLKPSQ and DLKPM, with the strongest staining 
observed in DLKPSQ tumours, using an antibody specific to INA (Magnification, x400; scale 
bar = 200µm). 
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3.8.5 Expression SPR in vivo 
Expression of SPR was previously studied in DLKP and its clones (see section 3.2.7). 
The expression of SPR was examined in explanted tumour cells and xenograft tumours 
derived from DLKP and its clones. 
Western blot analysis was carried out to establish the expression of SPR in membrane 
enriched fractions which were prepared from cells recovered from xenograft tumours via 
explant culture. Figure 3.8-9 confirmed expression of SPR in recovered cells (DLKPt, 
DLKPSQta, DLKPIt and DLKPMt) compared to cells cultured under control conditions 
(DLKP, DLKPSQ, DLKPI and DLKPM). Expression of SPR was maintained in all cell 
lines derived from tumours, with explanted DLKPt and DLKPSQta having highest 
expression.  
Immunohistochemistry was carried out to determine the expression of SPR in paraffin 
embedded sections of the xenograft tissues. Figure 3.8-10 shows strong staining for SPR 
in xenograft tissues in (A) DLKP, (B) DLKPSQ, (C) DLKPSQ and (D) DLKPM. The 
expression pattern of SPR in xenografts is broadly in line with expression seen in Western 
blot validations, indicating all cell lines maintained expression of SPR in vivo. 
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Figure 3.8-9:- Expression of SPR in the explanted DLKP tumour cells. 
Represents expression of SPR in membrane enriched fractions from explanted tumour cells 
(DLKPt, DLKPSQta, DLKPIt and DLKPMt) compared to control cells (DLKP, DLKPSQ, 
DLKPI and DLKPM), using an antibody specific to SPR (n=1). 
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Figure 3.8-10:- Expression of SPR in the xenograft tumours. 
Xenograft tumours derived from; (A) DLKP implanted with (i) 1x106 cells (ii) 5x106 cells, (B) 
DLKPSQ implanted with (i) 1x106 cells (ii) 5x106 cells, (C) DLKPI implanted with (i) 1x106 cells 
(ii) 5x106 cells and (D) DLKPM implanted with (i) 1x106 cells (ii) 5x106 cells. immunoreactivity 
was observed in all cell lines with DLKPSQ and DLKPM derived tumours showing strongest 
staining, using an antibody specific to SPR (Magnification, x400; scale bar = 200µm). 
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4.1 DLKP and its clonal subpopulations 
It is well established that primary and metastatic tumours are heterogeneous in nature and 
are home to subpopulations of cancer cells that differ in their genetic, phenotypic and 
behaviour characteristics. Two theories have been described to explain the establishment 
and maintenance of tumour heterogeneity; the cancer stem cell (CSC) theory and the 
clonal evolution/selection model. Both had been thought to be exclusive from each other, 
however, the processes are now believed to be potentially complementary. Heterogeneity 
in tumours can limit therapeutic efficacy and lead to resistance to therapies [88-90]. 
DLKP is a cell line established from the lymph node metastasis of a primary lung tumour 
histologically, described as a poorly differentiated squamous cell carcinoma. In early 
studies, DLKP was found to contain at least three morphologically distinct 
subpopulations, DLKPSQ, DLKPI and DLKPM. DLKPSQ resembled a squamous like 
morphology, with distinct cell boundaries and a cobble stone appearance. DLKPM 
resembled mesenchymal appearance with and fibroblast-like morphology, while DLKPI 
grew in tightly packed colonies with indistinct cell boundaries. The ratio of clones present 
within the DLKP parental cell line seems to be tightly controlled through a proposed 
model of interconversion [93]. This model proposed that DLKPSQ may convert to 
DLKPI and DLKPI may convert with DLKPM (and vice versa). Initial observations 
suggest that DLKPSQ and DLKPM they must pass through the DLKPI ‘phase’ first. The 
mechanism that allows the DLKP clones to interconvert remains unknown, but further 
investigations should be carried out in order to investigate interconversion in the DLKP 
clones. However, this model of interconversion could suggest also that DLKP may also 
represent a possible in vitro model of EMT. These observations suggested that DLKPI 
may resemble a potential stem cell-like population in DLKP given its ability to 
interconvert and give rise to both DLKPSQ and DLKPM cells. A core property of a stem 
cell is one with a self-renewal capacity and expression of specific cell surface markers. A 
number of different markers have been identified for lung cancer stem cells including 
ALDH1A1, CD177 and EpCAM. ALCAM has also been suggested as a putative stem 
cell marker for NSCLC [122, 123]. ALCAM is expressed in the DLKP clones but is 
expressed strongest in DLKPI and may, with further investigation, help confirm DLKPI 
as a stem cell population within DLKP (Figure 3.2-4). Expression of the cancer stem 
marker, ALCAM, may also suggest that the cancer stem cell model may fit the DLKP 
cell line model.  
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The initial studies also indicated that DLKP should be classified as either; variant small 
cell lung carcinoma (vSCLC) or non-small cell lung carcinoma with neuroendocrine 
differentiation [93]. vSCLC is distinguished from classic SCLC by having large cell 
undifferentiated carcinoma, with large cells and prominent nucleoli [124]. One of the 
interesting findings of the comparative proteomic study performed in this thesis, was that 
the identified proteins were associated with a variety of cellular processes, some of the 
proteins that were identified and subsequently validated appear to have strong neuronal 
association (e.g. INA, SPR, AHNAK), but also that their expression appeared to be 
strongest in SCLC cell lines (see section 3.3.1). These findings appear to correlate with 
these suggestions made by McBride 1998. In addition, later studies carried out on DLKP 
and its clonal variants indicated that the clones displayed differences in the levels of in 
vitro invasion, migration and anoikis resistance. Also, differences in its expression of key 
proteins associated with cancer progression were also found to be different between the 
clones. The DLKPSQ clone displays a poor invasive and migratory capacity, is anoikis 
resistant in vitro and displays low level expression of integrin αv. The DLKPM clone 
displays a high invasive and migratory capacity but is anoikis sensitive. The DLKPI clone 
displays an intermediate level of invasive and migratory capacity, with an intermediate 
ability to resist anoikis [95]. Anoikis is a Greek word used to describe the loss of a ‘home’ 
or ‘homelessness’[125]. Effectively, anoikis is a form of apoptosis which is induced by 
loss of attachment of cells from its ECM or by attachment to the incorrect ECM. However, 
some tumour cells have the ability to ‘resist anoikis’. Anoikis resistance is one of the 
hallmarks of cancer progression. If tumour cells resist anoikis they may develop the 
ability to survive in suspension or under anchorage-independent conditions. Cells given 
the ability to grow under these conditions may be able to disseminate throughout the body 
and give rise to metastasis [126]. Under normal conditions, anoikis is a control 
mechanism to prevent cells from colonizing elsewhere in the body, for this reason, the 
process of anoikis has been described as a physiologically relevant process in tissue 
homeostasis and development [127]. In gastric and ovarian cancers, it has been reported 
that anoikis is important for the peritoneal dissemination of cells [128, 129]. Interestingly, 
results from the DLKP in vivo study appear to suggest that the anoikis resistant cell line, 
DLKPSQ, appeared to display peritoneal dissemination of cells. There are a number of 
mechanisms whereby cells develop the ability to resist anoikis, one of those is through 
the loss of adhesion through integrin mediated cell-matrix attachment [130, 131]. 
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DLKPI and DLKPM both display high adherence capacity to bind fibronectin and 
vitronectin, potentially explained by their increased expression of integrin αv. Integrins 
are heterodimeric cell surface receptors that are involved in signal transduction. In 
addition, integrins also function to mediate attachment of cells to their substratum, e.g. 
integrin αvβ3 functions as a receptor for proteins with exposed Arg-Gly-ASP tripeptide, 
examples of such proteins include; fibronectin, vitronectin, fibrinogen, laminins and 
collagens. It has been reported that integrin αvβ3 binds MMP-2 and co-localises with 
degraded collagen type 1 [132]. Matrix metalloproteases (MMPs) are a diverse family of 
endopeptidases, which are enzymes capable of breaking down components of 
extracellular matrix (ECM). Common properties of MMPs are their dependence on zinc 
in the catalytic site for activity but also they are generally synthesised as inactive 
zymogens that require proteolytic cleaving to become active. They are known to be 
expressed in normal tissues only when and where they are required e.g. wound healing 
and embryonic development. However, aberrant expression of MMPs has been associated 
with roles tumour cell invasion and metastasis [133]. Differences in expression of MMP2 
and MMP10 was observed between the DLKP clones [96].   
Previous attempts were made to identify specific markers for the clones, through 
Immunocytochemical methods. A marker would serve to identify the individual clones 
from each other in a mixed population.  Therefore, to select a protein that is specific to 
one of the clones (i.e. a marker), ideally, it would be expressed in one or two of the clones, 
not in all three. To date, no specific markers have been identified that can allow us to 
distinguish the individual DLKP clones. Quantitative proteomic analysis potentially 
allows for the identification of differentially expressed proteins between the DLKP clones 
and thus could potentially act as markers for the individual clones. Also, identification of 
such membrane protein markers could provide the means to study the previously 
proposed model of interconversion between the clones, as well as their potential 
involvement in cell invasion and migration. This study also presents an opportunity to 
identify potentially novel membrane associated proteins that could be associated with 
lung cancer. The phenotypic differences of DLKP and its clones present a prime 
opportunity to investigate both heterogeneity in lung cancer, but also the mechanisms 
associated with lung heterogeneity, in vitro.  
 204 
 
4.2 Proteomic analysis of DLKP and its subpopulations 
To identify proteins that could act as potential markers for the DLKP clones and also 
potentially novel proteins associated with lung cancer, the comparative proteomic 
analysis was carried out on DLKP, DLKPSQ, DLKPI and DLKPM cell lines. In this 
study, the four cell lines were grown in triplicate under standard culture conditions until 
approx. 90% confluent. To ensure cells were healthy, the cell culture media was changed 
the day before processing (section 2.2.1). Isolated proteins were then prepared for LC-
MS/MS as described in section 2.2.2 and 2.2.3. Peptide identification was performed 
using proteome discoverer 2.0 against MASCOT and SEQUEST databases against the 
UniProtKB-SwissProt database. Comparative proteomic analysis was performed using 
Progenesis label-free software to identify proteins from 3 biologicals and 3 technical 
replicates of the 4 cell lines (DLKP, DLKPSQ, DLKPI and DLKPM) (section 2.2.4). 
Principle component analysis (PCA) revealed good separation of the cell lines and each 
of the replicates into their corresponding groups, indicating that the isolation and 
subsequent proteomic analysis performed in this study was robust and reproducible 
(section 3.1.2). 
A proteomic profile of proteins associated with the cell membrane of the DLKP and its 
clones was developed in vitro. Six lists of differentially expressed protein lists were 
generated from comparative proteomic analysis of DLKP vs. DLKPSQ, DLKP vs. 
DLKPI, DLKP vs. DLKPM, DLKPSQ vs. DLKPI, DLKPSQ vs. DLKPM and DLKP vs. 
DLKPI. Six statistically significant differentially expressed proteins were identified in 
DLKP and the DLKP clones (SQ, I and M); AHNAK, ROBO2, ALCAM, IQGAP1 and 
SPR (see section 3.1.3), ), less stringent criteria revealed HDGF as having statistical 
significance (p= 0.0302) and was also chosen for validation studies (see section 3.1.4). 
The objective of this analysis was to find proteins that could potentially be used as 
markers for the DLKP clones and, in addition, identify novel proteins associated with 
lung cancer. Proteins showing membrane association could be (with further investigation 
and validation) extrapolated to other tumour types and may lead to the identification of 
novel targets for treatment of other lethal cancers such as pancreatic cancer. Table 4.2-1 
below indicates the comparison from which each protein was identified. Two further 
proteins INA and SLIT2 were added to the panel of proteins selected for validation 
studies. Early studies suggested that DLKP could be classified as a non-small cell lung 
carcinoma with neuroendocrine differentiation. Another comparative proteomic study 
found INA to be increased in DLKPSQ vs. DLKPM (~2.5-fold). Increased INA 
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expression was recently associated with pancreatic neuroendocrine cancer tumour 
aggressiveness [104], hence why INA was selected for validation. ROBO2 acts as a 
receptor for SLIT2 and both of these genes were identified by microarray analysis of the 
DLKP clones previously carried out in our laboratory, thus both proteins were validated 
in this thesis [96]. 
 
Selected proteins for validation studies: identified from comparative proteomic 
analysis of DLKP and its clones 
Gene 
name 
Protein Name 
DLKP 
vs. 
DLKPSQ 
DLKP 
vs. 
DLKPI 
DLKP 
vs. 
DLKPM 
DLKPSQ 
vs. 
DLKPI 
DLKPSQ 
vs. 
DLKPM 
DLKPI 
vs. 
DLKPM 
AHNAK 
Neuroblast 
differentiation 
associated 
protein 
5.0 5.5 --- 10 8.0 --- 
ALCAM 
Activated 
leukocyte cell 
adhesion 
molecule 
--- --- 5.9 24.3 --- 30.2 
HDGF 
Hepatoma 
derived growth 
factor 
--- 2.2 --- --- --- --- 
IQGAP1 
Ras GTPase 
activating-like 
protein 1 
1.7 7.6 8.9 --- --- --- 
ROBO2 
Roundabout 
Homolog 2 
--- --- 60.6 21.8 --- 26.9 
SPR 
Sepiapterin 
Reductase 
--- --- --- 3.6 --- --- 
Table 4.2-1:- Summary of all proteins selected for validation studies. 
The table above indicates the proteins identified from the comparative proteomic analysis as 
potential markers for DLKP. Proteins are organised in alphabetical order, the list/s from which 
they came and their fold change. 
4.2.1 Neuroblast differentiation-associated protein 
Neuroblast differentiation-associated protein (AHNAK) or desmoyokin, is an 
exceptionally large protein (~629kDa), originally identified as a nuclear phosphoprotein 
in human neuroblastomas and skin epithelial cells. It has been reported as a membrane 
scaffold protein with three structurally distinct regions; an amino-terminal (500 amino 
acids), a large central region (4388 amino acids) and a carboxyl-terminal 1003 amino 
acids [134]. The specific localisation of AHNAK is controversial, with studies reporting 
localisation to the nucleus, Golgi apparatus, cytoplasm and association with the plasma 
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membrane. Its translocation from the cytoplasm and the plasma membrane in the Ca2+ 
and Protein Kinase C dependent manner in keratinocytes may potentially explain 
AHNAK’s ability to localise to different sites in the cell [135]. It has also been reported 
that in the presence of arachidonic acid, AHNAK binds and activates phospholipase C-
γ1 [136], a protein believed to play a key role in cell migration and invasion [137]. It also 
acts as a key molecular switch in the regulation of tumour migration [138]. AHNAK was 
recently found to be essential for pseudopodia formation and tumoural 
migration/invasion [134]. One study in mesothelioma showed that siRNA knockdown of 
AHNAK induced pseudopodia retraction, inhibited cell migration and invasion, reduced 
actin cytoskeleton dynamics and induced mesenchymal to epithelial transition [139]. 
Chen et al., reported that the AHNAK gene was among eight genes to show an association 
with relapse-free survival in lung and breast cancer patients treated with chemotherapy 
[140]. 
AHNAK was chosen as a potential marker for DLKPI or DLKPM, based on its 
comparative proteomic analysis carried out in section 3.1.3. AHNAK protein expression 
was increased in DLKP vs. SQ (increased in DLKP 5 fold), DLKP vs. DLKPI (increased 
in DLKPI 5.5 fold), DLKPSQ vs. DLKPI (increased in DLKPI 9.3 fold) and DLKPSQ 
vs. DLKPM (increased in DLKPM 8 fold). The large size of AHNAK made it difficult 
for validation by Western blot analysis and Immunohistochemistry. A number of attempts 
were made using gels that allow for the separation of high molecular weight proteins and 
the use of two separate antibodies targeting AHNAK. It was not possible to identify the 
AHNAK reactive band and staining of formalin fixed paraffin embedded tissues did not 
reveal AHNAK immunoreactivity. However, Immunofluorescence staining did show 
membrane immunoreactivity for AHNAK (see section 3.2.1), with high expression 
observed in both DLKPI and DLKPM compared to DLKP. Also, lower expression levels 
were observed in DLKPSQ, where individual cells showed strong membrane 
immunoreactivity. This could indicate a potential subpopulation within DLKPSQ. 
Survival analysis was carried out using the BreastMark algorithm to evaluate AHNAK 
expression in Luminal A, Luminal B, Her2+ and Basal-like molecular subtypes of breast 
cancer. The analysis indicates a significant association of AHNAK expression with 
outcome in patients with Luminal B (p=0.032) breast cancer (Figure 3.2-8). AHNAK has 
been reported to function as a tumour suppressor in breast cancer due to its involvement 
as a mediator of TGFβ signalling leading to cell cycle arrest. Mechanistic studies 
performed by Lee et al., indicated that TGFβ-induced nuclear translocation of AHNAK 
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leads to potentiation of R-Smad function and downregulation of c-Myc and cyclin D1/D2 
as well as inhibition of cell growth [141]. While the comparative proteomic analysis 
indicated differential expression of AHNAK within the DLKP clones, the subsequent 
validation studies confirmed high expression in DLKPI and DLKPM cells. AHNAK 
expression was also observed in DLKP and DLKPSQ cell lines, but membrane 
immunoreactivity was only observed in a specific population of these cell lines (see 
Figure 3.2-1). This may indicate the presence of further subpopulations in DLKP and 
DLKPSQ. Further investigations could include cell sorting using a fluorescent-activated 
cell sorting (FACS) to characterise any potential subpopulations. However, AHNAK 
would not serve as a good marker for identification of the individual DLKP clones. There 
is still little known about the role of AHNAK in lung cancer and could be investigated 
further in the DLKP cell line model by use of inhibitors targeting PI3K/MAK/MTOR 
pathways or through the use of siRNA mediated knockdown of the AHNAK gene. 
4.2.2 Hepatoma-derived growth factor 
Hepatoma-derived growth factor (HDGF) has a molecular weight of approximately 
37kDa. HDGF is a heparin-binding growth factor originally purified from media 
conditioned with the human hepatoma cell line HuH-7. Its precise function is unclear, 
however, HDGF is believed to translocate to the nucleus which is essential for its effect 
on cell growth by binding to DNA using its PWWP motif [142]. HDGF lacks the N-
terminal hydrophobic sequence that is characteristic of most signal proteins, therefore 
suggesting that HDGF is secreted via an alternative pathway and is independent of the 
golgi secretion system. [143-145].  
HDGF was selected as a potential marker for DLKP based on its comparative proteomic 
data which compared protein expression in DLKP vs. DLKPI (see appendix 1.1). A 
putative receptor for HDGF has not been established [105]. However, part of the HATH 
region, containing 80-100 amino acids, has been proposed as a potential receptor binding 
site [146]. Immunocytochemical analysis and Western blot analysis subsequently 
confirmed highest expression of HDGF in DLKP compared to DLKPSQ, DLKPI and 
DLKPM (Figure 3.2-2). Levels of expression in the clones appear to be similar. HDGF 
was initially isolated from conditioned medium (CM) of HuH-7 cells and its secretory 
expression seems to correlate with the high levels of HDGF in CM generated from DLKP 
and its clones.  
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There are accumulating findings suggesting that HDGF is closely related to the aggressive 
biological potential of cancer cells and could be of prognostic value for patients with 
pancreatic cancer [147]. In the studies presented in this thesis, HDGF expression was 
investigated across representative tumour cell line panels from lung cancer (Figure 3.3-1), 
TNBC (Figure 3.3-6), pancreatic cancer (Figure 3.3-9), colon, glioma and melanoma 
(Figure 3.3-12). Results indicate that higher expression of HDGF may be associated with 
a more invasive/metastatic phenotype, in vitro. The invasive MiaPaCa2 Clone3 showed 
increased expression compared to the less invasive MiaPaCa2 parent and high expression 
was also observed in AsPc-1; a pancreatic cancer cell line derived from a metastatic 
ascites (www.atcc.org) and in the metastatic colon cell line (SW620) compared to its 
primary cell line counterpart (SW480). High expression was observed in LoxIVMI, a cell 
line derived from a metastatic melanoma. Survival analysis was carried out using the 
BreastMark algorithm to evaluate HDGF expression in Luminal A, Luminal B, Her2+ 
and Basal-like molecular subtypes of breast cancer. The analysis indicated that low 
expression of HDGF was associated with better outcome in patients with Luminal A 
breast cancer (Figure 3.2-9). High expression of HDGF was observed across a 
representative panel of cell lines: basal-like 1, basal like 2, mesenchymal and 
mesenchymal-like TNBC cancer cell lines. Validation studies confirmed increased 
expression of HDGF in DLKP and similar levels observed across the clones. Therefore, 
HDGF could not act as a selective marker to distinguish the individual DLKP clones. 
However, the preliminary evidence relating to HDGF expression in TNBC suggest a 
potential association with invasiveness, in vitro (Figure 3.3-6). Further investigations into 
the role for HDGF in metastatic cancers such as pancreatic, breast, colon or lung cancer 
should be performed. 
4.2.3 SLIT2 and ROBO2 
SLIT2 belongs to the Slit family of large extracellular matrix-secreted glycoproteins and 
consists of 3 genes (slit1, slit2, and slit3). The slit2 gene is located on chromosome 4p15.2 
and acts as a ligand for the repulsive guidance receptors, the robo gene family (robo1-4) 
[148]. SLIT2 interacts with ROBO1 and possibly ROBO2 receptors. SLIT–ROBO 
interactions are believed to play an important role in axon guidance in the central nervous 
system, but in human cancers, the slit2 gene is frequently inactivated by 
hypermethylation in its promoter region or allele loss in the lung, breast, colorectal 
cancers and malignant gliomas. This suggests a tumour-suppressive role for SLIT2, 
which inhibits cell migration and invasion in breast cancer and medulloblastoma [149]. 
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Studies in breast cancer and lung cancer have shown that SLIT2 elicits its tumour 
suppressor effects by its regulation of β-catenin and PI3K/Akt signalling pathways. In 
breast cancer, this regulation has shown to enhance β-catenin/E-cadherin-mediated cell-
cell adhesion [148, 150].   
ROBO2 was selected as a potential marker for DLKPI based on the comparative 
proteomic data analysis of DLKP vs. DLKPSQ (increased in DLKP ~57-fold), DLKP vs. 
DLKPM (increased in DLKP ~61-fold), DLKPSQ vs. DLKPI (increased in DLKPI ~22-
fold) and DLKPI vs.  DLKPM (increased in DLKPI ~27-fold), see section 3.1.3. Not only 
did ROBO2 appear in this differentially expressed proteomic analysis, but also in 
microarray analysis previously carried out by Dr. Helena Joyce indicated that ROBO2 
was overexpressed in DLKPI cells. Unpublished proteomic analysis performed on CM of 
DLKP and the clones also suggests secreted ROBO2 is increased in DLKPSQ and 
DLKPM compared to DLKP and DLKPI, providing supporting evidence for carrying out 
validation studies. 
The expression of both SLIT2 and ROBO2 was investigated in the DLKP cell line model 
using Immunofluorescence, Western blot analysis and Immunocytochemistry. SLIT2 and 
ROBO2 expression was highly varied across the DLKP clones. High expression of SLIT2 
was observed in DLKP and DLKPM only, with a lower level of expression observed in 
DLKPSQ and DLKPI. Western blot analysis indicated that expression of SLIT2 is highest 
in DLKPM and suggesting a potential use as a marker for DLKPM (Figure 3.2-3). SLIT2 
is a secreted protein and this was confirmed by Immunofluorescence and 
Immunocytochemical analysis, where immunoreactivity was visually observed in the 
extracellular space surrounding DLKP, DLKPI and DLKPM cells. To investigate a 
potential role for SLIT2 in the invasive process of DLKPI and DLKPM, siRNA 
transfections targeting SLIT2 were carried out. However, inconclusive results were 
observed following invasion assays (data not shown). Further investigations should be 
carried out to establish a functional role, if any, for the SLIT/ROBO signalling system in 
DLKP (e.g. this could include overexpression of SLIT2 in DLKPSQ). SLIT2 and ROBO2 
were investigated in parallel as potential markers for the DLKP clones. Following 
validation studies, expression was confirmed in DLKP and its clones. While a correlation 
of expression was observed between ROBO2 and SLIT2 in the DLKP cell line model, 
both, SLIT2 and ROBO2 expression was not considered specific enough to be able to 
identify the individual clones and was not carried forward as a potential marker for DLKP 
clones. 
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4.2.4 Ras-GTPase-activating-like protein 1 
Ras-GTPase-activating-like protein 1 (IQGAP1) is a scaffolding protein that binds to 
actin, which functions to cross-link and stabilise actin filaments through its calponin 
homology domain. IQGAP1 is approximately 189kDa and is a member of the IQGAP 
family of proteins of which three isoforms have been described in humans: IQGAP1, 
IQGAP2 and IQGAP3. IQGAP1 is the best characterized and the most widely studied. It 
is believed that they interact with signalling and structural molecules and are usually 
overexpressed in metastatic breast cancer [111] and advanced colorectal cancer [151]. 
IQGAP1 localizes to sites of cell–cell contact in epithelial cells and has been shown to 
regulate E-cadherin-mediated cell–cell adhesion as well as a number of signal 
transduction pathways, including Ca2+/ calmodulin, CDC42 and Rac MAPK and 
mTORC1–Akt. IQGAP1 shows elevated levels in a variety of cancer types, including 
pancreatic cancer [152, 153]. Jameson et al., investigated tumour formation in IQGAP1 
-/- mice with RAS-driven cancer and their studies indicated that there was diminished 
tumour formation in the knock out mice [154].  
IQGAP1 was selected as a potential marker for the DLKP clones based on comparative 
proteomic analysis of DLKP vs. DLKPSQ (increased in DLKPSQ ~1.7-fold), DLKP vs. 
DLKPI (increased in DLKPI ~8-fold), DLKP vs. DLKPM ~9-fold) and DLKPSQ vs. 
DLKPM (increased in DLKPM ~6.2-fold) see section 3.1.3. Unpublished proteomic 
analysis performed by Dr. Joanne Keenan in our laboratory also indicated that IQGAP1 
was present in CM of DLKP and the clones. A further reason for selecting IQGAP1 for 
validation studies was its reported interaction with ALCAM [112]. 
Immunofluorescence, Western Blot analysis and Immunocytochemical analysis 
confirmed that expression of IQGAP1 was highest in DLKPI and DLKPM compared to 
both DLKP and DLKPSQ (Figure 3.2-5). A good marker would theoretically allow for 
the identification of one clone from another in a mixed culture because IQGAP1 was 
expressed in all DLKP cell lines it would therefore not serve as a good choice. Jannie 
(2012) reported that ALCAM co-localised with N-cadherin, and, with IQGAP1 bound to 
the cytoplasmic tail of ALCAM, it elicits an effect on β-catenin. High expression of N-
cadherin had been previously shown in DLKPI, but also at lower levels in DLKP, 
DLKPSQ and DLKPM. ALCAM and N-cadherin appear to display a similar pattern of 
expression in DLKP and the clones. This suggests that, as proposed by Jannie (2012), 
IQGAP1 may interact with ALCAM and NCAD in DLKP, this potential interaction 
would need to be compared through immunoprecipitation. 
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4.2.5 Activated Leukocyte Cell Adhesion Molecule  
Activated leukocyte cell adhesion molecule (ALCAM) is a 105kDa protein that belongs 
to the immunoglobulin superfamily and is expressed by epithelial cells in several organs 
with reported functions in embryogenesis, angiogenesis, haematopoiesis and the immune 
response [155]. Originally, ALCAM was discovered as a ligand for CD6 in leukocytes 
[156] and is known to mediate both heterophilic (ALCAM-CD6) and homophilic 
(ALCAM-ALCAM) cell-cell interactions. ALCAM expression has been correlated with 
invasiveness of malignant melanoma and has been proposed as a prognostic marker of 
melanoma, prostate cancer, breast cancer, colorectal cancer, bladder cancer, oesophageal 
squamous cell carcinoma and ovarian cancer [157].  However, reports relating to tumour 
expression of ALCAM are conflicting, with one study suggesting that membranous 
expression in colorectal cancer appears to correlate with a shortened patient survival 
[158]. However, another suggests cytoplasmic localisation in breast cancer correlates 
with poorer patient outcome [159]. To investigate the association of ALCAM with 
survival in breast cancer, we used the BreastMark algorithm to evaluate ALCAM 
expression in Luminal A, Luminal B, Her2+ and Basal-like molecular subtypes of breast 
cancer. The analysis did not indicate significance in association with ALCAM expression 
in the molecular subtypes of breast cancer (Figure 3.2-12), therefore ALCAM was not 
investigated in the panel of TNBC cell lines. 
ALCAM was selected as a potential marker for DLKPI based on its comparative 
proteomic analysis of DLKP vs. DLKPI (increased in DLKPI ~19 fold), DLKP vs. 
DLKPM (increased in DLKP ~6-fold), DLKPSQ vs. DLKPI (increased in DLKPI ~24-
fold) and DLKPI vs. DLKPM (increased in DLKPI ~30-fold) see section 3.1.3. The stem 
cell theory proposes that a subpopulation of tumour cells initiates and maintains the 
tumour due to its ability to undergo asymmetrical divisions [122]. A number of studies 
have identified ALCAM as a lung cancer stem cell marker, other markers include 
aldehyde dehydrogenase isoform 1 (ALDH1), CD133 and CD44. The proteins have also 
been investigated as potential stem cell markers in colorectal cancer, melanoma, 
glioblastoma, ovarian and breast cancer. [110]. ALCAM has also been associated with 
colorectal cancer stem cells [160, 161]. Tachezy et al., reported that ALCAM expression 
was more frequent in smaller tumours without lymph node metastasis and with a benign 
grading that didn’t affect patient survival. They suggested that this was not consistent 
with a cancer stem cell, but instead reported ALCAM as an ‘inert’ cancer stem cell marker 
for NSCLC [122]. As an intermediate subpopulation in DLKP and with a potential ability 
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to give rise to DLKPSQ and DLKPM cells through interconversion, it was previously 
proposed that the DLKPI resembled a stem cell population in DLKP. There is little known 
about the function of ALCAM in lung cancer, so we wanted to investigate if ALCAM 
played a role in the invasion process in DLKP. Previous microarray and proteomic 
analyses indicate that ALCAM was highly overexpressed in DLKPI only and increased 
shedding of ALCAM from DLKPSQ and DLKPM cells was observed compared to DLKP 
and DLKPI, in conditioned media. sALCAM is a soluble isoform of ALCAM that is 
thought to be produced by alternative splicing. It is believed to play a regulatory effect 
on ALCAM may function but also potentially modulate endothelial function through 
ALCAM-dependent and ALCAM-independent pathways [109]. Immunofluorescence, 
Western blot analysis and immunocytochemical analyses confirmed that expression of 
ALCAM was highest in DLKPI while DLKP, DLKPSQ and DLKPM showed low levels 
of expression. Expression in CM did correlate with expression observed in the whole cell 
lysate and membrane enriched fractions (Figure 3.2-4). Soluble ALCAM (sALCAM) is 
believed to have a lower molecular weight than ALCAM [109].  Western blot analysis, 
using an ALCAM specific antibody revealed an additional band at approximately 60kDa 
(data not shown) in CM of DLKP, DLKPSQ, DLKPI and DLKPM and with higher 
expression in DLKPSQ. This band may represent sALCAM and potentially indicate its 
presence in the conditioned medium. To confirm this result, a Western blot analysis could 
be carried out using an antibody specific to sALCAM. 
We investigated a possible role for ALCAM in the invasive process of DLKPM, DLKPI 
and DLKPSQ-mitox-BCRP-6P, using siRNA knockdown of ALCAM. As previously 
shown in the validation experiments in section 3.2.4; DLKPI displayed the highest levels 
of ALCAM, while DLKPM showed lower expression levels compared to DLKPI. Dr 
Helena Joyce developed the DLKPSQ-mitox-BCRP-6P cell line after pulsing DLKPSQ 
with mitoxantrone. Subsequent characterisation of this cell line by Western blot analysis 
and Immunofluorescence analysis indicated increased expression of ALCAM in the drug 
resistant variant compared to DLKPSQ, its parental cell line (Helena Joyce PhD). In 
addition, DLKPSQ-mitox-BCRP-6P was also shown to have an increased ability to 
invade in vitro. It was therefore thought that DLKPSQ-mitox-BCRP-6P would be a good 
candidate cell line to investigate the role of ALCAM in lung cancer. There was no effect 
on proliferation in both DLKPSQ and DLKPM cell lines following siRNA knockdown 
of ALCAM, indicating that ALCAM does not appear to play a role in the growth of DLKP 
SQ or DLKPM. 
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4.2.5.1 Effect of ALCAM siRNA knockdown in DLKP 
High expression of ALCAM in DLKPI made it challenging for transient siRNA 
knockdown studies. Western blot analysis showed only a partial reduction of ALCAM at 
the protein level, with very little functional effect on proliferation and invasion. However, 
a reduction in protein levels occurred in both DLKPSQ-mitox-BCRP and in DLKPM, 
showing opposing roles in these cell lines. In DLKPSQ-mitox-BCRP-6P, an increase in 
invasion was observed following knockdown of ALCAM, with a significant increase 
observed using ALCAM-2 siRNA (p=0.0040) see section 3.4.1.1. A reduction in invasion 
was observed following siRNA knockdown of ALCAM in DLKPM, with a significant 
decrease shown using ALCAM-2 siRNA (p= 0.0041) see section 3.4.1.2. As discussed, 
there are contradictive roles for sALCAM and ALCAM in human cancers. sALCAM is 
reported to attenuate invasion of metastatic melanoma BLM cells [161, 162] but promotes 
invasion of glioblastoma [163]. In breast cancer ALCAM expression has been associated 
with suppression of invasion of breast cancer cells [164], while ALCAM promotes 
tumour cell invasion of glioblastoma cells. Membranous expression of ALCAM 
enhanced invasion and migration of NSCLC cells in vitro and was associated with poor 
survival of patients with NSCLC [165]. In this study, we have shown that invasion is 
significantly reduced in DLKPM and significantly increased in drug resistant cell line 
DLKPSQ-mitox-BCRP-6P. Our results suggest that siRNA knockdown of ALCAM does 
not affect cell growth but may have opposing roles in cancer cell invasion within a lung 
cancer cell line model, thus reflecting the contradicting roles for ALCAM reported in the 
literature.  
4.2.6 Alpha-Internexin 
Alpha-Internexin (INA) is a 66-kDa intermediate filament protein that maps to 
chromosome 10q24.33.  It is a component of the primary neurofilament triplet proteins 
of the central nervous system which include neurofilament subunits of low molecular 
weight (68kDa), a middle molecular weight (160kDa) and a high molecular weight 
(205kDa). To date, INA has mainly been investigated in cancers related to the brain such 
as Glioblastoma [166], Oligodendroglioma [113, 167] and medulloblastoma [168].  Using 
gene expression arrays, Ducray et al (2011) found that neuronal associated proteins were 
preferentially expressed in gliomas that were 1p19q codeleted and of these genes INA 
was one of the most differentially expressed [169], suggesting that INA may act as a 
surrogate marker for the 1p19q co-deletion. However, a recent study hypothesized that 
INA could be expressed in pancreatic neuroendocrine tumours (PNETs) [104]. Shirley 
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McBride initially characterised DLKP and suggested that DLKP should be classified as 
either a variant small cell lung carcinoma or non-small cell lung carcinoma with 
neuroendocrine differentiation [93]. This association led us to investigate the expression 
and a potential role of INA in the lung cancer cell line model DLKP. Presently, there are 
no reports relating to a functional role for INA in lung cancer.  
4.2.6.1 Effect of siRNA knockdown of INA on DLKPSQ and DLKPM 
Increased expression of INA has been associated with pancreatic neuroendocrine cancer 
tumour aggressiveness. A previous comparative proteomic study carried on DLKP cell 
line model in our laboratory found INA to be increased in DLKPSQ vs. DLKPM (~2.5-
fold). As previously stated, early studies suggested that DLKP could be characterised as 
a non-small cell lung carcinoma with neuroendocrine differentiation. INA was chosen for 
validation based on its recent association with PNETs.  
Western blot analysis, Immunofluorescence and Immunocytochemical analysis 
confirmed expression of INA was highest in DLKPSQ compared to both DLKP and 
DLKPM, with the lowest expression seen in DLKPI, see section 3.2.6. To investigate 
whether INA expression had a functional role in invasion and migration in the DLKP 
lung cancer cell line model, siRNA knockdown of the INA gene was carried out in two 
of the DLKP clones, DLKPSQ and DLKPM. DLKPSQ displays highest levels of INA 
expression and DLKPM which showed lower INA expression. There was no effect on 
proliferation in both DLKPSQ and DLKPM cell lines following siRNA knockdown of 
INA, indicating that INA does not appear to play a role in the growth of both cell lines. 
Two independent siRNAs were used to knockdown INA in DLKPSQ. The invasive and 
migratory ability of DLKPSQ, using both INA-6 and INA-8 siRNAs remained unchanged 
following transfection (see section 3.4.2.1). By comparison, siRNA knockdown in 
DLKPM using four independent siRNAs resulted in a variety of effects. Firstly, a 
morphological change was observed with two out of four siRNAs. Under normal 
conditions, DLKPM cells are irregularly shaped with fibroblastoid-like morphology and 
do not appear to form colonies. This morphology has been suggested to be typical of 
highly invasive and motile cancer cells. However, in DLKPM cells that were transfected 
with INA-7, the cells appeared to display a more elongated morphology, whilst cells 
transfected with INA-9 cells became more isolated and lost their fibroblastoid-like 
morphology (see section 3.4.2.2). One of the biological functions of INA is its 
involvement in cellular differentiation (www.uniprot.org) and it has been shown to be 
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expressed in neuronal cells as they begin to differentiate [170]. This observation may be 
evidence of potential differentiation of DLKPM from a highly invasive to a less invasive 
phenotype. We then looked at the effect on invasion and migration following knockdown 
of INA in DLKPM. A reduction in the invasive capacity of DLKPM was observed 
following INA knockdown, a significant reduction using INA-7 (p=0.0021) and INA-9 
(p=0.0016), while a reduction was also observed for INA-6 (n=2). Migratory ability was 
also reduced following INA knockdown, significantly with INA-6 (p=0.024). However, 
an increase in the invasive and migratory ability was noted using INA-8 siRNA, 
significantly for migration using INA-8 (p=0.015 (n=3)). A decreased migratory ability 
was also noted for the remaining two siRNAs (INA-7 and INA-9 (n=2)) see section 
3.4.2.2. This, to our knowledge, is the first report associating INA with both invasion 
/migration of lung cancer in vitro, suggesting that INA may have a potential role in the 
invasion and migratory process of lung cancer. 
INA expression was investigated by Western blot analysis in panels of cell lines 
representing various tumour types including lung cancer (Figure 3.3-4), TNBC (Figure 
3.3-7), neuroblastoma and glioma (Figure 3.3-14). Investigation of INA expression across 
a panel of pancreatic ductal adenocarcinoma (PDAC) cell lines appeared to show no 
detectable levels of expression (results not shown). This is not surprising considering the 
only reported association of INA with pancreatic cancer has been an association with the 
aggressiveness of PNETs [104]. In addition, Immunohistochemical analysis performed 
on a small number of pancreatic cancer tissues were negative for INA immunoreactivity. 
These findings suggest that INA may not play a role in PDAC, but further investigation 
would need to be carried out in order to confirm this finding. In the panel lung cancer of 
cell lines, there was also a low level of expression of INA, with the exception of NCI-
H69, a SCLC cell line. Expression of INA in NCI-H69 is not unexpected considering it 
is reported to express neuronal markers such as neuronal cell adhesion molecule and 
neuroendocrine markers such as neuronal specific enolase, chromogranin A and 
synaptophysin [171]. In addition, a lung cancer tissue microarray (TMA) was 
immunohistochemically stained for INA expression. Overall immunoreactivity on the 
TMA showed very specific reactivity of individual cells in lung adenocarcinoma and 
squamous cell carcinoma. However, the most intense staining was observed in the lung 
neuroendocrine tissues see Figure 3.4-28. This result could potentially suggest specificity 
of INA for neuroendocrine cells within different lung tumour types and thus suggest that 
INA may represent a potential marker for neuroendocrine lung cancer. Further 
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immunohistochemical analysis would need to be carried out on a larger number of 
neuroendocrine tissues of different tumour types. 
To date, there have been no reports of INA expression in breast cancer. TNBC is an 
aggressive form of breast cancer with high rates of relapse and overall poor prognosis. 
Survival analysis using the BreastMark algorithm was carried out and indicated that high 
expression of INA was associated with better outcome in patients with Luminal B breast 
cancer (Figure 3.2-14). This was a surprising result since increased INA expression had 
been reported as a marker for tumour aggressiveness in PNETs. The expression of INA 
was investigated in a panel of cell lines representing various TNBC sub-types. INA 
specific bands were detected at ~60kda in 4 out of 10 cell lines; HCC-1937, HCC-1143 
(BL-1), HDQP-1 (BL-2) and MDA-MB-157 (MSL), whereas the remaining 6 cell lines 
displayed very low expression of INA (Figure 3.3-7). In the remaining cell lines, INA 
expression was also observed in the neuroblastoma (SK-N-SH) cell line relative to glioma 
(SNB-19) as shown in Figure 3.3-14. The findings in relation to INA appear to suggest 
that INA expression could be associated with neuroendocrine cancer and that INA has 
potential as a marker for neuroendocrine cancer. Schimmack et al., have investigated the 
clinical relevance of INA as a potential marker for gastroenteropancreatic neuroendocrine 
neoplasms [172]. It is tempting to suggest that the four TNBC cell lines showing reactivity 
for INA, could indicate a neuroendocrine association. To verify this association, further 
investigation would need to be carried out to confirm expression of neuronal markers in 
these cell lines. In addition to breast cancer, INA should be investigated further as a 
potential neuroendocrine marker in other cancers. 
4.2.6.2 Summary 
In summary, we have shown that siRNA knockdown of INA in DLKPM; (i) does not 
affect cell growth, (ii) induces morphological changes to a potentially less invasive 
phenotype that may be associated with differentiation and (iii) results in significant 
reduction of invasion and migration. Western blot analysis indicates that INA is expressed 
at low levels across representative tumour cell line panels including lung cancer and 
TNBC cell lines. IHC analysis of a lung TMA also indicates that INA is expressed at low 
levels in various lung tumours. We have shown through IHC analysis that expression of 
INA may be associated with neuroendocrine cancer and that INA has the potential for use 
as a marker of neuroendocrine cancer. We have shown that targeting INA, through siRNA 
silencing may potentially indicate a role for INA in the invasive and migratory processes 
of lung cancer. This investigation may also support early findings suggesting that DLKP 
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should be classified as non-small cell lung carcinoma with neuroendocrine 
differentiation, through its expression of INA. 
4.2.7 Sepiapterin Reductase  
The SPR gene encodes for a 27kDa cytoplasmic enzyme. SPR is a homodimeric enzyme 
belonging to the family of short chain dehydrogenase/reductases and is inhibited by N-
acetyl derivatives of both serotonin and dopamine.  The SPR gene, which is located on 
chromosome 2p14-p12 and disease causing mutations, can cause a rare inherited error in 
pterin metabolism leading to Levodopa-responsive disorder [173, 174].  Individuals with 
this disorder frequently manifest motor disorders, cognitive delays and more frequently 
neurological disorders [175]. SPR is localised to the cytoplasm where it functions as an 
aldo-keto reductase catalysing the NADPH-dependent formation of dihydrobiopterin 
(BH2), a precursor for tetrahydrobiopterin (BH4) [176]. BH4 is an essential co-factor for 
enzymes such as nitric oxide synthase (NOS), Phenylalanine-3-3-hydroxylase, and 
catecholamine, but also for serotonin-biosynthesis enzymes tyrosine-4-hydroxylase and 
tryptophan-5-hyrdoxylase [174]. BH4 production appears to be crucial for normal cell 
functions with richest sources of SPR found in erythrocytes, the liver and the brain. 
Biosynthesis of BH4 (Figure 4.2-1) is regulated by the BH4 de novo synthesis pathway, 
the BH4 salvage pathway and a BH4 regeneration system [177]. It has been reported that 
homeostasis of BH4, dopamine, norepinephrine, serotonin and phenylalanine were greatly 
disturbed in SPR-/- mice leading to dwarfism and impaired body movement. The study 
did not investigate the activities of nitric oxide (NO) in the SPR mutant [178]. 
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Figure 4.2-1:- Mechanisms of BH4 biosynthesis. 
BH4 is synthesised through the de-novo pathway (green), salvage pathway (red) and BH4 
recycling (yellow). BH4 biosynthesis is regulated by the de novo pathway in which guanidine 
triphosphate (GTP) is converted to BH4 under the control of the rate-limiting enzyme GTP 
cyclohyrolase I (GTPCHI) and two intermediate enzymes pyruvoyl tetrahydrobiopterin synthase 
(PTPS) and sepiapterin reductase (SR - red star). BH4 is also synthesized by a “salvage pathway,” 
whereby sepiapterin is converted to 7,8-dihydrobiopterin (BH2) via SR and subsequently reduced 
to BH4 by dihydrofolate reductase (DHFR) [179]. 
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4.2.7.1 Effect of siRNA knockdown of SPR on DLKPSQ and DLKPM 
SPR was selected as a potential marker for DLKPSQ based on its comparative proteomic 
analysis of DLKPSQ vs. DLKPI (increased in DLKPSQ ~3.6-fold). Western Blot analysis 
confirmed expression of SPR was highest in DLKPSQ compared to DLKP and DLKPM, 
with the lowest expression seen in DLKPI (see section 3.1.3). Proteomic analysis and 
subsequent Western blot analysis of conditioned medium (CM) did not indicate 
expression of SPR in DLKP or its clones (data not shown). SPR is primarily localised to 
the cytoplasm. Immunofluorescence staining confirmed cytoplasmic staining in all four 
cell lines. membrane immunoreactivity was observed in a small population of DLKPSQ 
cells.  
There is limited knowledge related to the potential functional role of SPR in cancer. One 
study presented data demonstrating a functional role in proliferation for SPR in 
neuroblastoma through a novel association with Ornithine Decarboxylase (ODC) [180], 
see Figure 4.2-2. Two independent studies have associated Sepiapterin (SP) with 
proliferation and migration in ovarian cancer through downregulation of p70S6K-
dependent VEGFR2 expression [181] and in lung cancer through an association with 
Sepiapterin and integrin α3β1 and p53 [182]. Whilst these studies have reported findings 
directly related to proliferation and migration, presently there is no report in the literature 
associating SPR with cancer invasion, in vitro. A lung cancer TMA was 
immunohistochemically stained to examine SPR expression across different lung cancers. 
Variable staining was observed across the lung tumour types. The most intense and 
strongest staining was observed in the lung squamous cell carcinoma tumours (Figure 
3.4-29). DLKP was established from a “poorly differentiated squamous carcinoma”, so 
the intense staining in this tumour type was expected [92]. We wanted to see if SPR had 
a functional role in invasion and migration in the DLKP lung cancer cell line model. 
Knockdown of SPR was carried out in DLKPSQ and DLKPM because both cell lines 
show different levels of invasion and migration. There was a negligible effect on cell 
growth of both cell lines, however, one siRNA significantly (SPR-6, p=0.015) reduced 
cell growth of DLKPM. 
Two independent siRNAs were used to knockdown SPR in DLKPSQ. The invasive and 
migratory abilities using SPR-6 siRNA were reduced, but a high degree of variability was 
observed within a single biological replicate. By carrying out siRNA knockdown in a 
lowly invasive cell line, we were hoping to observe an increase in the invasion levels of 
DLKPSQ. Invasion levels of DLKPSQ are very low, so we were unable to determine if 
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the decrease was as a result of the knockdown or due to the low invasive and migratory 
capacity of DLKPSQ (see section 3.4.3.1). It was therefore decided to focus on DLKPM. 
Four independent siRNAs were used to knockdown SPR in DLKPM (SPR-1, SPR-2, 
SPR-5 and SPR-6). The invasive capacity of DLKPM cells was significantly reduced; 
SPR-1 (p=0.0031) and SPR-6 siRNA (p=0.0014) and the migratory ability was also 
significantly reduced using SPR-1 (p=0.0054) and SPR-6 (p=0.0048) see section 3.4.3.2. 
This is to our knowledge, the first report associating SPR with invasion and migration in 
vitro, suggesting that SPR may have a potential role in the invasive and migratory process 
of lung cancer. 
4.2.7.2 Effect of SPR knockdown in TNBC and pancreatic cancer 
Survival analysis using the BreastMark algorithm indicated that low expression of SPR 
was significantly associated with poor outcome in patients with Luminal A (p=0.0019) 
and Basal-like (p=0.022) breast cancer (section 3.2.8). Currently, there are no available 
targeted therapies for triple negative breast cancer (TNBC). SPR expression was 
investigated in a panel of cell lines representing various TNBC sub-types. SPR specific 
bands were detected at ~27kDa in TNBC cell lines, with the highest level of expression 
observed in MDA-MB-468, a basal-like 1 breast cancer subtype (Figure 3.3-8). PDAC is 
the most common type of pancreatic cancer, accounting for up to 90% of cases. Several 
mutations have been associated with pancreatic cancer development; KRAS, TP53, 
CDKN2A, EGFR and SMAD4. These mutations may lead to pancreatic tumour 
development and potentially chemo-resistance  [183]. A role for SPR in the invasion or 
migration processes is not currently described in TNBC or pancreatic cancer. Preliminary 
siRNA knockdown studies were carried out to investigate a potential role for SPR in 
TNBC (MDA-MB-468: BL-1) and pancreatic cancer (MiaPaCa2 Clone3 and AsPc-1). 
These cell lines were selected based on their increased expression profile of SPR in 
representative TNBC and PDAC cell line panel (Figure 3.3-8 and Figure 3.3-11). siRNA 
knockdown studies in MDA-MD-468 cells resulted in a reduction in invasion using at 
least two siRNAs targeting SPR, a significant reduction for SPR-6 (p=0.000908). 
Preliminary transfections were also carried out on MiaPaCa2 clone3 and AsPc-1 cells; 
reduced invasion and migration was observed for MiaPaCa2 clone 3 cells, while 
migration was only reduced for AsPc-1 cells. Although further investigations will need 
to be carried out in these pancreatic cancer cell lines, preliminary results indicate a 
potential role for SPR in breast and pancreatic cancer (Figure 3.4-26). BreastMark 
analysis indicated that SPR expression may be significant in relation to survival of 
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patients with breast cancer. SPR expression was examined in a small panel of breast 
cancer tissues (subtypes unknown), we found increased expression of SPR in these tissues 
compared to normal. In addition, a TMA containing 12 invasive ductal breast carcinomas 
also showed moderate to weak membrane staining (see section 3.4.7). This study aimed 
to evaluate SPR expression in a small cohort of breast cancer tissues, however, a larger 
number of tissues would need to be stained to verify the distribution of SPR in breast 
cancer.  
4.2.7.3 Hypoxia and tumour progression 
Tumour hypoxia occurs as a result of inadequate supply of blood borne oxygen to tumours 
due to the rapid cell proliferation that exceeds the development of the tumours blood 
supply. This can cause changes in the expression pattern of certain proteins in the tumours 
can induce hypoxia. Such proteins can act as makers for hypoxia, for example, Hypoxia-
inducible factors (HIFs) transcription factors that respond to a decrease in oxygen in the 
cellular environment. Activation of HIF-l (hypoxia-inducible factor 1) in cancer can 
increase the transcription of genes involved in glucose metabolism, apoptosis resistance, 
proliferation, invasion, metastasis and angiogenesis. Elevated levels of HIF-1α and or 
HIF-2α have been found in the majority of human cancers and their metastases and has 
been associated with higher patient mortality. Two other proteins have been described as 
intrinsic markers of hypoxia: Glucose-transport protein-1 (GLUT-1) and Carbonic 
anhydrase 9 (CAIX). Hypoxic conditions can lead to changes in characteristics of cells 
within a tumour and potentially lead to tissue heterogeneity, some cells may adapt and 
escape leading to potential local invasion and metastatic spread [184, 185]. Some of the 
changes in hypoxic conditions may result in increased sensitivity of cells as well as 
increased resistance to chemotherapy, the latter presenting a major clinical challenge in 
the treatment of certain cancers [186]. 
4.2.7.4 Reactive oxygen species 
Reactive oxygen species (ROS) are derived from the metabolism of molecular oxygen 
and are highly reactive. The major source of endogenous ROS is hydrogen peroxide and 
superoxide anion, which are generated as by-products of cellular metabolism such as 
mitochondrial respiration. ROS can be categorized into two groups. The first group 
include free oxygen radicals e.g. superoxide, hydroxyl radical, nitric oxide, organic 
radicals, peroxyl radicals, alkoxyl radicals, thiyl radicals, sulfonyl radicals, thiyl peroxyl 
radicals and disulphides. The second group are non-radical ROS which include: hydrogen 
peroxide, singlet oxygen, ozone/trioxygen, organic hydroperoxide, hypochloride, 
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peroxynitrite, nitrosoperoxycarbonate anion, nitrocarbonate anion, dinitrogen dioxide, 
nitronium, and highly reactive lipid-or carbohydrate derived carbonyl compounds. ROS 
exists in all aerobic cells but is tightly balanced by biochemical antioxidants. When this 
critical balance is disrupted oxidative stress occurs due to excess production of ROS 
coupled with depletion of antioxidants [187]. 
ROS are potential carcinogens because they facilitate mutagenesis, tumour promotion and 
progression [188]. The growth promoting effects of ROS are related to redox-responsive 
cell signalling cascades and have been implicated in the regulation of the mitogen-
activated protein (MAP) kinase/Erk cascade, phosphoinositide-3-kinase (PI3K)/Akt-
regulated signalling cascades, as well as the IκB kinase (IKK)/nuclear factor κ-B (NF-
κB)-activating pathways). [187, 188]. In addition to this, DFMO used to inhibit invasion 
in DLKPM cells (see section 3.4.3.3) has been implicated in two opposing cellular actions 
(cell survival and cell cycle arrest) in neuroblastoma through the inhibition of ornithine 
decarboxylase (ODC), leading to the activation of both AKT/Protein kinase B and 
p27Kip1 [189]. 
4.2.7.5 Effect of SPR knockdown on generation of ROS in DLKPM 
To investigate the effect of SPR on the generation of reactive oxygen species (ROS). 
DLKPM cells were transfected using four independent siRNAs targeting SPR and were 
then tested for generation of ROS. There was a reduction in ROS generation in SPR 
transfected cells using four independent siRNAs when compared to negative control cells. 
For SPR-1, SPR-5 and SPR-6, a 22% (p= 0.04), 32% (p= 0.006) and 31% (p= 0.009). The 
results in section 3.4.3.5, indicate that ROS generation may be potentially impaired as a 
result of knockdown of SPR.  
4.2.7.6 Investigation of the role of NOS and ODC in invasion of DLKPM 
To further develop our understanding of the role of SPR in the invasive process of the 
lung cancer cell line DLKPM, we performed preliminary studies to investigate the role 
of NOS and ODC in the invasion of DLKPM. We used two inhibitors; Nω-Nitro-L-
arginine (L-NNA) and DL-α-Difluoromethylornithine (DFMO) inhibitors for this study. 
An appropriate concentration was established for each inhibitor prior to carrying out 
invasion assays.  
4.2.7.7 Effect of L-NNA on DLKPM invasion 
As mentioned earlier, SPR is an enzyme that catalyses the final one or two steps in the 
production of BH4. BH4 is an essential co-factor for a number of enzymes including NOS. 
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There are three isoforms of NOS in mammalian tissues NOS-1 or nNOS was first purified 
from neuronal tissue, NOS-3 or eNOS was first found in endothelial cells. Both are 
constitutively expressed in epithelial tissues and are dependent on the transient influx of 
calcium to activate calmodulin. NOS-2 or iNOS permanently binds calmodulin and 
functions independent of calcium, its inducible by pro-inflammatory stimuli and once 
induced, NO is produced in high concentrations for longer periods. Also, sustained high 
levels can contribute to stroke and neurotoxic effects. NO is generally a short lived, 
endogenously produced gas and is responsible for numerous physiological functions such 
as vasodilation, inhibition of platelet aggregation and neurotransmission in central and 
peripheral nervous systems. However, it has been reported that components of the tumour 
microenvironment of breast cancer, may be important in the regulation of NOS in vitro. 
IL-8, TLR4, TIMP1, S100A8 and IL-6 were all implicated in this regard [190] 
L-NNA is a competitive inhibitor for all isoforms of NOS, it interacts non-covalently with 
all NOS’es but its coupling with iNOS is reported to be immediate and rapidly reversible 
with arginine. The role of NOS was investigated using the inhibitor L-NNA. The cell 
viability of DLKPM cells following treatment with L-NNA was determined by the acid 
phosphatase assay as described in section 2.5. Three different concentrations of L-NNA 
inhibitor were used (50μM, 100μM and 150μM) over a 5-day period. Results indicate that 
the growth inhibitory effects of L-NNA at all concentrations were negligible. In fact, at 
the higher concentration of 150μM, L-NNA treatment resulted in an increase cell growth 
of DLKPM. This concentration range of between 50μM and 150μM was used to 
investigate the effect of NO on the invasive capacity of DLKPM. Invasion assays were 
performed using two approaches. Firstly, a co-treatment, whereby L-NNA was added 
directly to the cells in the invasion assay and secondly, whereby the cells were treated for 
24hrs prior to invasion assay. The results indicate that there was no inhibitory effect 
following co-treatment with L-NNA. However, a 37% reduction in invasion (Figure 
3.4-21) was observed following the 24hr pre-treatment, indicating a potential role for NO 
in lung cancer cell invasion, in vitro. 
4.2.7.8 Effect of DFMO on DLKPM invasion 
Ornithine decarboxylase (ODC) is an enzyme that catalyses the first step of polyamine 
biosynthesis in humans: the decarboxylation of ornithine to putrescine. ODC is 
indispensable because of its central role in polyamine biosynthesis and because 
polyamines play essential roles in normal cell growth and differentiation. The resulting 
low molecular weight polyamines, spermidine, spermine and putrescine, are known to 
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interact with various macromolecules and have a variety of cellular effects. Polyamines 
are known to be involved in cell growth and have also been implicated in the process of 
cell transformation. In cancer, elevated levels of polyamine biosynthesis and 
accumulation have been associated with rapid tumour growth [191, 192]. SPR has been 
previously shown to interact with and activate ODC in order to elicit an effect on 
proliferation in neuroblastoma, the proposed mechanism for crosstalk between SPR and 
ODC is illustrated in Figure 4.2-2 [180]. We have also shown a potential role for SPR in 
the invasive and migration processes of DLKPM cells (section 3.4.3.3).  
 
 
Figure 4.2-2:- Proposed crosstalk between polyamine and nitric oxide (NO) pathways. 
Arginine is converted to ornithine by the action of arginase in the urea cycle. The enzyme ODC 
converts ornithine to putrescine and is a key enzyme in the biosynthesis of higher polyamines 
(spermidine, spermine). The NO pathway enzyme sepiapterin reductase (SPR) converts 6-
pyruvoyl tetrahydropterin to tetrahydrobiopterin (BH4), a cofactor for NO synthase (NOS) which 
converts arginine to citrulline. In reverse, citrulline converts to arginine via argininosuccinate 
(AS).  ODC forms a heterodimer complex with SPR which activates ODC and stimulates cell 
proliferation.  
 
The role of ODC was investigated using the inhibitor, L-α-difluoromethylornithine 
(DFMO). DFMO is an irreversible inhibitor of ODC which is used to induce the depletion 
of polyamines. Three different concentrations of the DFMO inhibitor were used (1mM, 
2.5mM and 5mM) over a 5-day period. Results indicate that there were growth inhibitory 
effects of associated with DFMO at 1mM and 2.5mM, (between 40-47% reduction in 
growth), while the highest concentration of 5mM showed little or no inhibitory effects on 
DLKPM cells. To investigate a potential role for ODC in the invasion of DLKPM cells, 
2.5mM and 5mM of DFMO was used. Invasion assays were performed using the same 
approach as used for L-NNA, a co-treatment and a 24hr pre-treatment. There was a 
significant reduction in the invasive capacity (p=0.04) of DLKPM following co-treatment 
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with the DFMO inhibitor, indicating that ODC (and potentially the production of 
polyamines) may be important for invasion of DLKPM (Figure 3.4-20). 
4.2.7.9 Summary 
In summary, the effect of SPR silencing was investigated in the invasive cell line, 
DLKPM. We have shown that siRNA knockdown of SPR; (i) does not appear to affect 
cell growth but (ii) results in a significant reduction of invasion and migration in DLKPM. 
We also suggest a potential association with MDA-MB-468 (TNBC) and MiaPaCa3 
Clone3 and AsPc-1 (PDAC). We have indicated that NOS and ODC (through the use of 
inhibitors) may also have a role in the invasive process of DLKPM cells.  
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4.3 Investigation of the growth of DLKP and its clones, in vivo 
A pilot study was carried out to investigate the growth of DLKP and its clones in vivo. 
DLKP, DLKPSQ, DLKPI and DLKPM cell lines were previously used in the in vitro 
generation of xenografts, no tumours were produced in this case. However, unlike the 
previous study SCID mice were selected for use in this study, so it was not known whether 
these cell lines would grow and result in the formation of tumours. The main aims of this 
study were to see if DLKP and the clones would grow and result in tumour formation in 
SCID mice.  
4.3.1 Examination of DLKP and its clones in vivo 
In vitro observations of the growth of DLKP and the clones indicated that they display 
different growth rates. DLKPSQ appears to be the slowest growing and DLKPM appears 
to grow the fastest, with DLKP and DLKPI displaying similar growth patterns [93]. Since 
an in vivo study such as this had not previously been carried out using DLKP and the 
clones, it was decided to use three different cell densities (1x106cells, 5x106cells and 
1x107cells) for implantation. When the cell lines were implanted into the mice, they 
appeared to show an initial lag in their growth, this characteristic also resembles their 
growth in vitro. Up to day 21, small palpable tumours were present in mice inoculated 
with DLKP, DLKPSQ and DLKPI cells, after this period the tumours appeared to grow 
at a rapidly (see section 3.5.2), while DLKPM cells produce tumours but at a slower rate 
to the other clones. The growth of DLKP and its clones in vitro is well established, they 
appear to exhibit slow growth for up to 2 days post trypsinisation, after which they appear 
to show an increased rate of growth. However, tumours developed using all cell lines, but 
DLKP and DLKPI cells appeared to behave similarly in vivo. DLKP (Figure 3.5-3 and 
Figure 3.5-4) and DLKPI (Figure 3.5-7 and Figure 3.5-8) were the fastest growing and 
largest, giving rise to tumours of over 100mm3 by 21 days, DLKPI were marginally faster. 
In contrast, DLKPSQ also gave rise to large tumours that were highly vascularised and 
angiogenic tumours (Figure 3.5-5 and Figure 3.5-6), while tumours produced by DLKPM 
were small, compact and more ‘solid’ in appearance (Figure 3.5-9 and Figure 3.5-10). 
The size of the tumours produced by the cell lines may be reflected in the expression of 
Ki67. Ki67 is a marker for proliferation and is expressed by proliferating cells in all active 
phases of the cell cycle (G (1), S, G (2), and mitosis), [193, 194]. Strong expression of 
Ki67 was observed in all tumours, a reduced level was observed in DLKPM derived 
tumours. The relatively high levels of ki67 expression observed in the xenograft tumours 
indicate that cells are actively proliferating and suggest a reason why such large tumours 
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were produced with DLKP, DLKPSQ and DLKPI. Ki67 expression in DLKPM derived 
tumours were reduced relative to the other tumours and thus potentially explaining why 
small tumours were produced for DLKPM cells. The large size of the tumours produced 
by DLKP and DLKPI indicated evidence of necrosis or potential hypoxia (Figure 3.5-3 
and Figure 3.5-7). This was not surprising due to the lack of visible vasculature in these 
tumours. Immunohistochemical analysis of the tumours for markers of hypoxia (e.g. HIF-
1α or Glut-1) would help confirm the presence of a hypoxic environment in these 
tumours.   
Use of different cell numbers for subcutaneous injection of cell lines allowed for 
examination of potential dose responses relating to tumour growth of the cell lines. In the 
case of DLKP and DLKPI, large tumours formed with all cell numbers, however, a lower 
cell number of 1x106 cells may be optimal for the in vivo growth of DLKP and DLKPI in 
future experiments. It appears that DLKPSQ produced tumours at each cell number, but 
failed to produce tumours in two mice out of four at 5x106 cells, however, an optimal cell 
number for DLKPSQ would be between 1x106 cells and 5x106 cells. DLKPM seemed to 
be cell density dependent showing optimal tumour growth using an inoculation density 
of 1x107cells. While all cell lines produced tumours, tumours were not produced at all 
three cell densities, indicating that there may be an optimal seeding density tot could be 
used for further experimentation. However, where tumours were produced by DLKP, 
DLKPSQ and DLKPI, they very large tumours and were produced very quickly. DLKPM 
appeared to be the exception producing smaller more solid tumours.  An optimal cell 
number for tumour growth would prevent excessively large tumours being produced in 
future studies and potentially allow for the examination of the effect of drugs on tumour 
growth over a longer period of time. The fact that all four cell lines produced tumours 
indicates that DLKP is an invaluable cell line model that could be used to carry out further 
in vivo experiments. A role for INA and SPR in tumour growth and development could 
be investigated through stable knockdown of DLKPSQ or DLKPM, shRNA transfected 
cells could be implanted into SCID mice as performed in this study and examined for 
effects on tumour growth. But also the effect of potential drug candidates on lung cancer 
tumour growth could also be examined using this cell line model. 
To examine the animals for evidence of potential metastasis, at day 21 one animal was 
sacrificed. The organs of each animal in this group were embedded in paraffin wax, 
sectioned and examined by a pathologist (Prof. Susan Kennedy) for evidence of 
metastasis. In this group of animals, there was no evidence of metastasis found in these 
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organs. The organs from the remaining mice in this study should be examined for 
metastasis. Tumours from one group of mice were also examined using Haematoxylin 
and Eosin staining, the xenografts were described as “poorly differentiated squamous cell 
carcinoma”. This description of the xenograft tumours is consistent with the original 
tumour from which DLKP was isolated. When harvesting the organs and tumours, the 
mice were examined for potential metastasis in the abdomen.  Upon inspection one 
injection site inoculated with DLKPSQ at an inoculation density of 5x106 cells failed to 
produce a tumour, this mouse in addition to one other produced small growths throughout 
their abdomen, indicating evidence of suspected metastasis or peritoneal carcinomatosis 
as described by Mr. Vincent Lynch (Figure 3.5-5). Carcinomatosis is very rare and is 
detected in about 10% of patients at the time of primary resection. The mechanisms 
causing carcinomatosis include dissemination of free cancer cells as a result of serosal 
involvement of the primary tumour, implantation of free cancer cells or the presence of 
cancer cells in the lymph fluid or venous blood retained in the peritoneal cavity [195]. 
Interestingly these growths did not appear in mice inoculated with DLKP, DLKPI or 
DLKPM, which would be considered to have moderate to high levels of invasion in vitro. 
CD31 is an established marker for angiogenesis [196], CD31 that has been associated 
with multiple cellular functions including adhesion, apoptosis, coagulation, host 
response, and protein synthesis that could influence tumour growth [197]. CD31 
expression was examined in the xenograft tumours, while the xenograft tumours showed 
extremely low expression in all tumours, DLKPSQ derived tumours did show some CD31 
immunoreactivity. The low expression of CD31 in DLKPSQ derived tumours may 
indicate why evidence of potential metastasis was observed in only three out of ten mice 
and why there was no observed evidence of potential metastases in mice inoculated with 
DLKP, DLKPI and DLKPM (Figure 3.7-3). 
The observation of potential evidence of metastasis in a total of three out of ten mice 
inoculated with DLKPSQ was an unexpected result due to the poorly invasive nature of 
this cell line.  One possible explanation for the distribution of these growths may be the 
ability of DLKPSQ to survive in suspension or rather its ability to resist anoikis [95]. 
Anoikis is an important process that contributes to cancer metastasis and is a particular 
type of apoptosis that occurs as a result of detachment or the absence of attachment to 
extracellular matrix (ECM), or to an inappropriate ECM [198, 199]. Evasion of anoikis 
is mainly regulated by integrins. Integrins protect the cell from anoikis, and so also do 
several kinases activated by integrins, like SRC, FAK and ILK [200]. Some tumour cells 
 229 
 
use ROS to avoid anoikis through oxidative stress, where by the production of ROS leads 
to the oxidation/activation of tyrosine kinase SRC leading to the activation of mechanisms 
that promotes survival and metastasis [201]. In a follow-up experiment, six mice were 
inoculated with DLKPSQ with the aim of replicating the original experiment i.e. to the 
production of growths in the peritoneal cavity. This study resulted in production growths 
in just one out of the six mice, this time, the growths were smaller than previously 
observed. In total 3 out of 10 mice produced evidence of potential metastasis. This result 
could indicate that not all DLKPSQ cells have the capacity to produce these growths and 
possibly suggesting that there may be potential tumorigenic and non-tumorigenic 
subpopulations in DLKPSQ [202]. This could indicate potential cellular heterogeneity 
within DLKPSQ. 
This study indicated that DLKP, DLKPSQ, DLKPI and DLKPM cell lines were all 
capable of forming tumours in vivo (section 3.5.2). Apart from the growths produced by 
DLKPSQ, there was no other evidence of metastasis. However only organs from one 
mouse inoculated with each cell line were examined for metastasis, it would, therefore, 
be important to examine the organs from the remaining animals for evidence of 
metastasis.  It is possible that the tumour microenvironment, which comprises of a 
complex network of tumour cells, immune cells, stromal cells and extracellular matrix, 
may have favoured the growth of a stem-like subpopulation within DLKPSQ, that 
resulted in the dissemination of DLKPSQ cells throughout the peritoneal cavity. This 
study provided a unique opportunity to study each of the cell lines under in vitro 
conditions but after a period of time in a tumour. We wanted to examine DLKP and its 
clones post tumour growth for changes in their invasive and migratory capabilities. 
Explant culture was performed by placing small pieces of the tumours into dishes 
containing serum free media and allowing the tumour cells migrate outward over a 
number of days. During the initial culture of cells derived from tumours, DLKPSQta 
appeared to display a more rounded morphology and had difficulty bedding down, while 
DLKPMt appeared to be smaller and more elongated and was capable of bedding down. 
Interestingly cells explanted from the DLKPSQ growths displayed marked changes in 
their morphology, while DLKPIt became slightly more fibroblastoid-like. However, after 
culturing over a number of passages, cells derived from DLKPSQ and DLKPI tumours 
appeared to revert to a morphology that resembled their original culture. Cells derived 
from DLKPM tumour appeared to retain its newly established morphology (Figure 3.6-1). 
In addition, cells derived from DLKPM tumours exhibited a reduced invasive and 
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migratory capacity (Figure 3.6-5) over prolonged growth in culture but also showed 
reduced expression of N-cadherin, this could be evidence of a move to a less aggressive 
cell type [202]. Perhaps this reduced expression of N-cadherin is indicative of reduced 
tumorigenic capacity of DLKPM cells. In contrast, cells derived from DLKP parental 
showed large tumour production, whilst an increased N-cadherin expression was 
observed in the explanted cells (Figure 3.7-6). N-cadherin is a known marker for EMT 
[203, 204]. The change in N-cadherin expression could indicate the start of the processes 
of epithelial to mesenchymal transition (EMT) in the case of DLKP or potentially 
mesenchymal to epithelial transition (MET) the case of DLKPM. It could also indicate 
potential interconversion of DLKPM to DLKPI-like cells. There was no change in E-
cadherin expression in xenograft tumours or in explanted cells (Figure 3.7-4 and Figure 
3.7-5). The EMT model indicates that cancer cells with an EMT phenotype can invade 
and intravasatate, but cannot form metastatic nodules. Cancer cells without an EMT 
phenotype cannot invade, but are able to form metastatic nodules. Cancer cells with a 
mixed EMT and non-EMT phenotype can complete the entire process of spontaneous 
metastasis. However, an additional model of EMT has been described and may be 
relevant to the results obtained in our in vivo study, where DLKPSQ, poorly invasive cell 
line produced evidence of metastasis in vivo. The model indicates, EMT cells with an 
enhanced invasive and migratory phenotype are responsible for degrading the 
surrounding ECM and penetrating the local tissues and blood or lymphatic vessels 
(intravasation). It is thought that the non-EMT cells migrate with EMT cells and thereby 
follow them into the circulation [205]. We suggested earlier that there may be an 
additional subpopulation present in DLKPSQ that was responsible for producing 
evidence of metastasis. That subpopulation may have played a role in initiating the 
process that led to the production of the growths in the peritoneal cavity. 
4.3.2 Investigation of the expression of validated proteins in vivo 
Eight proteins selected for validation studies in section 3.2, were also examined in 
xenograft tumours that were produced from the growth of DLKP, DLKPS, DLKPI and 
DLKPM in SCID mice. Proteins were identified from the comparative proteomic analysis 
carried out as part of this thesis (section 3.1.3), but also from an examination of other 
analyses performed in the NICB. Xenograft tumours were immunohistochemically 
examined using antibodies specific to each of the proteins and also by Western blot 
analysis of the cells recovered from the tumours. Table 4.3-1 shows overall expression of 
SLIT2, ROBO2, ALCAM, IQGAP1, INA and SPR from both xenograft tumours, while 
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Table 4.3-2 shows the expression of SLIT2, ALCAM, IQGAP1 and SPR in explanted 
cells recovered from tumours compared to control cells.  
 
Overall expression in xenograft tumours 
 DLKP DLKPSQ DLKPI DLKPM 
ALCAM ++ + ++++ ++ 
INA + + - + 
IQGAP1 + + ++ +++ 
ROBO2 ++ + + ++ 
SLIT2 +++ ++ ++ +++ 
SPR +++ +++ ++ ++ 
Table 4.3-1:- Expression of validated protein in xenograft tumours. 
Scoring reflects overall expression in tumours from two injection sites (1x106 cells and 5x106 
cells). ++++ Very Strong; +++ Strong; ++ Intermediate; + weak; +/- very weak; - negative 
 
 
Expression of proteins in control vs. explanted cells 
  DLKP DLKPSQ DLKPI DLKPM 
ALCAM 
Control + +/- ++++ +/- 
Explant +/+ +/- ++++ +/- 
IQGAP1 
Control +/- + ++ +++ 
Explant ++ + ++ ++ 
SLIT2 
Control ++ +/- + +++ 
Explant + +/- + +++ 
SPR 
Control ++ ++ + + 
Explant ++ ++ + + 
Table 4.3-2:- Expression of validated proteins was maintained in recovered cells from 
DLKP in vivo study. 
Expression of proteins in control cells was compared to expression in cells recovered by explant 
culture from DLKP tumours. ++++ Very Strong; +++ Strong; ++ Intermediate; + weak; +/- very 
weak; - negative 
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ROBO2 and SLIT2 expression was examined in xenograft tumours (section 3.8.1). 
Expression trends in vivo appear to be similar to that seen in culture. For SLIT2, strong 
expression was observed in all cell line derived tumours with DLKP and DLKPM 
showing the most intense level of expression, whilst DLKPSQ and DLKPI showed lower 
levels of expression. 
ALCAM expression was confirmed by Western blot analysis in DLKP and its clones 
(section 3.8.2), with the highest expression observed in DLKPI and lower levels observed 
in DLKP and DLKPM cells. Investigation of ALCAM expression in xenograft tumours 
appears to show similar trends in the expression of ALCAM between each of the cell line 
derived tumours. Briefly, DLKPSQ shows the lowest level of expression. However, 
strong expression was observed in isolates areas of both tumours produced from 1x106 
and 5x106 cells. DLKPI shows the strongest expression throughout both tumours while 
DLKPI and DLKPM shows a moderate level of expression in areas of each tumour 
(summarised in Table 4.3-1 and Table 4.3-2). Fujiwara et al., carried out a study to 
investigate the significance of ALCAM expression in pancreatic cancer. They found that 
ALCAM+ve pancreatic cancer cells exhibited stronger tumourigenicity than that of 
ALCAM-ve cells, whereas ALCAM-ve pancreatic cancer cells exhibited comparatively 
stronger invasive and migratory activities [206]. The DLKP cell line model shows varied 
levels of expression of ALCAM and all cell lines produced tumours in vivo, it could 
further indicate the contradictory role of ALCAM in cancer, as discussed previously. 
Validation studies (Section 3.2) confirmed that expression of IQGAP1 is lowest in DLKP 
with increasing levels in DLKPSQ, DLKPI and in DLKPM. Examination of IQGAP1 
expression observed in xenograft tumours appears to show similar trends in its expression 
in vivo vs. in vitro expression (see section 3.8.3). Strong membrane reactivity was 
observed in tumours from all cell lines, however, DLKP showed the lowest level of 
expression in both tumours produced from 1x106 and 5x106 cells. DLKPM shows the 
most intense membrane immunoreactivity throughout both tumours, while DLKPSQ and 
DLKPI shows a more moderate level of expression (Table 4.3-1). As mentioned earlier 
Jameson et al., investigated tumour formation in IQGAP1-/- mice and showed that there 
was diminished tumour formation in the knock-out mice [154]. We have a cell line model 
showing strong expression of IQGAP1, which appears to be maintained in vivo, 
suggesting that IQGAP1 may play an important role in tumourigenicity of DLKP, 
DLKPSQ, DLKPI and DLKPM cell lines in vivo. For confirmation of the role of IQGAP1 
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in tumour growth of DLKP and its clones, further investigations would need to be 
performed. 
INA expression in xenograft tumours shows similar trends to that seen in culture. Briefly, 
DLKP, DLKPSQ and DLKPM appear to show moderate levels of expression of INA, 
while DLKPI shows an absence of expression in both tumours produced from 1x106 and 
5x106 cells (see section 3.8.4, Figure 3.8-8). It is unlikely that INA is required for tumour 
growth, given that DLKP and its clones were all capable of tumour development in SCID 
mice. 
In vivo expression of SPR in xenograft tumours (see section 3.8.5) appears to show similar 
expression trends to that seen in culture. However strong immunoreactivity was observed 
in all four cell lines, DLKP and DLKPSQ showed the highest immunoreactivity for SPR, 
while DLKPI and DLKPM appear to show a lower level of expression - especially in 
tumours derived from 1x106 cells. A number of different dilutions of the SPR antibody 
were used to stain the xenograft tumours and all concentrations resulted in extremely 
strong staining. The antibody dilution used for the purposes of this these was 1:3000.  A 
more optimal concentration of SPR antibody should be used to examine fully the extent 
of expression of SPR in the tumours. However, there is evidence of membrane staining 
within tumours developed from DLKP, DLKPSQ and DLKPI. Preliminary Western blot 
analysis of membrane enriched samples appears to show maintenance of SPR expression 
in cells recovered from the tumours compared to cells in control culture. High expression 
of SPR in the xenografts may indicate that SPR is important for the development of 
tumours. Evidence of membrane expression of SPR in the xenograft tissues indicates that 
SPR may be important for use as a potential membrane target for therapy. 
4.3.3 Summary 
The in vivo study presented here shows that DLKP, DLKPSQ, DLKPI and DLKPM are 
all capable of forming tumours in SCID mice. We have shown that the expression of 
proteins identified from the comparative proteomic analysis was maintained in both 
recovered cells and also in xenograft tumours. We have shown DLKP and its clones 
display tumorigenic abilities in SCID mice and at certain cell densities, these conditions 
will make it easier to perform further in vivo studies using the DLKP cell line as a model. 
DLKP and its clones having distinctly different levels of invasion and other phenotypical 
characteristics could, therefore, prove to be an invaluable model to study the efficacy of 
chemotherapy drugs or monoclonal antibody therapies for lung cancer in vivo.  
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Chapter 5  CONCLUSIONS AND FUTURE WORK 
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5.1 Conclusions 
1. Proteomic profiling of membrane associated proteins of DLKP, DLKPSQ, DLKPI 
and DLKPM cell lines identified a number of statistically significant differentially 
expressed proteins: AHNAK, ALCAM, IQGAP1, HDGF, ROBO2 and SPR. All 
candidate membrane proteins including two further proteins; INA and SLIT2 were 
validated in DLKP and its clones, indicating that the method used in this study 
successfully isolated potentially biologically relevant membrane proteins. 
 
2. A dual invasion role for ALCAM was demonstrated through siRNA silencing of the 
ALCAM gene, a significant decrease in the invasive potential of DLKPM was 
observed, while a significant increase in the invasive potential was observed in the 
DLKPSQ-mitox-BCRP-6P cell line.  
 
3. A functional role for SPR and INA in invasion/migration of DLKPM cells was 
demonstrated through siRNA silencing of their respective genes, a significant 
decrease in the invasive and migratory potential of DLKPM was observed. In 
addition, a role for ROS was shown through a significant reduction in ROS 
generation following siRNA knockdown of SPR in DLKPM cells.  
 
4. Survival analysis using the BreastMark algorithm indicated that low expression of 
SPR was associated with poor outcome of Luminal A breast cancer and TNBC. A 
significant reduction in the invasive capacity of MDA-MB-468 (TNBC cell line) was 
also demonstrated following siRNA knockdown of SPR gene, indicating a potential 
role for SPR in breast cancer invasion. IHC analysis of SPR in a small panel of breast 
cancer tissues showed evidence of membrane reactivity, suggesting that SPR could 
be used as a potential therapeutic target. 
 
5. The differentially expressed proteins markers; HDGF, SLIT2, ALCAM, INA and 
SPR were all shown to be highly expressed in DLKP and SCLC cell lines, indicating 
an association of DLKP with SCLC. In addition, IHC analysis of INA carried out on 
lung cancer tumours indicated expression was observed mainly in lung 
neuroendocrine, suggesting that INA could serve as a marker for neuroendocrine 
cancers. 
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6. A study indicated that DLKP, DLKPSQ, DLKPI and DLKPM were highly 
tumorigenic in SCID mice. DLKP and DLKPI produced the largest and fastest 
growing tumours. DLKPSQ produced large, but extremely vascularised tumours 
with three out of ten mice showing evidence of potential metastasis in the peritoneal 
cavity. Immunohistochemical analysis of xenografts revealed strong Ki67 
immunoreactivity in xenografts derived from all four cell lines, suggesting that all 
cell lines were highly proliferative in vivo, particularly for DLKP, DLKPSQ and 
DLKPI. 
 
7. Explant culture revealed a significant decrease in the migratory potential of DLKPSQ 
cells, but also a significant decrease in both invasive and migratory potential of 
DLKPM cells. Western blot analysis of explanted cells and immunohistochemical 
analysis of xenograft tumours revealed that the expression of the differentially 
expressed proteins was maintained in vivo. 
 
8. We have shown that DLKP and its clones display tumorigenic abilities in SCID mice, 
the conditions used in this study will make it easier to perform further in vivo studies 
using the DLKP cell line as a model. 
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5.2 Future work 
1. Immunohistochemical analysis should be carried out to determine the distribution of 
ALCAM in a range of human cancer tissues (e.g. lung cancer, pancreatic cancer). To 
explore the mechanism responsible for the dual invasion role of ALCAM in the 
DLKP cell line model, further investigations should be carried out using siRNA 
knockdown followed by analysis of protein expression (e.g. E-cadherin, N-Cadherin, 
Vimentin, β-catenin, T-ERK/P-ERK etc.) by western blot analysis. 
 
2. BreastMark survival analysis indicated that SPR expression was significant in 
relation to survival of patients with Luminal A and Basal-like breast cancers. To 
further investigate a functional role for SPR in TNBC, siRNA knockdown studies 
should be carried out on additional cell lines associated with these cancer subtypes. 
SPR also displayed evidence of membrane association in a number of breast cancer 
tissues. Further immunohistochemical analysis should be carried out on a larger 
cohort of breast tumour types (including triple negative, HER2+, ER+, invasive and 
non-invasive) to further investigate if SPR is amenable as a potential drug target. 
 
3. To further examine the involvement of Nitric Oxide Synthase and Ornithine 
decarboxylase as a mechanism by which SPR decreased invasion and migration in 
DLKPM cells, further assays could be carried out using additional inhibitors of ODC 
and NOS. Inhibitors could be used in combination to establish a synergistic role. In 
addition to inhibitor studies, siRNA knockdown studies could to carried out to further 
evaluate a role for NOS (eNOS, nNOS, iNOS) or ODC in invasion and migration of 
the DLKPM cell line and TNBC cell lines. 
 
4. SPR and INA should be investigated in representative colon cancer cell lines to 
establish potential differences in their expression between primary and metastatic 
cell types (e.g. SW480 and SW620). Immunohistochemistry should be performed to 
establish the expression of these proteins in non-cancerous tissues and in other 
tumour types such as melanoma or glioma. 
 
5. Using commercially available antibodies, immunoprecipitation should be performed 
to identify potential binding partners of SPR and INA, which would help us to further 
understand the mechanism by which they effect invasion and migration in DLKPM 
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cells. Immunoprecipitation studies may also help identify further potentially novel 
proteins involved in cancer.  
 
6. Functional roles for target proteins should be investigated in other cellular processes 
such as anoikis, adhesion, through siRNA knockdown. Use of 3D assays could be 
useful to look at the effect of transfected cells on cellular growth in vitro. 
 
7. DLKPSQ produced evidence of potential metastasis in the peritoneal cavity of a 
number of mice in the pilot in vivo study. A further in vivo study with DLKPSQ using 
a larger number of mice should be performed to further investigate DLKPSQ as 
having a potential metastatic subgroup or subpopulation capable of producing 
metastasis. DLKP and its clones could, therefore, prove to be an invaluable model to 
study the efficacy of chemotherapy or monoclonal antibody therapies for lung cancer 
in vivo. 
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Description Accession 
Anova 
(p) 
Max fold 
change 
Roundabout homolog 2  Q9HCK4 2.51E-02 56.88 
Intercellular adhesion molecule 1  P05362 1.40E-02 56.16 
Catenin alpha-1  P35221 9.23E-03 30.84 
Fumarylacetoacetase  P16930 4.53E-03 19.87 
Fascin  Q16658 1.41E-03 14.08 
Catenin beta-1  P35222 1.98E-02 12.58 
Cathepsin Z  Q9UBR2 1.60E-03 6.85 
Neutral cholesterol ester hydrolase 1  Q6PIU2 4.15E-03 6.39 
Neuroblast differentiation-associated protein AHNAK  Q09666 1.02E-02 5.00 
D-3-phosphoglycerate dehydrogenase  O43175 1.43E-03 4.52 
Serpin H1  P50454 2.14E-04 4.21 
Shootin-1  A0MZ66 2.49E-04 3.87 
Procollagen galactosyltransferase 1  Q8NBJ5 1.40E-03 3.31 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic  Q01581 1.57E-03 3.10 
Protein CutA  O60888 1.46E-04 2.59 
Melanoma-associated antigen 4  P43358 5.30E-03 2.44 
RNA-binding protein 14  Q96PK6 2.29E-02 2.40 
Myosin-9  P35579 9.02E-03 2.33 
GDP-fucose protein O-fucosyltransferase 1  Q9H488 1.46E-02 2.33 
Microtubule-associated protein 2  P11137 2.22E-02 2.24 
Nucleolar RNA helicase 2  Q9NR30 6.24E-03 2.24 
Non-POU domain-containing octamer-binding protein  Q15233 1.11E-02 2.21 
Transcription intermediary factor 1-beta  Q13263 7.40E-03 2.15 
Barrier-to-autointegration factor  O75531 3.05E-02 2.15 
Glucose-6-phosphate isomerase  P06744 2.94E-02 2.12 
Protein disulfide-isomerase A6  Q15084 1.79E-02 2.06 
Leucine-rich PPR motif-containing protein, 
mitochondrial  
P42704 2.49E-02 2.05 
Protein disulfide-isomerase  P07237 1.42E-02 2.04 
Tubulin beta-6 chain  Q9BUF5 3.23E-03 2.01 
X-ray repair cross-complementing protein 5  P13010 3.60E-02 1.97 
Filamin-A  P21333 5.35E-03 1.97 
Importin-5  O00410 1.33E-02 1.96 
Elongation factor 1-gamma  P26641 5.09E-03 1.87 
Endoplasmin  P14625 1.33E-03 1.81 
Peroxiredoxin-1  Q06830 5.97E-03 1.75 
Neutral alpha-glucosidase AB  Q14697 1.00E-02 1.74 
Ras GTPase-activating-like protein IQGAP1  P46940 2.32E-02 1.73 
Endoplasmic reticulum resident protein 29  P30040 1.66E-04 1.72 
Exportin-2  P55060 7.60E-03 1.71 
78 kDa glucose-regulated protein  P11021 7.71E-04 1.71 
Kinectin  Q86UP2 3.73E-03 1.68 
Calponin-3  Q15417 1.20E-02 1.65 
Glyceraldehyde-3-phosphate dehydrogenase  P04406 1.37E-02 1.62 
Far upstream element-binding protein 1  Q96AE4 8.71E-03 1.58 
Fatty acid synthase  P49327 2.49E-03 1.56 
 257 
 
Talin-1  Q9Y490 1.99E-02 1.56 
Membrane-associated progesterone receptor 
component 1  
O00264 3.16E-02 1.54 
ATP-dependent RNA helicase A  Q08211 1.34E-02 1.54 
Peroxiredoxin-6  P30041 9.64E-03 1.54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 258 
 
 
 
 
 
 
 
 
 
Appendix 1.2 
 
Comparative proteomic analysis: DLKP vs. DLKPI 
 
 
 
 
 
 
 
 
 
 
 259 
 
Description Accession 
Anova 
(p) 
Max fold 
change 
Chondroitin sulfate proteoglycan 4  Q6UVK1 1.65E-02 82.94 
Intercellular adhesion molecule 1  P05362 1.18E-02 55.65 
Receptor-type tyrosine-protein phosphatase C  P08575 1.52E-02 37.62 
Peroxiredoxin-2  P32119 4.59E-04 31.26 
CD166 antigen  Q13740 3.79E-02 18.80 
Collagen alpha-1(XIV) chain  Q05707 1.58E-02 15.61 
Cathepsin Z  Q9UBR2 4.18E-03 9.26 
Prohibitin  P35232 1.15E-02 7.71 
Prohibitin-2  Q99623 1.28E-02 7.64 
Ras GTPase-activating-like protein IQGAP1  P46940 1.78E-03 7.61 
Filamin-B  O75369 2.19E-02 7.44 
Ras-related protein Ral-A  P11233 1.21E-02 6.55 
Prelamin-A/C  P02545 2.12E-02 5.75 
Neuroblast differentiation-associated protein AHNAK  Q09666 7.38E-04 5.55 
Tubulin-specific chaperone A  O75347 6.18E-03 5.34 
Ran-specific GTPase-activating protein  P43487 1.06E-03 5.21 
Creatine kinase B-type  P12277 2.80E-03 4.63 
Extended synaptotagmin-1  Q9BSJ8 4.04E-02 4.61 
Filamin-A  P21333 1.38E-02 4.59 
PDZ and LIM domain protein 5  Q96HC4 7.21E-03 4.55 
Exportin-2  P55060 6.62E-03 4.48 
Aconitate hydratase, mitochondrial  Q99798 5.66E-03 4.00 
ATP synthase subunit d, mitochondrial  O75947 2.92E-03 3.81 
Prosaposin  P07602 6.87E-03 3.63 
Lamin-B1  P20700 1.57E-04 3.57 
Superoxide dismutase [Cu-Zn]  P00441 2.74E-03 3.57 
Eukaryotic initiation factor 4A-II  Q14240 1.22E-03 3.53 
Alpha-aminoadipic semialdehyde dehydrogenase  P49419 7.26E-04 3.48 
Glutathione S-transferase P  P09211 5.78E-03 3.43 
Calponin-3  Q15417 4.24E-02 3.42 
Macrophage migration inhibitory factor  P14174 1.13E-03 3.41 
Annexin A2  P07355 9.00E-03 3.30 
Glutathione reductase, mitochondrial  P00390 5.35E-03 3.30 
Heat shock protein beta-1  P04792 5.91E-04 3.25 
Pirin  O00625 3.21E-02 3.18 
Cystatin-B  P04080 3.49E-02 3.10 
Vimentin  P08670 1.53E-02 3.09 
Calnexin  P27824 2.49E-02 3.07 
Lamina-associated polypeptide 2, isoform alpha  P42166 2.73E-04 3.05 
Serpin H1  P50454 1.78E-03 3.03 
Spectrin beta chain, non-erythrocytic 1  Q01082 2.00E-02 2.94 
Chloride intracellular channel protein 1  O00299 1.05E-02 2.93 
GDP-fucose protein O-fucosyltransferase 1  Q9H488 4.07E-03 2.91 
Enoyl-CoA delta isomerase 1, mitochondrial  P42126 3.37E-03 2.90 
Calreticulin  P27797 1.48E-03 2.88 
Actin, cytoplasmic 1  P60709 1.97E-02 2.83 
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Spectrin alpha chain, non-erythrocytic 1  Q13813 2.65E-02 2.78 
Platelet-activating factor acetylhydrolase IB subunit 
gamma  
Q15102 3.17E-03 2.75 
Thioredoxin-dependent peroxide reductase, 
mitochondrial  
P30048 9.13E-03 2.75 
Heat shock protein 105 kDa  Q92598 7.11E-03 2.73 
Thioredoxin domain-containing protein 12  O95881 1.51E-02 2.68 
Band 4.1-like protein 2  O43491 1.70E-03 2.68 
Ubiquitin-conjugating enzyme E2 variant 1  Q13404 2.18E-02 2.66 
Crk-like protein  P46109 2.06E-03 2.64 
6-phosphogluconate dehydrogenase, decarboxylating  P52209 5.00E-03 2.60 
Triosephosphate isomerase  P60174 1.47E-02 2.59 
ADP/ATP translocase 2  P05141 9.57E-03 2.58 
Phosphoglycerate kinase 1  P00558 4.28E-03 2.57 
ATP synthase subunit O, mitochondrial  P48047 9.10E-03 2.57 
X-ray repair cross-complementing protein 5  P13010 3.30E-03 2.57 
Thioredoxin domain-containing protein 5  Q8NBS9 4.01E-02 2.56 
Histone H4  P62805 2.06E-02 2.56 
Leucine-rich repeat-containing protein 59  Q96AG4 1.59E-02 2.51 
Rho GDP-dissociation inhibitor 1  P52565 4.65E-03 2.50 
Neutral alpha-glucosidase AB  Q14697 6.76E-03 2.44 
Nuclear autoantigenic sperm protein  P49321 4.16E-03 2.38 
Nucleoside diphosphate kinase A  P15531 5.95E-03 2.37 
Ataxin-10  Q9UBB4 6.54E-03 2.34 
Leucine-rich PPR motif-containing protein, 
mitochondrial  
P42704 1.35E-02 2.34 
Fatty acid synthase  P49327 3.28E-02 2.30 
Cytosolic acyl coenzyme A thioester hydrolase  O00154 8.01E-03 2.30 
Fumarate hydratase, mitochondrial  P07954 4.22E-03 2.27 
DNA-dependent protein kinase catalytic subunit  P78527 4.32E-02 2.27 
Myosin-11  P35749 8.06E-03 2.25 
Nucleophosmin  P06748 8.09E-03 2.21 
Electron transfer flavoprotein subunit alpha, 
mitochondrial  
P13804 3.05E-02 2.19 
Hepatoma-derived growth factor  P51858 3.02E-02 2.19 
L-lactate dehydrogenase B chain  P07195 8.46E-04 2.18 
Puromycin-sensitive aminopeptidase  P55786 6.70E-03 2.13 
ATP synthase subunit alpha, mitochondrial  P25705 6.55E-03 2.13 
Transitional endoplasmic reticulum ATPase  P55072 1.76E-02 2.10 
Putative nucleoside diphosphate kinase  O60361 1.24E-02 2.08 
Phosphoglycerate mutase 1  P18669 7.31E-03 2.07 
ATP synthase subunit beta, mitochondrial  P06576 1.07E-02 2.04 
10 kDa heat shock protein, mitochondrial  P61604 2.17E-02 2.04 
60 kDa heat shock protein, mitochondrial  P10809 9.79E-03 2.04 
Transaldolase  P37837 7.76E-03 2.03 
Ubiquitin carboxyl-terminal hydrolase isozyme L1  P09936 9.89E-03 2.03 
ATP-dependent RNA helicase A  Q08211 8.30E-03 2.01 
Glucose-6-phosphate isomerase  P06744 5.91E-03 1.98 
Malate dehydrogenase, cytoplasmic  P40925 1.11E-02 1.94 
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Heat shock protein HSP 90-beta  
P08238; 
Q58FF8; 
Q58FG1 
1.11E-02 1.94 
Ubiquitin-like modifier-activating enzyme 1  P22314 3.68E-02 1.93 
Myosin-9  P35579 1.44E-03 1.93 
Aspartate aminotransferase, mitochondrial  P00505 4.33E-03 1.90 
Polypyrimidine tract-binding protein 1  
P26599; 
Q9UKA9 
1.43E-02 1.88 
Annexin A1  P04083 3.37E-02 1.88 
Actin-related protein 3  P61158 4.77E-03 1.86 
Protein disulfide-isomerase A6  Q15084 6.06E-03 1.86 
Adenosylhomocysteinase  P23526 2.50E-02 1.85 
Heterogeneous nuclear ribonucleoprotein H  P31943 9.34E-04 1.82 
Tumor protein D52  P55327 1.60E-02 1.81 
Rab GDP dissociation inhibitor beta  P50395 3.65E-03 1.78 
Microtubule-associated protein 2  P11137 1.14E-02 1.77 
Peptidyl-prolyl cis-trans isomerase A  P62937 1.26E-02 1.75 
Cytochrome c  P99999 9.35E-03 1.72 
Transketolase  P29401 5.12E-03 1.71 
Heat shock 70 kDa protein 1A/1B  P08107 1.42E-02 1.69 
Stress-70 protein, mitochondrial  P38646 1.63E-02 1.67 
78 kDa glucose-regulated protein  
P11021; 
P17066 
1.89E-02 1.64 
Melanoma-associated antigen 4  P43358 1.31E-02 1.63 
Heat shock cognate 71 kDa protein  P11142 1.55E-02 1.63 
Cytosol aminopeptidase  P28838 1.95E-02 1.59 
LETM1 and EF-hand domain-containing protein 1, 
mitochondrial  
O95202 1.93E-02 1.52 
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Description Accession 
Anova 
(p) 
Max fold 
change 
Receptor-type tyrosine-protein phosphatase F  P10586 4.00E-02 89.23 
Intercellular adhesion molecule 1  P05362 1.09E-02 61.31 
Roundabout homolog 2  Q9HCK4 1.93E-02 60.59 
Chondroitin sulfate proteoglycan 4  Q6UVK1 2.28E-02 45.49 
Plexin-B2  O15031 3.79E-02 27.33 
Nectin-2  Q92692 2.59E-02 25.06 
Hematopoietic progenitor cell antigen CD34  P28906 1.29E-02 24.97 
PDZ and LIM domain protein 5  Q96HC4 1.48E-03 13.80 
Collagen alpha-1(XIV) chain  Q05707 6.85E-04 12.64 
Inactive tyrosine-protein kinase 7  Q13308 4.86E-02 10.40 
Cathepsin Z  Q9UBR2 5.08E-04 10.01 
Ras GTPase-activating-like protein IQGAP1  P46940 4.89E-03 8.99 
Keratin, type II cytoskeletal 6A  P02538 3.68E-03 8.81 
Ras-related protein Ral-A  P11233 1.92E-02 8.81 
Prohibitin-2  Q99623 8.46E-03 8.35 
Probable 28S rRNA (cytosine(4447)-C(5))-
methyltransferase  
P46087 9.45E-03 8.25 
U5 small nuclear ribonucleoprotein 200 kDa helicase  O75643 1.99E-02 8.00 
Prohibitin  P35232 1.18E-02 7.83 
Cytoskeleton-associated protein 5  Q14008 3.39E-03 7.80 
Filamin-B  O75369 2.67E-02 7.75 
Importin-5  O00410 1.53E-03 7.44 
Histone H4  P62805 3.39E-02 6.86 
Alpha-2-macroglobulin receptor-associated protein  P30533 8.30E-03 6.68 
Protein disulfide-isomerase A6  Q15084 1.95E-02 6.05 
CD166 antigen  Q13740 2.10E-02 5.97 
Paraspeckle component 1  Q8WXF1 2.73E-03 5.90 
Hypoxia up-regulated protein 1  Q9Y4L1 9.52E-03 5.83 
Splicing factor, proline- and glutamine-rich  P23246 2.81E-03 5.65 
Caldesmon  Q05682 4.35E-02 5.60 
Voltage-dependent anion-selective channel protein 2  P45880 1.55E-02 5.54 
Spectrin beta chain, non-erythrocytic 1  Q01082 1.91E-02 5.52 
Band 4.1-like protein 2  O43491 2.41E-04 5.44 
Neutral cholesterol ester hydrolase 1  Q6PIU2 1.74E-03 5.23 
Neuroblast differentiation-associated protein AHNAK  Q09666 2.80E-03 5.04 
Spectrin alpha chain, non-erythrocytic 1  Q13813 2.51E-02 5.02 
Heat shock 70 kDa protein 1A/1B  P08107 1.51E-03 4.88 
60S ribosomal protein L13  P26373 4.41E-02 4.81 
Cleavage and polyadenylation specificity factor 
subunit 6  
Q16630 9.95E-03 4.79 
Non-POU domain-containing octamer-binding protein  Q15233 5.05E-03 4.75 
Keratin, type II cytoskeletal 1  P04264 1.38E-02 4.61 
Ornithine aminotransferase, mitochondrial  P04181 2.04E-02 4.51 
ATP-dependent RNA helicase DDX3X  O00571 4.86E-03 4.40 
ATP synthase subunit alpha, mitochondrial  P25705 1.92E-02 4.26 
Heat shock 70 kDa protein 1-like  P34931 2.76E-03 4.22 
Exportin-1  O14980 6.30E-03 4.19 
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60S ribosomal protein L12  P30050 3.04E-02 4.00 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1  
P04843 3.39E-02 3.90 
Exportin-2  P55060 5.86E-03 3.90 
Nucleolar RNA helicase 2  Q9NR30 9.75E-03 3.79 
Barrier-to-autointegration factor  O75531 5.20E-04 3.79 
ATP synthase subunit O, mitochondrial  P48047 1.43E-02 3.76 
Phospholipase D3  Q8IV08 4.30E-03 3.70 
ATP synthase subunit beta, mitochondrial  P06576 2.83E-02 3.69 
Cytosolic acyl coenzyme A thioester hydrolase  O00154 2.38E-03 3.66 
Annexin A2  P07355 1.86E-02 3.55 
60S ribosomal protein L4  P36578 3.57E-02 3.55 
60S acidic ribosomal protein P0-like  Q8NHW5 1.95E-02 3.52 
Calnexin  P27824 1.83E-02 3.50 
Trifunctional enzyme subunit beta, mitochondrial  P55084 3.50E-02 3.49 
Proliferation-associated protein 2G4  Q9UQ80 9.76E-03 3.48 
Calreticulin  P27797 7.16E-03 3.47 
Cadherin-2  P19022 2.10E-02 3.39 
Glutathione S-transferase kappa 1  Q9Y2Q3 2.99E-03 3.30 
Tropomyosin alpha-4 chain  P67936 3.87E-03 3.27 
Keratin, type I cytoskeletal 9  P35527 3.17E-02 3.26 
Fumarate hydratase, mitochondrial  P07954 4.26E-03 3.22 
RNA-binding protein 14  Q96PK6 1.23E-02 3.21 
Peroxisomal multifunctional enzyme type 2  P51659 4.03E-02 3.18 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic  Q01581 1.74E-03 3.13 
60S ribosomal protein L5  P46777 1.05E-02 3.12 
Inorganic pyrophosphatase  
Q15181; 
Q9H2U2 
2.40E-02 3.06 
Prolyl 3-hydroxylase 1  Q32P28 2.84E-03 3.03 
Peroxiredoxin-6  P30041 1.38E-02 3.02 
Protein CutA  O60888 1.96E-02 3.00 
Nucleophosmin  P06748 1.18E-02 2.99 
Protein disulfide-isomerase A4  P13667 5.68E-03 2.97 
Cytoplasmic dynein 1 heavy chain 1  Q14204 6.08E-03 2.94 
Lamin-B1  P20700 1.20E-03 2.94 
Prelamin-A/C  P02545 2.19E-02 2.90 
60S ribosomal protein L7a  P62424 3.04E-02 2.89 
Drebrin-like protein  Q9UJU6 5.69E-03 2.85 
Fructose-bisphosphate aldolase C  P09972 2.83E-02 2.82 
THO complex subunit 4  Q86V81 9.47E-03 2.80 
Transitional endoplasmic reticulum ATPase  P55072 2.31E-02 2.78 
Adenylyl cyclase-associated protein 1  Q01518 1.80E-03 2.78 
Annexin A1  P04083 3.11E-02 2.77 
Adenylate kinase 2, mitochondrial  P54819 2.79E-02 2.74 
Fructose-bisphosphate aldolase A  P04075 2.13E-02 2.74 
Valine--tRNA ligase  P26640 4.78E-03 2.72 
Receptor-type tyrosine-protein phosphatase C  P08575 1.39E-02 2.65 
26S proteasome non-ATPase regulatory subunit 2  Q13200 3.17E-03 2.64 
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Thioredoxin domain-containing protein 12  O95881 2.21E-02 2.63 
DNA replication licensing factor MCM7  P33993 1.22E-02 2.63 
F-actin-capping protein subunit beta  P47756 7.98E-04 2.61 
60S acidic ribosomal protein P1  P05386 2.71E-02 2.60 
6-phosphogluconate dehydrogenase, decarboxylating  P52209 2.87E-03 2.60 
Adenosylhomocysteinase  P23526 1.38E-02 2.53 
Myosin-9  P35579 2.74E-02 2.45 
X-ray repair cross-complementing protein 5  P13010 4.32E-05 2.45 
Heat shock protein beta-1  P04792 1.33E-02 2.44 
Malate dehydrogenase, mitochondrial  P40926 4.96E-03 2.42 
Serine/arginine-rich splicing factor 7  Q16629 1.30E-02 2.39 
Alpha-enolase  P06733 5.48E-03 2.38 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial  
P36957 4.13E-03 2.35 
Isoleucine--tRNA ligase, mitochondrial  Q9NSE4 2.15E-02 2.31 
Putative heat shock protein HSP 90-beta-3  Q58FF7 2.57E-02 2.31 
78 kDa glucose-regulated protein  
P11021; 
O95399 
1.00E-03 2.30 
Bifunctional glutamate/proline--tRNA ligase  P07814 4.45E-04 2.29 
Fatty acid synthase  P49327 3.99E-03 2.29 
Protein SET  Q01105 7.34E-03 2.26 
Heat shock protein HSP 90-beta  
P08238; 
Q58FG1 
5.16E-03 2.23 
Heterogeneous nuclear ribonucleoprotein U  Q00839 3.31E-04 2.23 
Ran-specific GTPase-activating protein  P43487 6.93E-03 2.22 
60S ribosomal protein L24  P83731 1.56E-02 2.22 
Serpin H1  P50454 9.30E-03 2.13 
T-complex protein 1 subunit beta  P78371 2.98E-02 2.12 
Proteasome subunit alpha type-3  P25788 1.59E-02 2.11 
Hypoxanthine-guanine phosphoribosyltransferase  P00492 2.82E-02 2.09 
Heat shock protein HSP 90-alpha  P07900 2.61E-03 2.09 
Neutral alpha-glucosidase AB  Q14697 3.13E-03 2.07 
Far upstream element-binding protein 1  Q96AE4 6.99E-03 2.05 
Endoplasmin  P14625 1.97E-03 2.03 
Glucosidase 2 subunit beta  P14314 5.14E-04 2.01 
Heat shock protein 105 kDa  Q92598 1.54E-02 2.00 
C-1-tetrahydrofolate synthase, cytoplasmic  P11586 2.43E-02 2.00 
Protein disulfide-isomerase  P07237 1.14E-02 1.97 
Elongation factor 1-gamma  P26641 1.02E-02 1.91 
Nucleoprotein TPR  P12270 7.77E-03 1.90 
Heterogeneous nuclear ribonucleoprotein Q  O60506 1.67E-03 1.89 
Tubulin beta-6 chain  Q9BUF5 1.96E-03 1.88 
T-complex protein 1 subunit theta  P50990 9.30E-03 1.87 
Transcription intermediary factor 1-beta  Q13263 1.11E-02 1.85 
T-complex protein 1 subunit eta  Q99832 1.91E-03 1.84 
Endoplasmic reticulum resident protein 29  P30040 5.94E-03 1.84 
Leucine-rich PPR motif-containing protein, 
mitochondrial  
P42704 4.71E-03 1.81 
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Heterogeneous nuclear ribonucleoprotein M  P52272 2.32E-02 1.75 
Actin-related protein 2/3 complex subunit 4  P59998 3.49E-02 1.74 
Protein phosphatase 1G  O15355 6.27E-03 1.74 
Glyceraldehyde-3-phosphate dehydrogenase  P04406 2.61E-02 1.70 
T-complex protein 1 subunit gamma  P49368 1.40E-02 1.64 
Retinal dehydrogenase 1  P00352 2.07E-03 1.57 
Transketolase  P29401 1.28E-02 1.57 
Peroxiredoxin-1  Q06830 2.86E-02 1.55 
Heat shock cognate 71 kDa protein  P11142 2.90E-02 1.53 
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Description Accession 
Anova 
(p) 
Max fold 
change 
Receptor-type tyrosine-protein phosphatase C  P08575 1.43E-02 42.10 
Cadherin-2  P19022 4.13E-02 29.00 
Splicing factor, proline- and glutamine-rich  P23246 3.07E-02 28.92 
Catenin beta-1  P35222 5.52E-03 26.80 
CD166 antigen  Q13740 2.75E-02 24.30 
Roundabout homolog 2  Q9HCK4 1.66E-02 21.85 
BH3-interacting domain death agonist  P55957 1.82E-03 18.07 
RNA-binding protein 14  Q96PK6 3.22E-02 17.52 
Desmoglein-2  Q14126 2.62E-02 17.34 
Non-POU domain-containing octamer-binding protein  Q15233 3.02E-02 14.81 
Fascin  Q16658 4.17E-02 14.34 
Catenin alpha-1  P35221 1.42E-02 10.81 
Prohibitin-2  Q99623 6.30E-03 10.26 
Prohibitin  P35232 7.57E-03 10.06 
Neuroblast differentiation-associated protein AHNAK  Q09666 5.60E-05 9.29 
Kinectin  Q86UP2 1.26E-02 8.37 
Prelamin-A/C  P02545 4.68E-02 7.38 
D-3-phosphoglycerate dehydrogenase  O43175 1.08E-03 7.36 
Filamin-A  P21333 6.95E-03 7.07 
Pirin  O00625 2.06E-04 6.45 
Ataxin-10  Q9UBB4 1.59E-03 6.23 
Extended synaptotagmin-1  Q9BSJ8 1.77E-02 6.23 
Creatine kinase B-type  P12277 5.94E-04 6.08 
Ran-specific GTPase-activating protein  P43487 3.38E-03 5.89 
Filamin-B  O75369 2.30E-02 5.68 
Ras GTPase-activating-like protein IQGAP1  P46940 3.27E-03 5.50 
Nucleolar RNA helicase 2  Q9NR30 8.07E-03 5.36 
3-hydroxyisobutyrate dehydrogenase, mitochondrial  P31937 3.09E-03 5.12 
Superoxide dismutase [Cu-Zn]  P00441 3.46E-03 5.07 
Tropomyosin alpha-1 chain  P09493 2.19E-02 4.78 
Heat shock protein beta-1  P04792 3.03E-04 4.76 
Serine hydroxymethyltransferase, mitochondrial  P34897 2.04E-03 4.68 
Tubulin-specific chaperone A  O75347 1.76E-02 4.44 
Glutathione S-transferase P  P09211 9.46E-03 4.41 
Glutathione reductase, mitochondrial  P00390 6.73E-03 4.31 
U5 small nuclear ribonucleoprotein 200 kDa helicase  O75643 2.03E-02 4.20 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic  Q01581 2.22E-02 4.15 
Prosaposin  P07602 2.62E-02 4.14 
Phosphoglycerate kinase 1  P00558 5.72E-03 4.13 
Lamin-B1  P20700 1.51E-04 4.06 
Ras-related protein Ral-A  P11233 1.06E-02 4.03 
Proliferating cell nuclear antigen  P12004 9.88E-03 3.86 
Tumor protein D54  O43399 5.08E-03 3.72 
Sepiapterin reductase  P35270 2.61E-02 3.64 
Crk-like protein  P46109 1.46E-02 3.64 
Lamina-associated polypeptide 2, isoform alpha  P42166 1.49E-02 3.60 
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Macrophage migration inhibitory factor  P14174 3.81E-04 3.56 
Puromycin-sensitive aminopeptidase  P55786 9.45E-03 3.46 
Actin, cytoplasmic 1  P60709 2.94E-02 3.45 
Spermidine synthase  P19623 2.89E-02 3.45 
Melanoma-associated antigen 4  P43358 9.84E-03 3.44 
Adenine phosphoribosyltransferase  P07741 2.50E-02 3.39 
Annexin A2  P07355 1.52E-02 3.37 
Histone H4  P62805 4.78E-03 3.34 
Peptidyl-prolyl cis-trans isomerase A  P62937 2.96E-02 3.31 
Actin, aortic smooth muscle  P62736 2.86E-02 3.26 
Spectrin alpha chain, non-erythrocytic 1  Q13813 1.11E-02 3.23 
PDZ and LIM domain protein 5  Q96HC4 1.20E-02 3.19 
Ubiquitin carboxyl-terminal hydrolase isozyme L1  P09936 2.41E-02 3.02 
Alanine--tRNA ligase, cytoplasmic  P49588 5.42E-03 2.98 
Alpha-actinin-4  O43707 1.14E-02 2.93 
Alpha-aminoadipic semialdehyde dehydrogenase  P49419 3.32E-03 2.93 
Carbonyl reductase [NADPH] 1  P16152 3.27E-02 2.90 
Electron transfer flavoprotein subunit alpha, 
mitochondrial  
P13804 1.15E-02 2.80 
Phosphoglycerate mutase 1  P18669 6.68E-03 2.79 
Puromycin-sensitive aminopeptidase-like protein  A6NEC2 1.62E-02 2.76 
Ubiquitin-conjugating enzyme E2 variant 1  Q13404 1.39E-02 2.74 
Aconitate hydratase, mitochondrial  Q99798 1.20E-02 2.73 
Heat shock protein 105 kDa  Q92598 1.53E-02 2.70 
ATP-dependent RNA helicase A  Q08211 3.92E-03 2.70 
Calnexin  P27824 1.91E-02 2.70 
Heterogeneous nuclear ribonucleoprotein H3  P31942 2.77E-03 2.67 
Transitional endoplasmic reticulum ATPase  P55072 3.92E-03 2.56 
Exportin-2  P55060 3.40E-02 2.49 
Alpha-enolase  P06733 1.67E-02 2.49 
C-1-tetrahydrofolate synthase, cytoplasmic  P11586 4.56E-04 2.48 
Stathmin  P16949 2.68E-02 2.44 
Microtubule-associated protein 2  P11137 1.93E-02 2.42 
Aspartate aminotransferase, mitochondrial  P00505 1.59E-03 2.37 
Heat shock protein 75 kDa, mitochondrial  Q12931 1.06E-02 2.37 
L-lactate dehydrogenase B chain  P07195 3.60E-02 2.34 
Ubiquitin-like modifier-activating enzyme 1  P22314 8.50E-03 2.31 
60 kDa heat shock protein, mitochondrial  P10809 4.17E-03 2.31 
Succinyl-CoA ligase [GDP-forming] subunit beta, 
mitochondrial  
Q96I99 1.38E-02 2.23 
Peptidyl-prolyl cis-trans isomerase B  P23284 1.32E-02 2.22 
Nuclear autoantigenic sperm protein  P49321 1.40E-02 2.16 
Malate dehydrogenase, cytoplasmic  P40925 2.08E-02 2.15 
Nucleophosmin  P06748 2.93E-02 2.07 
Bifunctional purine biosynthesis protein PURH  P31939 1.38E-02 1.99 
Transketolase  P29401 2.08E-02 1.94 
Stress-70 protein, mitochondrial  P38646 1.00E-02 1.92 
Peroxiredoxin-1  Q06830 3.52E-03 1.80 
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ATP synthase subunit alpha, mitochondrial  P25705 2.16E-02 1.74 
Malate dehydrogenase, mitochondrial  P40926 5.91E-03 1.56 
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Comparative proteomic analysis: DLKPSQ vs. 
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Description Accession Anova (p) 
Max fold 
change 
Probable 28S rRNA (cytosine(4447)-C(5))-
methyltransferase  
P46087 1.70E-03 12.26 
U5 small nuclear ribonucleoprotein 200 kDa helicase  O75643 1.44E-02 11.69 
Prohibitin-2  Q99623 5.54E-03 11.52 
Splicing factor, proline- and glutamine-rich  P23246 5.15E-03 10.66 
Non-POU domain-containing octamer-binding 
protein  
Q15233 2.00E-03 10.17 
PDZ and LIM domain protein 5  Q96HC4 1.77E-03 9.67 
Prohibitin  P35232 1.41E-02 9.45 
Neuroblast differentiation-associated protein 
AHNAK  
Q09666 5.56E-04 8.04 
Histone H4  P62805 1.63E-02 7.84 
RNA-binding protein 14  Q96PK6 4.59E-03 7.59 
Ras-related protein Ral-A  P11233 9.63E-03 7.46 
Shootin-1  A0MZ66 1.29E-03 7.02 
Caprin-1  Q14444 1.26E-02 6.91 
D-3-phosphoglycerate dehydrogenase  O43175 2.51E-04 6.70 
Ras GTPase-activating-like protein IQGAP1  P46940 8.84E-03 6.17 
Catenin beta-1  P35222 2.19E-02 5.71 
Kinectin  Q86UP2 8.39E-03 5.30 
Glutathione S-transferase kappa 1  Q9Y2Q3 1.28E-02 5.22 
Nucleolar RNA helicase 2  Q9NR30 2.41E-03 5.13 
Guanine nucleotide-binding protein G(i) subunit 
alpha-1  
P63096; 
Q03113 
1.91E-02 5.01 
Pirin  O00625 3.10E-04 4.95 
Heat shock 70 kDa protein 1A/1B  P08107 2.36E-03 4.84 
Filamin-B  O75369 2.61E-02 4.72 
Tumor protein D54  O43399 1.76E-02 4.31 
Calreticulin  P27797 9.51E-03 4.12 
Cytoskeleton-associated protein 5  Q14008 1.60E-02 4.10 
Collagen alpha-1(XIV) chain  Q05707 9.72E-03 4.05 
Filamin-A  P21333 3.83E-02 4.04 
Heat shock 70 kDa protein 1-like  P34931 4.09E-03 3.98 
Exportin-1  O14980 1.43E-02 3.96 
Spectrin alpha chain, non-erythrocytic 1  Q13813 3.00E-02 3.93 
Adenosylhomocysteinase  P23526 6.64E-03 3.86 
Tropomyosin alpha-4 chain  
P67936; 
P07951 
5.00E-04 3.74 
Importin-5  O00410 1.27E-03 3.65 
Putative heat shock protein HSP 90-beta-3  
Q58FF7; 
Q58FF8 
3.55E-03 3.58 
Cleavage and polyadenylation specificity factor 
subunit 6  
Q16630 1.76E-02 3.57 
Serpin H1  P50454 3.21E-03 3.52 
Heat shock protein beta-1  P04792 5.26E-03 3.52 
Calnexin  P27824 5.69E-03 3.48 
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Lamin-B1  P20700 9.74E-04 3.35 
Neutral alpha-glucosidase AB  Q14697 7.90E-03 3.25 
Nucleophosmin  P06748 2.05E-02 3.24 
Cytosolic acyl coenzyme A thioester hydrolase  O00154 2.46E-03 3.11 
Exportin-2  P55060 3.95E-03 3.10 
ATP-dependent RNA helicase DDX3X  O00571 1.30E-02 3.08 
Annexin A2  P07355 8.36E-03 3.05 
Probable ATP-dependent RNA helicase DDX5  P17844 1.57E-02 3.02 
ATP synthase subunit alpha, mitochondrial  P25705 1.09E-02 3.02 
Serine hydroxymethyltransferase, mitochondrial  P34897 6.34E-03 2.99 
Receptor-type tyrosine-protein phosphatase C  P08575 2.13E-02 2.94 
Protein disulfide-isomerase A4  P13667 1.29E-03 2.94 
Peroxiredoxin-6  P30041 3.40E-03 2.92 
60S ribosomal protein L5  P46777 1.77E-02 2.90 
F-actin-capping protein subunit beta  P47756 1.33E-03 2.90 
Fumarate hydratase, mitochondrial  P07954 3.48E-03 2.90 
Myotrophin  P58546 1.13E-02 2.90 
60S acidic ribosomal protein P0-like  Q8NHW5 3.35E-02 2.89 
Tropomyosin alpha-1 chain  P09493 2.93E-02 2.87 
Drebrin-like protein  Q9UJU6 3.40E-03 2.84 
Hypoxanthine-guanine phosphoribosyltransferase  P00492 5.74E-04 2.84 
Histone H2A type 1-B/E  P04908 5.36E-03 2.81 
Phosphoglycerate kinase 1  P00558 2.78E-02 2.75 
THO complex subunit 4  Q86V81 2.62E-02 2.69 
Acetyl-CoA acetyltransferase, mitochondrial  P24752 4.15E-03 2.69 
6-phosphogluconate dehydrogenase, decarboxylating  P52209 7.68E-03 2.69 
Probable ATP-dependent RNA helicase DDX6  P26196 5.91E-03 2.68 
Protein disulfide-isomerase A6  Q15084 9.22E-03 2.64 
Adenylate kinase 2, mitochondrial  P54819 1.13E-02 2.62 
Ran-specific GTPase-activating protein  P43487 1.20E-02 2.60 
Alpha-enolase  
P06733; 
P13929 
1.68E-02 2.58 
26S proteasome non-ATPase regulatory subunit 2  Q13200 4.17E-03 2.57 
Inorganic pyrophosphatase  
Q15181; 
Q9H2U2 
3.23E-02 2.56 
Peroxiredoxin-1  Q06830 6.14E-03 2.46 
Keratin, type II cuticular Hb4  Q9NSB2 1.70E-03 2.42 
Isoleucine--tRNA ligase, mitochondrial  Q9NSE4 1.05E-02 2.42 
Importin subunit beta-1  Q14974 1.08E-02 2.39 
Band 4.1-like protein 2  O43491 3.31E-02 2.34 
Keratin, type II cytoskeletal 1  P04264 4.95E-02 2.34 
Retinal dehydrogenase 1  P00352 2.33E-02 2.32 
Valine--tRNA ligase  P26640 8.10E-03 2.31 
Far upstream element-binding protein 1  Q96AE4 3.33E-03 2.25 
Heat shock protein HSP 90-beta  P08238 6.96E-03 2.23 
Heterogeneous nuclear ribonucleoprotein K  P61978 2.28E-02 2.21 
Heat shock protein 105 kDa  Q92598 1.36E-02 2.20 
Alpha-actinin-1  P12814 3.55E-02 2.19 
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Cytoplasmic dynein 1 heavy chain 1  Q14204 2.09E-03 2.18 
Catenin alpha-1  P35221 2.08E-02 2.17 
Calcyclin-binding protein  Q9HB71 1.45E-02 2.16 
Pyruvate kinase PKM  P14618 2.08E-02 2.15 
Actin, aortic smooth muscle  P62736 2.57E-02 2.13 
Heterogeneous nuclear ribonucleoprotein Q  O60506 1.67E-03 2.08 
Ras-related protein Rab-2A  P61019 2.71E-02 2.04 
Malate dehydrogenase, mitochondrial  P40926 2.11E-02 2.03 
Peptidyl-prolyl cis-trans isomerase A  P62937 1.45E-02 2.01 
Actin, cytoplasmic 1  P60709 1.17E-02 2.01 
Ubiquitin-like modifier-activating enzyme 1  P22314 1.20E-02 1.97 
ATP-citrate synthase  P53396 1.69E-03 1.97 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial  
P36957 6.17E-04 1.97 
T-complex protein 1 subunit theta  P50990 9.15E-03 1.92 
Puromycin-sensitive aminopeptidase-like protein  A6NEC2 3.35E-02 1.90 
78 kDa glucose-regulated protein  P11021 4.48E-04 1.90 
Fructose-bisphosphate aldolase A  P04075 2.44E-02 1.89 
Multifunctional protein ADE2  P22234 2.02E-02 1.85 
40S ribosomal protein S19  P39019 1.85E-02 1.85 
Fatty acid synthase  P49327 5.49E-04 1.84 
X-ray repair cross-complementing protein 5  P13010 1.75E-02 1.81 
Aspartate aminotransferase, mitochondrial  P00505 4.59E-03 1.69 
Stress-70 protein, mitochondrial  P38646 1.50E-02 1.61 
3-hydroxyacyl-CoA dehydrogenase type-2  Q99714 2.94E-03 1.54 
Heat shock cognate 71 kDa protein  P11142 9.38E-03 1.54 
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Description Accession Anova (p) 
Max fold 
change 
Receptor-type tyrosine-protein phosphatase C P08575 2.77E-02 41.79 
CD166 antigen Q13740 2.54E-02 30.15 
Roundabout homolog 2 Q9HCK4 6.95E-03 26.95 
Receptor-type tyrosine-protein phosphatase F P10586 1.78E-02 25.10 
Desmoglein-2 Q14126 1.68E-02 24.70 
Cadherin-2 P19022 3.44E-02 20.87 
Alpha-2-macroglobulin receptor-associated protein P30533 1.59E-02 9.17 
Nectin-2 Q92692 3.12E-02 7.93 
Catenin beta-1 P35222 1.42E-02 7.93 
3-hydroxyisobutyrate dehydrogenase, mitochondrial P31937 4.57E-03 7.33 
Creatine kinase B-type P12277 1.72E-03 7.29 
Tubulin-specific chaperone A O75347 4.50E-03 4.52 
Peroxisomal acyl-coenzyme A oxidase 1 Q15067 2.86E-02 4.48 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic Q01581 2.39E-02 4.26 
Alpha-aminoadipic semialdehyde dehydrogenase P49419 2.51E-03 4.12 
Glutathione S-transferase kappa 1 Q9Y2Q3 2.52E-02 4.05 
Filamin-A P21333 1.87E-02 3.89 
Heat shock 70 kDa protein 1-like P34931 4.53E-03 3.81 
L-lactate dehydrogenase B chain P07195 2.29E-02 3.47 
Adenine phosphoribosyltransferase P07741 7.56E-03 3.45 
Annexin A5 P08758 9.87E-04 3.45 
Ran-specific GTPase-activating protein P43487 1.31E-03 3.43 
Nucleoprotein TPR P12270 3.79E-02 3.35 
Glutathione S-transferase P P09211 1.28E-02 3.33 
Peroxisomal multifunctional enzyme type 2 P51659 1.07E-02 3.32 
Carbonyl reductase [NADPH] 1 P16152 4.63E-03 3.22 
Serpin H1 P50454 1.46E-02 3.18 
F-actin-capping protein subunit beta P47756 1.56E-03 3.07 
PDZ and LIM domain protein 5 Q96HC4 3.98E-02 3.03 
Peptidyl-prolyl cis-trans isomerase A P62937 2.28E-02 3.02 
Heat shock 70 kDa protein 1A/1B P08107 7.65E-03 2.93 
Superoxide dismutase [Cu-Zn] P00441 1.45E-02 2.88 
Macrophage migration inhibitory factor P14174 6.15E-03 2.79 
Band 4.1-like protein 2 O43491 3.50E-03 2.75 
ATP-dependent RNA helicase A Q08211 1.70E-02 2.74 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
P36957 1.73E-03 2.72 
Keratin, type II cytoskeletal 1 P04264 2.59E-02 2.68 
Malate dehydrogenase, cytoplasmic P40925 2.30E-02 2.66 
Tumor protein D52 P55327 1.62E-02 2.58 
Electron transfer flavoprotein subunit alpha, 
mitochondrial 
P13804 3.03E-03 2.49 
Phosphoglycerate mutase 1 P18669 4.10E-03 2.46 
C-1-tetrahydrofolate synthase, cytoplasmic P11586 5.35E-03 2.41 
Phosphoglycerate kinase 1 P00558 1.07E-02 2.39 
Actin-related protein 2/3 complex subunit 4 P59998 3.45E-03 2.37 
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Heat shock cognate 71 kDa protein P11142 1.35E-02 2.33 
Ubiquitin carboxyl-terminal hydrolase isozyme L1 P09936 2.45E-02 2.25 
Heat shock protein HSP 90-alpha P07900 9.74E-03 2.20 
Aconitate hydratase, mitochondrial Q99798 3.47E-02 2.14 
Fatty acid synthase P49327 4.08E-03 2.11 
Puromycin-sensitive aminopeptidase P55786 1.86E-03 2.09 
Peptidyl-prolyl cis-trans isomerase B P23284 4.24E-03 2.06 
Calreticulin P27797 2.68E-02 2.05 
Protein disulfide-isomerase A6 Q15084 2.80E-02 1.96 
Peroxiredoxin-1 Q06830 1.45E-02 1.95 
Enoyl-CoA delta isomerase 1, mitochondrial P42126 2.08E-03 1.86 
Melanoma-associated antigen 4 P43358 2.93E-02 1.82 
Fructose-bisphosphate aldolase A P04075 1.90E-02 1.76 
60 kDa heat shock protein, mitochondrial P10809 1.57E-02 1.70 
 
 
